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ABSTRACT
While peptides have impeccable potential due to their biological and therapeutic abilities,
they are inherently limited in clinical practice due to their instability towards proteolysis and poor
bioavailability. In the past few years peptidomimetics have emerged as a powerful class of
compounds that overcomes the shortcomings associated with peptides. Peptidomimetics
essentially mimic a natural peptide or protein in its chemical composition, structure and its ability
to perform a biologically relevant role. In addition to increased stability and bioavailability,
peptidomimetics can also have increased receptor binding affinity and selectivity, thereby making
these mimics lead compounds in the field of drug design and discovery. Most recently,
modifications to the peptide backbone have been introduced to increase the versatility of
peptidomimetic applications. This thesis work is based on the unrestricted ability to modify amino
acid side chain residues within biologically relevant peptides and form new classes of
peptidomimetics for studying their structure-function properties.
Motivated by the idea of introducing a multipurpose moiety to increase the functionality
of peptides, we sought to incorporate the cyclic urethane moiety otherwise known as 2oxazolidinone and to explore the plethora of applications that accompany this incorporation. In the
process of designing cyclic urethane containing peptides, we sought to peruse an approach where
the cyclic urethane moiety would be derived from naturally occurring amino acids serine,
threonine, glutamic acid, and/or cysteine.
Modification of serine’s hydroxymethyl side chain to a 2- oxazolidinone moiety activates
the peptide backbone chain and increases its susceptibility towards cleavage. Due to the versatility
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of this moiety, 2-oxazolidinone has been used to explore various applications such as protease
mimics, formation of peptide thioesters, and modified C-terminal peptides. When used as a
protease mimic, formation of 2-oxazolidinone allows for site-selective cleavage of extremely
unreactive peptide bonds using neutral aqueous conditions. This method exhibits broad substrate
scope and selectively cleaves various bioactive peptides with post-translational modifications (e.g.
N-acetylation and N-methylation) and mutations (D- and β-amino acids), which are unsuitable
substrates for enzymes. Further application of this method has been demonstrated by the
sequencing of cyclic peptides which is difficult to achieve by utilizing traditional methods such as
Edman’s degradation and MS/MS. Identifying the sequence of macrocyclic peptides is vital in
exploring potential therapeutic candidates found in nature and/or created through split and pool
techniques. Building on the susceptibility of 2-oxazolidinone to cleavage, this moiety was also
utilized for the formation of peptide thioesters, which is of significance in native chemical ligation
for the synthesis of large proteins. This approach allows the synthesis of peptide thioesters by using
Fmoc SPPS, which is usually an incompatible method due to the nucleophilic secondary amine
required for Fmoc removal. Moreover, 2-oxazolidinone was used for the synthesis of various Cterminally modified peptides which are otherwise unattainable without the use of specialized
resins, handles, or linkers. By exploring the various applications of the cyclic urethane moiety, this
thesis work has demonstrated the effectiveness and wide-spread applicability of cyclic urethane
derived peptidomimetics in the field of synthetic organic chemistry.
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CHAPTER 1: GENERAL OVERVIEW OF PEPTIDE
BIOCHEMISTRY
AND
METHODS
FOR
CHEMICAL
SYNTHESIS AND MODIFICATION
1.1 GENERAL INTRODUCTION TO AMINO ACID AND PEPTIDE
STRUCTURE
Amino acids play a fundamental role in nature as peptide building blocks and as intermediates
in metabolic processes.1 The twenty naturally occurring amino acids contain a wide array of
chemical versatility.2 The general structure of amino acids contains terminal amino and carboxyl
groups which are bound by a central α-carbon. Attached to the α-carbon is a H atom and a side
chain group designated as R, which serves as the basis of differentiation between one amino acid
and another (Figure 1.1). This R group is what gives each amino acid its distinct identity and
unique physical and chemical properties.

Figure 1.1 General amino acid ionic structure.
Based on the nature of the R group, amino acids can be classified into the following four categories:
hydrophobic (nonpolar side chains), polar (uncharged residues with hydrophilic character), acidic
(side chains with a negatively charged carboxyl group), and basic (side chains with a positively
charged amino group). Moreover, due to the presence of four different functional groups attached
1

to the α-carbon, amino acids can exist in the form of two enantiomers, D(R) and L(S). While the
L-form is predominant in nature, mutations can give rise to some D-amino acids as well. Amino
acids also have a predominant ionic structure at physiological pH. The neutral zwitterion is formed
by a balance in charges in between the N-/C-termini and it may also implicate a polar, charged
amino acids side chain group (Figure 1.1). The latter can also affect the acid/base properties of
amino acids which contain ionizable groups that can affect the overall/net charge of the amino
acids in solution and as a function of changes in pH of the buffer system (Figure 1.2).

Figure 1.2 Venn diagram of amino acid properties. Figure adapted from reference (2).
Individual amino acids can be further linked together through peptide (amide) bonds to form
a higher order structure, peptides. The formation of peptides takes place by condensation reactions
in between the carboxylic group of one amino acid and the amino group of the adjacent amino acid
thereby releasing a water molecule.1 Peptides are comprised of amino acid linkages encompassing
50 or less residues; they are essential to the most basic biological processes, including signal

2

transduction and metabolism. For peptides to have the ability to perform a biologically important
function, not only do they have to contain a certain amount of amino acids, the residues must also
be incorporated in a specific order. The primary sequence of amino acids which make up the
composition of a peptide is critical to its structure-function relationship. Small peptides ranging
from two to dozens of amino acid residues can have a discernable effect on organism physiology.

Scheme 1.1 Peptide bond formation. Scheme adopted from reference (1).
Nature carries an extraordinary selection of biologically active peptides which participate in
crucial roles in human function including hormones, neurotransmitters, and growth factors (Figure
1.3).3 Furthermore, they serve as regulatory molecules in defense, stress, and reproductive
processes.4 With the discovery of over 7000 naturally occurring peptides, they are at the core of a
living organism’s daily operation.3 Some of the most notable peptides include: carnosine (1.1), a
dipeptide found in muscle tissue; glutathione (1.2), a tripeptide that serves as a scavenger for
oxidizing agents which have been implicated in cancer; and enkephalins (1.3), two pentapeptides
that are naturally occurring pain relievers.5 Even more vital to the human body are oxytocin (1.4)

3

and vasopressin (1.5), two notable small peptide hormones with big effects.5 Oxytocin is essential
to child birth, where it aids in labor induction, contraction of the uterine muscle, and simulation of
milk flow in a nursing mother. It also stimulates emotions of bonding and affection. Meanwhile,
vasopressin maintains regular blood pressure level by acting as an antidiuretic in patients with low
blood pressure. As demonstrated by the abovementioned peptides, naturally occurring peptides
exhibit inherent properties which act as an inspiration for exploring their therapeutic profile and
structure-function activity through chemical synthetic routes.

Figure 1.3 Bioactive peptides found in nature.

4

1.2 PEPTIDE SYNTHESIS OVERVIEW
During the last 50 years, there has been immense expansion and progress in the field of peptide
and protein chemistry. Modern peptide chemistry includes many branches of study including
synthesis, purification, analysis, structure and conformation investigation, and molecular
modeling. Advances in biotechnology have facilitated the use of natural peptides as a starting point
for novel synthetic peptide therapeutics with excellent specificity and efficacy which
revolutionized peptide-based drug design and discovery. Since 2008, the peptide therapeutic
market has exceeded the multi-billion-dollar level and over 400 peptides have been entered into
clinical studies thus far.6 Moreover, chemical synthesis has provided a practical method for
allowing structural elucidation and synthetic manipulation of biologically relevant peptides that
can only be isolated in small quantities. Synthetically derived peptides have also been essential in
studying enzyme substrates, binding properties, and in NMR structural studies.
Generally, peptide synthesis can be described as the assembly of amino acid monomers
stepwise through a continuous cycles of coupling reactions in between adjacent amino acids
followed by the removal of a reversible protecting group leading to peptide elongation until the
point of completion. The term peptide was first coined by Fischer and Fourneau who performed
the first peptide synthesis at the turn of the 20th century.7 Next, benzyloxycarbonyl (Cbz), the first
reversible amino protecting group, was created which paved the way for further advances in the
newly discovered field.8 In 1953, Du Vigneaud was able to combine the earlier strategies and bring
them to sophistication to construct a peptide successfully mimicking the properties of the hormone
oxytocin.9

However,

the

true

breakthrough

came

with

the

introduction

of

dicyclohexylcarbodiimide (DCC), an unprecedented coupling reagent which refined the
methodology of peptide bond formation and led to the milestone of solid phase peptide synthesis
5

by Merrifield.10 Building on previous discoveries in addition to his own extensive research,
Merrifield was able to prefect the conditions for the synthesis of peptides on solid support and was
awarded the Nobel Prize in Chemistry in 1984 for his pioneering contributions to the field of solid
phase peptide synthesis.
While synthetic peptides can be made in solution or on a solid support, the solid support
method is preferred due to the inherent limitations of solution phase synthesis. In solution,
chemical synthesis gives rise to side products after each coupling step.

Therefore, the

intermediates and/or desired products must be purified, isolated, and characterized after each step
in the deprotection/coupling cycle. Equally important, peptide insolubility in the solvents essential
for synthesis proves problematic. Although attractive for large scale reactions due to quantitatively
high yields, the demanding and laborious task of solution phase synthesis in addition to being illsuited for synthesis of long peptides detract from its practical use in the advancement of peptide
chemistry.

1.3 SOLID PHASE PEPTIDE SYNTHESIS
The discovery of solid phase peptide synthesis (SPPS) created a paradigm shift in the field of
peptide synthesis by allowing the assembly of a peptide chain onto an insoluble and filterable
porous support without the tedious task of purification and characterization after each reaction
step. Pioneering the concept in the early 1960s, Merrifield proposed the use of a polystyrene-based
solid support to assemble peptides in a stepwise fashion from the C to N terminus using amino
terminal protected amino acids.10 He synthesized a tetrapeptide by utilizing Cbz as an Nα protecting
group, DCC as the coupling reagent, and hydrobromic acid (HBr) or saponification as the cleaving
agent that releases the peptide from the solid support.10

6

Further advancement of the SPPS technique included the use of t-butyloxycarbonyl (Boc)
as a terminal amino protecting group which would allow for the use of hydrogen fluoride (HF) as
the acid medium for peptide release from the resin.11,12 In its initial development stages, the
methodology was solely based on acidolysis where side chain protecting groups and the linkage
between the peptide and resin were relatively stable to moderate amounts of acid and labile in the
presence of strong acidic conditions. Strong acids allow for the simultaneous deprotection of the
amino acid side chain functionalities and liberation of the peptide from the resin support, thereby
yielding an unprotected peptide to be purified. While the chemistry of deprotection and coupling
was subject to variations, the standard procedure of SPPS allowed for the process to be automated,
unlike solution-based synthesis.

Scheme 1.2 SPPS procedure followed by Merrifield. Scheme adopted from reference (10) with
permission.
In the period ranging from the 1960s to 1980s, progress had been made in the refinement
of classical peptide synthesis methods to facilitate the synthesis of larger and biologically complex
7

peptides. The introduction of 9-fluorenylmethoxycarbonyl (Fmoc) by Carpino for Nα protection
of amino acids offered a mild alternative to the acid-labile Boc-based synthesis strategies.13,14 By
utilizing Fmoc as a protecting group, SPPS shifted from a pure acidylosis methodology to an
orthogonal technique which required a base for deprotection of the terminal Fmoc-protected amino
group and an acid for the removal of side chain protecting group and peptide cleavage.6
Advantages of utilizing Fmoc chemistry in comparison to the Boc protecting group include mild
synthetic conditions, rapid deprotection of the Nα protecting group, and the possibility of
monitoring coupling and deprotection through ultraviolet-visible spectroscopy (UV-Vis).
Moreover, some peptides may be susceptible to acid-catalyzed side reactions which will interfere
with the peptide efficacy and yields.
The advantages associated with SPPS outweigh the limitations that may be associated with
the yields related to the synthesis of lengthy peptides. Generally, reagents that are low in molecular
weight can be used in excess to yield a considerable quantity of product. Moreover, the easy
filtration of excess reagents eliminates the need for intermediate purification that consumes ample
amounts of time during solution phase synthesis. Equally important, the mild conditions promoted
by Fmoc chemistry eliminated the possibility of any side reactions that may have risen from acid
sensitive peptide components. Amino acid solubility is not an issue during the coupling cycle,
while the solid support used to anchor the peptide is chemically compatible with the needed
substrates, solvents, and reagents. The abovementioned benefits lend themselves to the successful
expansion of SPPS into the billion-dollar industry it is today.

8

Scheme 1.3 General SPPS Protocol. Scheme adopted from: Sigma Aldrich

1.3.1 SOLID SUPPORT RESINS
Since the development of SPPS, various resins including those with linkers and spacers
have been created to be adaptable to various synthetic conditions.15 Since each type of resin has
unique physical and chemical properties, the choice of solid support often dictates the success of
9

a peptide synthesized via SPPS. Currently, there are a plethora of commercially available solid
supports that are compatible with peptide synthesis. Solid support specifications include stability,
swelling and insolubility properties, and they must allow for filtration of excess reagents.
Moreover, the resin must be unreactive towards all reagents and solvents that may be used during
the synthesis process. Even more crucial to the successful chain elongation is extensive swelling
to allow for reagent penetration into the resin pore and attachment of the first amino acid to the
resin linker.

Figure 1.4 Solid support for peptide synthesis.
Resins are mainly classified into two main categories: polystyrene (PS) and polyethylene
glycol (PEG). The hydrophobic PS resins can either be lightly or highly cross-linked, where the
amount of divinylbenzene (DVB) can vary.16 Lightly cross-linked PS resins tend to be gel-type
and microporous, where space in between crosslinks contains solvent and solutions of polymer
segments. Meanwhile, the more polar PEG resins are predominantly composed of ethylene glycol
spacers. Moreover, they have no preference for swelling solvent since the PEG chain has good
compatibility with most solvents. Other materials that have also been utilized as solid supports for
SPPS including: silica, polymethacrylate, and controlled pore glass.16 Another important resin
property that influences reactivity and kinetics is size distribution. Most commonly, resin beads
have a diameter of 100-200 mesh and 200-400 mesh which allow for effective swelling and
coupling.16
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Since SPPS is traditionally executed in the C to N terminal direction, the linker present in
the resin pore dictates the functional group that will be present at the C-terminus following
cleavage of the peptide from the solid support since it serves as the point of connection between
the first amino acid and resin bead.17 The first resin ever used for SPPS was the non-polar crosslinked PS with a chloro-methyl group as a linker, which was later named the Merrifield resin. The
first amino acid is loaded onto the resin by nucleophilic displacement of the chloride by the
carboxylate group located on the amino acid. Upon HF-mediated cleavage of the peptide from the
solid support, the carboxylic acid is regenerated at the C-terminus of the peptide. Presently, the
Wang linker is more commonly used to yield a carboxylic acid at the C-terminus of a peptide; it
was specifically designed for Fmoc-based synthesis, where the resulting peptide can be cleaved by
TFA.18 Another resin that can popularly yield a C-terminal carboxylic acid in addition to a peptide
with protected side chains is 2-chlorotrityl chloride resin. In addition to generating a carboxylic
acid at the C-terminus of a peptide, a carboxyamide is also another standard choice which is
obtained by using the Rink linker.19 There are a multitude of readily available resins and linkers
which ease the synthetic burden and allow flexibility in the choice of C-terminal protecting group
and loading condition pertaining to the first amino acid.

1.3.2 COUPLING REAGENTS
In the process of SPPS, the coupling step consists of the formation of an amide bond
between two neighboring amino acid residues. The peptide bond is formed through activation of
the carboxy component of one amino acid and the subsequent attack of the Nα group. While this
reaction is thermodynamically favorable, the formation of a new amide bond has a high activation
energy requirement. To aid in the coupling reaction initiation, coupling reagents serve as carboxy
activators, often forming a more reactive C-terminal ester. In the past fifty years, many reagents
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have been used to increase the efficiency of amino acid couplings and play a key role in generating
considerably high yields and purities of the isolated, crude synthetic peptides.
Carbodiimides such as dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide
(DIC) are considered to be classical in situ coupling reagents.6,20,21 The activation step proceeds
via nucleophilic attack of the carboxylate oxygen on the carbodiimide carbon. Upon formation of
a reactive O-acylisourea species, a carboxylic ester with an activated leaving group, nucleophilic
attack by the N-terminal amino group results in the peptide bond formation. While DCC and DIC
proceed through similar mechanistic pathways, DIC is the reagent of choice due to its solubility in
a majority of organic solvents, which also makes the removal of the unwanted urea by-product
easier to accomplish via solvent filtration.

Scheme 1.4 One pot DIC coupling mechanism. Scheme adopted from reference (20) with
permission.
While DIC executes coupling with high efficiency, it can be problematic. This method of
activation has the potential to promote racemization and dehydration of asparagine (Asn) and
glutamine (Gln) side chains. Using an additive in combination with DIC eliminateds the
abovementioned limitations and accelerates carbodiimide-mediate couplings (Figure 1.5). Popular
additives include 1-hydroxy-benzotriazole (HOBt) [A] and 1-hydroxy-7-aza-benzotiazole (HOAt)
[B], which are triazoles that attack the O-acylisourea to form an activated ester.20 More recently,
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ethyl cyanohydroxyiminoacetete (Oxyma) [C] has been developed as an alternative to HOAt and
HOBt with comparable coupling efficiency.

Scheme 1.5 HOBt and DIC coupling mechanism. Scheme adopted from reference (18) with
permission.
While carbodiimide reagents were the standard coupling reagents in peptide synthesis,
newly developed activators have more commonly been put into practice due to their increased
coupling kinetics. Examples of newly established coupling reagents in SPPS include: benzotriazol1-yl-oxy tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) [D], O-benzotriazol-1-ylN,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) [E], O-(7-azabenzotriazol-1-yl)N,N,N'N'-tetramethyluronium hexafluorophosphate (HATU) [F], O-(6-Chlorobenzotriazol-1-yl)N, N,N',N'-tetramethyluronium hexafluorophosphate (HCTU) [G], and O-benzotriazol-1-ylN,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) [H].6 The abovementioned coupling
reagents also proceed via a similar mechanistic pathway to that of the carbodiimide reagents; the
main difference in reagents classes is the initial rate of activation which lends itself to rapid
coupling rates.
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Figure 1.5 Structure of reagents used as additives during peptide coupling.

1.3.3 MODIFIED AMINO ACIDS
While peptides have impeccable potential due to their biological and therapeutic abilities,
they are inherently limited due to their instability towards proteolysis and poor bioavailability. 22
In the past few years peptidomimetics have emerged as a powerful class of compounds which
overcomes the shortcomings associated with peptides. Modified peptides (peptidomimetics)
essentially mimic a natural peptide or protein in its chemical composition, structure and its ability
14

to perform a biologically relevant role. In addition to increased stability and bioavailability,
peptidomimetics can also have increased receptor binding affinity and selectivity, thereby making
these mimics leading compounds in the field of drug design and discovery.23 By mapping
structure-activity relationships, key residues that are responsible for a physiological effect can be
identified while other non-essential amino acids can be manipulated to yield a more potent effect.
Incorporation of unnatural amino acids or modification of the peptide backbone chain
provides peptidomimetics several advantages over naturally structured peptides. Unnatural amino
acids can include β/-amino acids, which respectively contain two and three carbon atoms between
the amino terminus and carboxyl terminus (Figure 1.6). In the case of β-amino acids, a total of 4
diastereomers are possible which expands the structural diversity in molecular design.24 Moreover,
D-amino acids can also be incorporated into a peptide to increase stability and induce a
conformational change. By including several D-amino acid residues, the propensity for a peptide
to form a secondary structure can be increased.25 Most recently, modifications to the peptide
backbone have been introduced to increase the versatility of peptidomimetic applications. Some
notable examples include: glutamic acid (Glu) side chain cyclization to form a backbone pyroglutamyl moiety (Figure 1.6),26 which has been used in the synthesis of a solid support thioester
precursor and enzyme mimetics; Hoffmann rearrangement of the Asn side chain to form a fivemembered N-acylurea moiety,27 which has been used as an enzyme mimic due to the susceptibility
of C-N bond proceeding N-acylurea to hydrolysis; and modification of Methionine’s (Met) side
chain to a homoserine lactone moiety via treatment with cyanogen bromide (CNBr) which has
long been used in the field of chemical cleavage as well.28,29 Inspired by the versatility of
applications relevant to the modification of amino acid side chains, this was designated as the topic
of choice for the purpose of this thesis work.
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Figure 1.6 Modified amino acids. (A) β-amino acid (B) γ-amino acid (C) pyro-glutamyl moiety
(D) N-acylurea (E) N-acylurea

1.4 CYCLIC URETHANE MOIETY
Amino acid modification to versatile moieties with broad applicability has gained
considerable attention in the past few years. Motivated by the idea of introducing a multipurpose
moiety to increase the functionality of peptides, we sought to incorporate the cyclic urethane
moiety otherwise known as 2-oxazolidinone and explore the plethora of applications that
accompany this incorporation (Figure 1.7).

Figure 1.7 General structure of cyclic urethane.
Before its incorporation into peptides, cyclic urethanes gained wide-spread recognition as
antimicrobial agents and chiral auxiliaries as popularized by Evans. As antimicrobial agents, they
exhibit activity against multi-drug resistant gram-positive bacteria including Staphylococcus
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aureus, Staphylococcus epidermis, Streptococcus pneumoniae, and enterococci.30 Factors
contributing to the successful application of 2-oxazolidinone in the medicinal chemistry field are
related to its novel mode of action, binding selectivity, and its inhibition at the initiation phase of
bacterial translation.30 Owing to its unique chemical and biological properties, this moiety has
promoted the development of derivatives that also exhibit potent activity.
Meanwhile, the use of chiral auxiliaries including oxazolidinones has been widely used in
the synthesis of enantiomerically pure compounds since the early 1980s.31Auxiliaries such as
oxazolidinone are substituted at the 4 and 5 positions to dictate controlled reactions. Through steric
hinderance, the substituted positions direct the manner by which stereoselective transformations
take place. Specifically, oxazolidinone chiral auxiliaries have been applied to aldol reactions,
alkylation reactions, Diels-Alder reactions, and the synthesis of β-amino acids among many other
synthetic transformations.32-34 Requirements for the efficient use of a chiral auxiliary include a
strong predisposition for a highly selective enolate reaction, a strong bias for enolate
diastereofacial selection in new bond formation, and cleavage must occur in mild conditions that
do not promote racemization of the desired product.34 The abovementioned requirements are easily
fulfilled through utilizing oxazolidinone as a chiral auxiliary.
Moreover, cyclic urethane has been incorporated into peptides to serve as a pseudo-proline
surrogate due to its structural similarity to 5-membered proline (Pro) and its stability towards
standard Fmoc synthesis, chemical ligation, and convergent synthesis conditions.35 Owing to its
structure, pseudo-prolines have the ability to introduce a “kink” into the peptide backbone which
allows for disruptions of β-sheet structures which tend to be problematic during chain elongation
due to intermolecular aggregation.36,37 Incorporation of cyclic urethane into the peptide chain
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increases peptide solvation, increases coupling kinetics, and induced a slight turn into the peptide
backbone.
Due to their versatile applicability, many synthetic routes have been explored in the
synthesis of oxazolidinones. Generally, this moiety is synthesized through the reaction of amino
alcohols with several reagents including phosgene, dialkyl carbonates, urea, carbon dioxide,
carbon monoxide, and oxygen.38 Several notable methods have also been used for the synthesis
process such as: the chiral resolution method, iodocyclocarbamation, The HewehKauffman/Speranza-Peppel Method, and direct catalytic asymmetric amination of aldehydes.30
Moreover, serine (Ser), threonine (Thr), and cysteine (Cys) have been used as building blocks for
amino acid derived pseudo-prolines through the reaction of carbonyl containing reagents such as
aldehydes and ketones.36,37 Building upon this knowledge, we progressed to develop a rational
design approach for the synthesis of cyclic urethane containing peptides.

1.4.1 DESIGN OF CYCLIC URETHANE CONTAINING PEPTIDES
In the process of designing cyclic urethane containing peptides, we sought to peruse an
approach where the cyclic urethane moiety would be derived from naturally occurring amino acids
serine, threonine, and/or cysteine. Moreover, this approach would include modification of the
amino acid residue(s) within the peptide sequence. Unique to our submonomer approach are a few
factors: i) the cyclic urethane is to be derived from a natural amino acid, ii) the modification would
take place within the peptide sequence rather than involving the prerequisite solution-phase
synthesis of the cyclic urethane modified amino acid building block followed by incorporation into
the peptide, and iii) modification to the desired moiety does not require a special protecting group
or yield the dehydrated product as previously reported.39
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We proceeded to rationalize the reaction mechanism. In this case, Ser was selected as the
reactive amino acid residue. Based on Ser’s nucleophilic side chain, we sought to activate the
hydroxymethyl side chain to promote nucleophilic attack on a carbonyl containing compound to
form an activated intermediate with a good leaving group (Scheme 1.6). Subsequently,
intramolecular nucleophilic attack of the amide nitrogen of the peptide backbone on the
intermediate could proceed to produce a five-membered cyclic urethane ring or a six-membered
ring. Based on proximity of the amidic nitrogen, we hypothesized that the five-membered cyclic
urethane would be the more kinetically favorable product, which would prove to be more
resourceful in its variety of application.40

1.4.2 SYNTHESIS
Once the rational resign was in place, we proceeded to execute the methodology
experimentally. The focus of our design was to form the cyclic urethane moiety on a solid support
post peptide synthesis. First, we screened carbonyl donating agents to determine the most effective
reagent in the synthesis of cyclic urethane.41

Scheme 1.6 Serine modification mechanism.
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For activation of serine’s side chain, various electrophilic reagents such as 4-nitrophenyl
chloroformate, 1,1-carbonyldiimidazole (CDI), and N, N-disuccinimidyl carbonate (DSC) were
screened and quantitative conversion of Ac-GGSAAG to the cyclic urethane containing version
was observed by HPLC. Further confirmation of the modification by molar mass was obtained by
mass spectrometry. With a conversion percentage of approximately 99%, DSC was determined to
be the reagent of choice for efficient conversion of Ser to cyclic urethane.
Table 1.1 Reagent screening for the backbone activation of serinea

Table adopted from reference (41) with permission.
Following reagent screening, formation of the cyclic urethane was further optimized on
solid support by exploring other reaction conditions including solvent, time, temperature, and
stoichiometry. A low conversion of 40% was observed in DCM (dichloromethane) due to poor
solubility of DSC. When a mixture of DCM: DMF (dimethylformamide) (1:1) was screened as a
solvent, the conversion increased by 20%. Meanwhile, an increased solubility in DMF led to a
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conversion increase to 99%. Moreover, the role of N-terminal protecting groups was explored in
the formation of cyclic urethane. Groups such as acetyl, tosyl, and Boc were investigated as to
determine whether they would influence the efficiency of modification. Contrary to previously
reported literature, the results indicated that formation of cyclic urethane is independent of the
nature of the N-terminal protecting group.39

Table 1.2 Optimization of reaction conditions for cyclic urethane formation on solid supporta

a

Table adopted from reference (41) with permission.
Following optimization studies on solid support, varying amounts of DSC were explored

on Fmoc-GASFAG post-cleavage from the solid support to determine the equivalents of reagent
required for solution-phase modification.40 Ten equivalents of DSC produced an 80% yield, while
twenty equivalents yielded 90% modified peptide.
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Table 1.3 Optimization of reaction conditions for cyclic urethane formation in solutiona
Entry

Equivalents

(%) Yieldb

1

5

75

2

10

80

3

20

90

a

Reaction conditions: peptide (1 equiv.), DSC (5-20), DIEA (5-20 equiv.) and a crystal of DMAP
in DMF were stirred overnight at room temperature. Purified by HPLC. bIsolated yield.

1.4.3 NMR CHARACTERIZATION
Upon optimization of the synthesis conditions, NMR characterization was performed to
confirm the formation of the five-membered cyclic urethane ring rather than the six-membered
ring on the sequence Fmoc-GS (Figure 1.8 and 1.9).40
The key differences in chemical shift that confirm the formation of the five-membered
cyclic urethane ring include: 1) the methine carbon has a predicted 13C shift of 55.5 ppm for the
cyclic urethane ring and the observed chemical shift value was 55.4 ppm 2) HMBS correlation
from both NH2 protons to the neighboring carbonyl carbon indicate that the amino group is free
and not involved in ring formation 3) the methine carbon would have a 13C shift value of 51.6 ppm
if the six-membered ring had formed.
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Figure 1.8 NMR spectra for modified Fmoc-GS. (A) 1H NMR (B) 13C NMR. Figure adopted
from reference (40) with permission.
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Figure 1.9 Comparison of NMR chemical shifts for cyclization of Ser to a five-membered ring
versus a six-membered ring. Figure adopted from reference (40).

1.5 THESIS OBJECTIVES
The growing number of applications related to the modification of the amino acid side chains
in a submonomer approach, i.e. directly within the peptide sequence, served as the framework for
this thesis work.42,43 Pursuing Ser as the model amino acid for the formation of the reactive cyclic
urethane moiety results in a labile C-N bond which renders it susceptible to cleavage. Building on
this principle, we sought to use the susceptibility of this moiety to cleavage and fulfill the following
objectives: (1) use cyclic urethane as an enzyme mimic, thereby providing a new chemical
cleavage methodology that is applicable to natural peptide sequences as well as mutated sequences
that tend to be highly resistant to proteolysis, (2) use the cyclic urethane as a chemical cleavage
method for cyclic peptides and uniquely structured lasso peptides which cannot be readily
sequenced by MS/MS due to complex fragmentation patterns, (3) use the cyclic urethane moiety
as a means for sequencing cyclic peptide libraries (4) use the cyclic urethane to make C-terminally
modified peptides with various functional groups from the Rink amide resin and (5) use the cyclic
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urethane to make the challenging peptide thioester precursor obtained from solid support through
Fmoc synthesis which would lend to important applications in the native chemical ligation of
synthetic peptides into chemically derived proteins.
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CHAPTER 2: SITE-SELECTIVE CHEMICAL CLEAVAGE OF
PEPTIDE BONDS
2.1 ABSTRACT
The cleavage of peptides and proteins is an essential tool used in bioanalytical, biotherapeutic,
and bioengineering techniques. While enzymatic digestion is the preferred method of protein
analysis, sequences which contain mutations and/or modifications deviate from nature’s design for
a native peptide/protein and tend to be resistant towards proteolysis. Therefore, there is a growing
need for chemical cleavage methods which can analyze peptidomimetics that are unable to be
recognized and processed by proteases. More recently, several methods have emerged which allow
for site-selective cleavage of extremely unreactive bonds, including amides, thereby providing
invaluable information regarding protein sequence, structure, and function. For controlled and
selective cleavage of peptide bonds, chemical cleavage must selectively bind to one or more amino
acid residues within a peptide chain and selectively cleave the peptide bond. Building on this
principle, we have developed an approach that utilizes DSC to selectively modify Ser, Thr, Cys,
and/or Glu, rendering them susceptible to peptide bond fragmentation. Subsequent incubation in
buffer leads to the hydrolysis of the peptide bond at the N-terminal side of the modified amino
acid. This methodology lends itself to peptide sequencing applications by exhibiting broad
substrate scope in the cleavage of various bioactive peptides with post-translational modifications
(e.g. N-acetylation and N-methylation) and mutations (D- and β- amino acids) which have been
implicated in age related diseases.
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2.2 CHAPTER OBJECTIVES
In this chapter, the development of an artificial chemical peptidase for site-selective cleavage
of unreactive peptide bonds at serine, threonine, and cysteine residues is discussed. The siteselective cleavage of a peptide bond is a crucial procedure in protein sequencing and various new
bioanalytical and bioengineering applications. Peptide bonds, however, are extremely stable
towards hydrolysis, with a half-life of 500-1000 years at room temperature and pH 4-8. This limits
the range of appropriate cleavage reagents, especially those that may trigger selective peptide bond
hydrolysis at specified amino acid residues. Commonly used reagents include proteases, selfcleaving intein sequences, metals, and chemical agents, such as cyanogen bromide, albeit with
certain restrictions associated with poor selectivity, efficiency and limited substrate scope,
especially related to fragmenting modified peptides or peptidomimetics. In order to address these
limitations, this strategy provides a method that selectively modifies serine, threonine, and cysteine
residues in any peptide chain and cleaves the peptide chain at the site of modification under neutral
aqueous buffer conditions. The site-selective cleavage parlays the reaction of an electrophilic
reagent with the nucleophilic hydroxymethyl group of serine/threonine and/or the thiol of cysteine
to activate the backbone amide chain. In this chapter, the rationale for site-selective modification
of these selected residues in a peptide chain, the potential for selective-cleavage under mild
conditions, and the effectiveness of the methodology for mutated and post-translationally modified
peptides is described. This artificial chemical peptidase provides a new scissile position, Pro-Ser
peptide bonds, which are typically resistant to cleavage by most proteolytic enzymes. Siteselective modification and cleavage of peptides is essential for ongoing efforts to determine the
structure activity relationship of various biologically relevant peptides/proteins in addition to their
modified analogs.
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2.3 GRAPHICAL ABSTRACT

Figure 2.1 Graphical abstract for Site-Selective Cleavage of Peptide Bonds. Figure adopted with
permission from: Elashal, H.; Raj, M. Chem. Commun. 2016, 52, 6304.1

2.4 INTRODUCTION
Site-selective cleavage of peptide bonds is an important reaction that has wide spread
application in the vast field of proteomics, including sequencing, therapeutics, and the
development of new bioanalytical techniques.2,3 Enzymatic digestion is one of the most prominent
methods of metabolizing proteins to their basic components in order to facilitate its sequence
analysis.4 Proteases that are commonly employed in protein hydrolysis include: trypsin which
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cleaves at charged residues (Arg and Lys), chymotrypsin which cleaves at aromatic residues (Phe,
Trp, and Tyr) in addition to Leu and Met, and pepsin which cleaves at residues with bulky side
chains (Leu and Phe). While proteases cleave proteins with high specificity, precision, and fidelity,
they have several disadvantages. Proteases have been known to contaminate the protein/peptide
digestion and they require specific ranges of temperature and pH for optimal activity or enzyme
denaturation can limit performance. Moreover, they lack efficacy when applied to diseased, posttranslationally modified, and unnatural sequences, where their utility is greatly needed to facilitate
the understanding of the onset of disease and the body’s purpose for modifying proteins from their
native state.

Figure 2.2 Protease digestion of a protein.
Owing to this limitation, efficient chemical cleavage methods have been developed as a way
of offsetting the limitations associated with enzymes. The most commonly utilized chemical
cleavage method is Edman degradation which gained wide spread popularity due to its broad
applicability.5 This technique utilizes phenyl isothiocyanate for N-terminal cleavage of peptides
without disrupting other peptide bonds within the peptide sequence. The cleavage process
proceeds under mild alkaline conditions; phenyl isothiocyanate is reacted with an uncharged Nterminal amino group to form a cyclized phenylthiocarbamyl derivatized moiety (Scheme 2.1). 6
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Upon the addition of acid, this N-terminal moiety is cleaved as a thiazolinone derivative which is
extracted into organic solvent. Once treated with acid, the stable phenylthiohydantoin can be
identified by utilizing chromatographic techniques or gel electrophoresis.6 While this process can
be executed repeatedly to identify the N-terminal residues in the protein chain, the efficiency of
this methodology diminishes after 30 cycles of cleavage. Moreover, the process of determining
each amino acid can be tedious and it lacks selectivity. Similar methods for N-terminal amino acid
determination include Sanger’s method, which has been widely applied in protein sequencing and
ultimately resulted in the Nobel prize awarded to Frederick Sanger in 1958.7,8

Scheme 2.1 Edman degradation. Scheme adopted from reference (6).
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More recently, chemical cleavage methodologies have been developed based on amino acid
side chain modification. These methodologies provide selectivity at the point of cleavage and they
are uncomplicated in their execution, thereby facilitating the cleavage process and analysis of
unknown sequences and/or proteolytically resistant sequences. Currently utilized selective
cleavage methods include: cyanogen bromide for Met (Scheme 2.2),9 2-nitro-5-thio-cyanobenzoic
acid,10 and dehydroalanine for Cys,11,12 and 2-iodosylbenzoic acid for Trp and Tyr.13

Scheme 2.2 Methionine mediated cleavage of peptide bonds. Scheme adopted with permission
from: Kaiser, R.; Metzka, L. Anal. Biochem. 1999, 266, 1.14
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While these techniques have proven complementary to proteases, they are limited by:
inadequate selectivity, harsh conditions and low yields.15 In the case of cyanogen bromide, the
methodology uses toxic conditions and has a limited scope due to side reactions in the presence of
methionyl-serine and methionyl-threonine.14 Most recently, diacetoxyiodobenzene (DIB) was
reported for asparagine-selective cleavage, yet oxidative modifications were observed at other
reactive amino acid residues such as Cys and Met (Scheme 2.3).16 Metals have been intensively
studied for hydrolysis of peptide bonds, but their practical use in structure determination of
proteins is still in its infancy.17-24 Even with their associated drawbacks, chemical cleavage
methods are a necessity in the analysis and characterization of proteolytically resistant
proteins/peptides. Chemical methods aid in cleaving large proteins into smaller fragments which
may be analyzed by complementary cleavage methods. They provide information regarding the
presence of a particular amino acid in the protein/peptide sequence, its quantity based on the
successful execution of cleavage, and they allow for cleavage even in the presence of unnatural
residues such as D an β amino acids.
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Scheme 2.3 Asparagine mediated cleavage of peptide bonds. Scheme adopted with permission
from reference (16).
Owing to the need for more efficient chemical cleavage methodologies that are applicable to
a broader variety of amino acids and peptide sequences, we sought to develop a chemical cleavage
method that utilizes a cyclic urethane. Chemically modifying the amide backbone chain at Ser to
include a cyclic urethane moiety renders the neighboring scissile peptide bond weak and
susceptible to hydrolysis under neutral, aqueous conditions (Scheme 2.4).
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Scheme 2.4 Rationale for the serine-selective modification and peptide cleavage in neutral
aqueous solution. Scheme adopted from reference (1) with permission.

2.5 RESULTS AND DISCUSSION
To achieve the cyclic urethane modification at Ser, reaction conditions were optimized using
varying amounts of DSC, 4-dimethylaminopyridine (DMAP), and N,N-diisopropylethylamine
(DIEA) on a model Fmoc-protected hexapeptide Fmoc-Gly-Ala-Ser-Phe-Ala-Gly [retention time
(Rt)=16.9 min)]. Previous attempts of utilizing DSC to form this cyclic urethane moiety on
Fmoc/Boc peptides lead to the formation dehydroalanine.25 Using our optimized conditions1, Ser
cyclization proceeded in 17 hrs as indicated by the sharp peak 2a with a Rt=17.9 min, which was
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analyzed by mass spectrometry (MS) (Figure 2.3). Following cyclization, the modified peptide
was incubated in phosphate buffer with a pH of 7.5 for 31 hrs, and the reaction was monitored by
HPLC. After the incubation period, the peak at 17.9 min disappeared and two new peaks appeared
which was indicative of peptide cleavage into two fragments. MS analysis of the peaks at 8.9 min
and 18.6 min proved these peaks to be the products resulting from cleavage at the N-terminal side
of Ser. The N-terminal fragment 3a eluted at 18.6 min, while the modified C-terminal fragment 4
eluted at 8.9 min.

Figure 2.3 HPLC charts of the reaction mixture of 1a and DSC (10 equiv.), DIEA (10 equiv.), and
a crystal of DMAP in DMF at (a) t = 0 h (top), (b) at t = 17 hrs (middle), and (c) after addition of
0.1 M phosphate buffer (pH 7.5) at t = 48 h(bottom) at 37 ºC. HPLC conditions: 0.1% FA (v/v) in
water, 0.1% FA in CH3CN, gradient: 0–80% in 25 min, 1.0 mL min_1 flow rate, detected at 254
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nm. Insets show the LCMS spectrum corresponding to Rt at 16.9 min (1a, top), 17.9 min (2a,
middle), 18.6 min (3a, bottom) and 8.9 min (4, bottom). Figure adopted from reference (1) with
permission.
Following initial cyclization and cleavage of Ser, we sought to determine the effects of side
chain functionality of the residue preceding Ser on the cyclization and cleavage efficiency of
peptides. Moreover, we wanted to explore the effect of reaction conditions on unprotected side
chains to determine if the reaction generated undesired side products. Using the sequence FmocGly-Xaa-Ser-Phe-Ala-Gly, various hexapeptides were synthesized to include different residues at
the Xaa position (Table 2.1).
Table 2.1 Serine-selective amide bond cleavage of Fmoc-Gly-Xaa-Ser-Phe-Ala-Gly (1a-j)a

Table 2.1 adopted from reference (1) with permission.
After incubation in buffer (pH=7.5) for 48 hrs, the C-terminal fragment Oxd-Phe-Ala-Gly
4 was obtained as a product post cleavage of all peptides with varying HPLC conversions ranging
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from 70 to 99%. Peptides which included Ala 1a, Gly 1b, Met 1c, His 1d, Tyr 1e, Trp 1f, and Asp
1i substituted at the Xaa position underwent conversion to the cleavage products after 48 hrs in a
highly efficient manner (entries 1-6 and 9, Table 2.1). This conversion proceeds smoothly in
contrast to other chemical cleavage methods which result in the over-oxidation of Tyr, Trp, and
Met containing peptides. Thus, our method is tolerable of many side chain functional groups.
Meanwhile, the peptide 1g containing Valine adjacent to Ser gave moderate yield after four days
in phosphate buffer (pH= 7.8) due to the presence of a bulky side chain (entry 7, Table). The
peptide containing Xaa= Lys 1h proceeded to modify in a unique manner due to the presence of a
free amine in the Lys side chain (Scheme 2.5). The amine side chain also reacted with DSC; upon
treatment with buffer, however, the desired Lys-Ser cleavage occurred, and an N-terminal
carboxylate lysine derivative was generated 3h in addition to Oxd-FAG-NH2. Eventually, the Nterminal carboxylated lysine derivative underwent decarboxylation of the unstable carbamic acid
to generate Fmoc-GK-OH (entry 8, Table 2.1) leaving the Lys residue unmodified. The final
substitution included Proline 1j in the position adjacent to Ser, and the cyclization and cleavage of
the Pro-Ser bond proceeded with high efficiency. Typically, enzymatic digestion at a location
neighboring to Pro is nearly unfeasible due to the cis amide bond rotation produced by Pro in the
peptide backbone which makes the enzyme active site inaccessible.26 However, in the case of
utilizing our DSC-mediated chemical methodology, peptide-bond cleavage smoothly proceeded
with a conversion of 98% which illustrated the efficiency of this technique regardless of the
neighboring amino acid to Ser.

39

Scheme 2.5 Modification scheme of lysine containing peptide. Scheme adopted from reference
(1) with permission.
Table 2.2 Substrate scope of site-selective cleavage of peptide bondsa

Table 2.2 adopted from reference (1) with permission.
The substrate scope of the reaction was further evaluated (Table 2.2). Modification of Thr
was also feasible as demonstrated by entries 1 and 2 (Table 2.2). After incubation with buffer,
cleavage was observed at the N-terminal side of Ser and Thr, which is expected due to the similar
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side chain functionality exhibited by both residues, thereby mimicking enzyme specificity towards
similar substrates. However, cyclization of Threonine’s side chain required a higher amount of
DSC, which may be due to the presence of a methyl group neighboring to the hydroxyl group
(entry 2, Table 2.2). Peptide Fmoc-GACFRFG-NH2 also underwent modification and cleavage at
the N-terminus of Cys and generated a thiazolidinone modified C-terminal fragment Thz-FRFGNH2 and the N-terminal fragment Fmoc-GA-OH. Peptides with longer lengths as well as multiple
Ser residues gave comparable results (75-79%) illustrating the utility of this methodology of
cleaving lengthy peptides into smaller fragments that are more easily analyzed (entries 3 and 4,
Table 2.2). Meanwhile, peptides that contained D-amino acid residues which are generally
resistant to enzymatic digestions due to their unnatural confirmation, were successfully cleaved
under the mild reaction conditions (entries 5 and 6, Table 2.2). Additionally, peptide 11 comprising
of an intramolecular disulfide bridge afforded the cleavage product without disrupting the disulfide
bond (entry 7, Table 2.2). Therefore, this methodology allows for the disulfide mapping, which is
an advantage over other chemical methodologies which tend to break the disulfide bond.27
While exploring the substrate scope in a Glu containing peptide 12, surprisingly, cleavage
occurred both at the N-terminal side of Glu and Ser to generate three fragments under the reaction
conditions (entry 8, Table 2.2). The activation of Glu by DSC proceeds through the formation of
a five-membered pyro-glutamyl imide moiety (pGlu) (Scheme 2.6).

41

Scheme 2.6 Modification scheme of glutamic acid to a pyro-glutamyl moiety. Scheme adopted
from reference (1) with permission.

In the presence of Asp 1i, while also containing a free carboxylic acid side chain, modification
and cleavage is not observed due to side chain length (Scheme 2.7).
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Scheme 2.7 Modification of Asp side chain vs. Glu side chain. Scheme adopted from reference
(1) with permission.
Next, compatibility with a free main chain carboxylic group was explored by synthesizing FmocGSGF-OH on Wang resin. Under the reaction conditions, cleavage was observed only at the Nterminus of Ser and generated an N-terminal Fmoc-Gly fragment and Oxd-Gly-Phe-OH as the Cterminal fragment (Scheme 2.8). This experiment in addition to the scope studied in Table 2.1
confirmed that most reactive side chains remain unmodified during the execution of these reaction
conditions, contrary to other cleavage methods which lead to the oxidation of reactive amino acid
side chains. Moreover, this method is applicable to peptide bond hydrolysis at Ser, Thr, reduced
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Cys and Glu residues. The observed rates of reaction indicated that the Ser residue was most
reactive to the DSC-mediated activation and hydrolysis conditions. Moreover, the multiple
fragmentation patterns at the selected Ser, Thr, Cys and Glu residues can facilitate peptide
sequencing of a broad range of naturally occurring peptides.

Scheme 2.8 DSC reaction scheme in the presence of a C-terminal carboxylic acid. Scheme
adopted from reference (1) with permission.
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Table 2.3 Site-selective cleavage of mutated and post-translationally modified peptides

Table 2.3 adopted from reference (1) with permission.
Subsequently, bioactive peptides, Bradykinin 1328 and type I hair keratin fragment 14, were
cleaved successfully with conversion rates ranging from 77-80% (entries 1 and 2, Table 2.3).
Furthermore, we extended the scope of the reaction conditions to the scission of bioactive peptides
with various post-translational modifications such as N-acetylated antimicrobial peptide AP00011
15, N-acetylated β amino acid containing antimicrobial peptide 16, and N-methylated bioactive
peptide 17, which serves as a substrate for cAMP-dependent protein kinases29 (entries 3-5, Table
2.3). The abovementioned modified peptides cleaved selectively at Ser with ease and high
conversion. Chemical cleavage of these peptides proceeds independently of the presence of
unnatural amino acid residues which is a great advantage over proteases which are unable to
selectively recognize and cleave these modified peptides.
Moreover, this methodology was successfully applied on an amyloid β peptide, Fmoc-Ileβ Ala-Gly-Lys-Asn-Ser-Gly-Val-NH2 18, which contained a mutated alanine β-amino acid
residue, which is a notable mutation responsible for various age-related disease such as cataracts
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and Alzheimer’s (entry 6, Table 2.3) (Scheme 2.9).30 Finally, the reaction was carried out on a
fully unprotected peptide, SGISGPLS, a fragment of antimicrobial Bovine β-defensin 13.
Treatment with DSC followed by hydrolysis generated fragments Oxd-GI, Oxd-GPL, and Oxd.

Scheme 2.9 Application of cleavage methodology on an amyloid β peptide fragment. Scheme
adopted from reference (1) with permission.

CONCLUSIONS
In this study, a site-selective approach for the cleavage of peptides at the N-terminal of Ser,
Thr, Cys, and Glu was developed by modification under metal free, mild conditions. The reactive
side chains of other amino acids remained unmodified under the optimal reaction conditions,
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which is an advantage over other chemical cleavage methods that yield modified fragments
resulting from over-oxidation. Moreover, disulfide bonds are stable to the reaction conditions,
thereby enabling the determination of disulfide positions within a peptide. The method also
demonstrated broad substrate scope including cleavage of mutated and post-translationally
modified peptides, which are unsuitable substrates for proteases. Additionally, a Pro-Ser bond was
successfully cleaved, which is generally a difficult task for proteases due to the conformational
restraints of Pro residues. Moreover, this method is also applicable to sequencing challenging
peptides that have a high propensity for aggregation such as the amyloid peptides. The latter may
be potentially applicable for determining the underlying mutations responsible for various agerelated disorders. These results provided a firm basis for subsequent studies aimed at the
development of artificial chemical proteases for the cleavage of target proteins.

2.6 EXPERIMENTAL SECTION
General: All commercial materials (Aldrich, Fluka, Nova) were used without further purification.
All solvents were reagent grade or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2,
and DMF were obtained from a dry solvent system (passed through column of alumina) and used
without further drying. All reactions were performed under air in round bottom flask. Yields refer
to chromatographically pure compounds; % conversion were obtained by comparison of HPLC
peak areas of products and starting material. HPLC was used to monitor reaction progress.

Materials: Fmoc-amino acids were obtained from Nova Biochem is under (EMD Millipore
Corporation) (Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin
was

obtained

from

ChemPep

Inc

(Wellington,

Florida).

N,N,N′,N′-Tetramethyl-O

(1Hbenzotriazol-uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville,
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Kentucky). N,N′-Disuccinimidyl carbonate (DSC) was obtained from Nova Biochem, under
(EMD Millipore Corporation) (Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP):
Merck KGaA (Darmstadt, Germany). N,N-Dimethylformamide (DMF): Macron Fine Chemicals
(Center Valley, Pennsylvania). Dichloroethane (DCE), acetonitrile, N,N-Diisopropylethylamine
(DIEA), N,N'-diisopropylcarbodiimide (DIC), were purchased from (EMD Millipore
Corporation)(Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill,
Massachusetts). Trifluoroacetic acid (TFA) was purchased from VWR 100 Matsonford Road
Radnor, PA. Diethyl Ether: Sigma Aldrich (St. Louis, Missouri). Water was purified using a
Millipore MilliQ water purification system.
NMR
This was done by Ryan Cohen at Merck facilities at Rayway, NJ. 1H NMR spectra were
recorded on a 600 MHz spectrometer and 13C NMR spectra on a151 MHz, spectrometer at ambient
temperature. All NMR chemical shifts () are referenced in ppm relative to residual solvent or
internal tetramethylsilane. 1H NMR chemical shifts referenced to residual DMSO-d6 at 2.50 ppm,
and 13C NMR chemical shifts referenced to DMSO-d6 at 39.52 ppm. 13C NMR spectra are proton
decoupled. NMR spectral data are reported as chemical shift (multiplicity, coupling constants (J),
integration). Multiplicity is reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet
of doubles (dd), doublet of triplet (td), triplet (t) and multiplet (m). Coupling constant (J) in Hertz
(Hz).
HPLC
Semi-Preparative HPLC:
Preparative HPLC chromatography (HPLC) was performed on Beckman Coulter equipped with
System Gold 168 detector and 125P solvent module HPLC with a 10 mm C-18 reversed-phase
column. All separations involved a mobile phase of 0.1% FA (v/v) in water (solvent A) and 0.1%
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FA (v/v) in acetonitrile (solvent B). Semi-preparative HPLC method using a linear gradient of 0–
80% acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate of 3.0 mL
min-1. The peptide absorbance was monitored at 220 nm (peptide bond) and 254 nm (aromatics)
unless otherwise noted.

Analytical HPLC:
Analytical HPLC chromatography (HPLC) was performed on an Agilent 1200 series HPLC
equipped with a 4.6x150 mm (5µm) C-18 reversed-phase column. All separations involved mobile
phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Peptide
compositions were evaluated by analytical reverse phase HPLC using a gradient of 0.1% FA in
acetonitrile versus 0.1% FA in water. Analytical HPLC method using a linear gradient of 0–80%
0.1% FA (v/v) acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate
of 1.0 mL min-1. The peptide was monitored by absorbance at 254 nm unless otherwise noted.

LCMS:
Mass spectrometry was performed using ultra high-performance liquid chromatography-mass
spectrometry using the Agilent 1100 Series ESI LC MSD Spectrometer.

Fmoc Solid-Phase Peptide Synthesis:31
Peptides were synthesized manually on a 0.25 mmol scale using Rink amide resin. Fmoc–group
was deprotected using 20% piperidine–DMF for 20 min to obtain a deprotected peptide-resin.
Fmoc-protected amino acids (1.25 mmol) were sequentially coupled on the resin using a HBTU
(1.25 mmol) and DIEA (1.25 mmol) for 2 h at room temperature. Peptides were synthesized using
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standard protocols.31 The peptide was cleaved from the resin using a cocktail of 95:2.5:2.5,
trifluoroacetic acid (TFA):triisopropylsilane (TIPS):water (H2O) for 2 h. The resin was removed
by filtration and the resulting solution was concentrated. The oily residue was triturated with
diethyl ether to obtain a white suspension. The resulting solid was analyzed and purified by RP
HPLC.

General procedure for cyclization: To a 5-mL round-bottom flask containing peptide (2-20mg
(1 equiv.) in 0.5-2 mL dimethylformamide (DMF) was added a solution of DSC (5-20 equiv.),
DIEA (5-20 equiv.) and crystal of DMAP in DMF (0.2-0.5 mL). The mixture was stirred at room
temperature for 10 h. The reaction was concentrated under vacuum and resulting peptide was
dissolved in 1:1 mixture of water and acetonitrile and purified by RP HPLC. The purified fractions
were lyophilized to afford cyclized peptide as a white powder; yield: (60-80 %).

NMR Chemical Shifts for Fmoc-G-Oxd:
Analysis done by Ryan Cohen utilizing Merck facilities located in Rahway, NJ. 1H NMR
chemical shifts referenced to residual DMSO-d6 at 2.50 ppm, and
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C NMR chemical shifts

referenced to DMSO-d6 at 39.52 ppm. 1 H NMR (600 MHz, DMSO-d6) δ 7.90 (d, J = 7.5 Hz, 2H),
7.75 (s, 1H), 7.72 (d, J = 7.4 Hz, 2H), 7.64 (t, J = 6.0 Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 7.39 (s,
1H), 7.33 (t, J = 7.4 Hz, 2H), 4.73 (dd, J = 9.1, 3.1 Hz, 1H), 4.60 (t, J = 9.0 Hz, 1H), 4.36 – 4.15
(m, 6H).
C NMR (151 MHz, DMSO-d6) δ 169.9, 169.1, 156.4, 153.5, 143.8, 140.7, 127.6, 127.1, 125.2,
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120.1, 66.8, 65.8, 55.4, 46.6, 44.1.
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CHAPTER 3: CYLIC AND LASSO PEPTIDES: STRUCTURE
DETERMINATION,
ROTAXANE
FORMATION,
AND
TOPOLOGY ANALYSIS
3.1 ABSTRACT
Natural products play a vital role in drug discovery and design as new peptide-based
therapeutics continue to enter clinical trials. Bioactive peptides produced by non-ribosomal
pathways such as N-methylated cyclic peptides and lasso peptides contain unique properties such
as high receptor-binding activity, specificity towards their target, metabolic stability, and
conformational rigidity. However, due to their distinctively complex topology, the ability to
effectively determine their sequence and utilize the structure activity relationship in developing
lead compounds remains limited. These limitations are primarily due to incompatibility with the
majority of available sequencing methods including enzymatic digestion, chemical methods, and
tandem mass spectroscopy. To overcome these limitations, we have developed a chemical
methodology that can modify the backbone peptide chain at Ser to generate the cyclic urethane
moiety, 2-oxazolidinone, thereby rendering the Ser N-terminal peptide bond susceptible to
cleavage under hydrolytic conditions. This fragmentation method allowed for easy and rapid
sequence determination by tandem mass spectroscopy. The methodology was applied to a broad
substrate scope including the ability to modify peptides containing Thr, Cys, Glu, and unnatural
amino acids such as homoserine which account for 60% of naturally occurring cyclic peptides.
Utilizing this methodology, the cleavage and sequencing of stable N-methylated cyclic peptides,
Polycarponin C and a Somatostatin analogue, has been accomplished. In addition, lasso peptides
lariatin A, albusnodin, and benenodin-1 have also been structurally validated. Additionally, we
created a peptide rotaxane by the selective cleavage of benenodin-1. This is the first chemical
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methodology to be effectively applied for the cleavage of lasso peptides which is a major milestone
in simplifying sequence determination of lasso peptides, studying the lasso topology, monitoring
the effect of cleavage on sterically locked residues, and using lasso peptides as scaffolds for
making rotaxane type interlocked machines.

3.2 CHAPTER OBJECTIVES
This study was a collaborative effort between our lab and the Link Lab at Princeton
University, which specializes in lasso peptides. Chuhan Zong expressed and supplied the lasso
peptides and helped in lasso data analysis post reaction. Meanwhile, cyclic peptide synthesis,
purification, modification, and analysis in addition to lasso peptide modification was executed by
the Raj group.
This chapter describes a simple and versatile chemical methodology that facilitates
sequence determination of cyclic and lasso peptides, explores the lasso topology and the effect of
cleavage on sterically locked residues, and uses lasso peptides as scaffolds for making rotaxane
type interlocked machines. This methodology is the first chemical methodology to be used for the
abovementioned applications which is a major milestone in understanding of the importance of
residue location in maintaining topologically distinct structures and harnessing their unique
activity. Based on the results described in Chapter 2, this chapter applies our strategy for the ring
opening of cyclic peptides and/or cleavage of lasso peptides to yield simplified fragments for
peptide sequencing. The significance of this approach is based on a wide substrate scope and its
compatibility with highly abundant amino acids which are found in over 60% of naturally
occurring cyclic and lasso peptides. Moreover, this method is chemo-selective and does not lead
to side reactions or byproducts in the presence of unprotected amino acid side chains. We have
developed a general method for the cleavage and sequencing of peptides with unique topologies.
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As compared to other cleavage methodologies, this method is the first chemical method to be
applied for the cleavage of N-methylated peptides and lasso peptides which provides a gateway to
further probe the mechanics of how the lasso structure is threaded and the effectiveness of steric
locks post cleavage. We have demonstrated the effectiveness of our method for the cleavage of
cyclic peptides, N-methylated cyclic peptides, and lasso peptides.

3.3 GRAPHICAL ABSTRACT
Me

MS/MS Spectrum
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Intensity
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Chemical
Cleavage
Me

Me

*Lasso *N-Me cyclic peptides
*non-ribosomal peptides
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*Rotaxanes *linear peptides
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Mass/Charge (M/z)
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Figure 3.1 Graphical abstract for Cyclic and Lasso Peptides: Sequence Determination, Topology
Analysis, and Rotaxane Formation. Figure adopted with permission from: Elashal, H. E.; Cohen,
R. D.; Elashal, H. E.; Zong, C.; Link, A.J.; Raj, M. Angew. Chem. 2018, DOI:
10.1002/anie.201801299.1

3.4 INTRODUCTION
The discovery of active natural products has been at the root of modern drug design and
they continue to play a vital role as ground-breaking peptide based drugs make their way towards
clinical trials.2 Biologically active peptides produced by non-ribosomal pathways carry unique
characteristics which allows them to have diverse functionalities.3 Specifically, cyclic peptides are
of considerable interest since they contain the following key properties: high receptor-binding
activity, specificity towards their target, metabolic stability, conformational rigidity, and the
potential to be cell permeable.4 Unique peptides such as Cyclosporine A (an immunosuppressant),5
peptides rich in N-methylation, microcin J25 (lasso peptide with anti- bacterial activity),6 and
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Kalata B17,8 (cyclotide with insecticidal activity) are all natural products with exceptional stability
and bioactivity. However, the ability to immediately study and harness the structure activity
relationship of these types of cyclic peptides in order to develop lead compounds is hindered due
to the difficulty in determining the sequence of cyclic peptides.
While enzymatic cleavage is one of the most utilized methods for peptide sequencing, lasso
peptides, cyclic peptides (especially those that are N –methylated), and other uniquely structured
peptides are resistant to enzymatic cleavage, with slower kinetic rates by 20-300 folds as compared
to their linear counterparts.9 Mechanistically, the decrease in cleavage rates results from a slower
rate of cleavage (kcat) and a weaker interaction with proteases (Km).10 On the other hand, chemical
methods for peptide bond cleavage can provide an efficient alternative to overcoming the
abovementioned limitations. However, the existing methods for selective cleavage carry several
limitations. Since cyclic peptides lack a free N-terminal amine, they cannot be sequenced via
Edman degradation.11 The most commonly used method for chemical cleavage of cyclic peptides
utilizes CNBr for the selective modification of methionine;12 however, methionine is the second
least abundant amino acid in nature,13 therefore its presence in a naturally isolated product is a
rarity. Moreover, the cleavage is dependent on the neighboring amino acids; for example if
methionine is followed by serine or threonine, side reactions convert methionine to homoserine
without peptide bond cleavage and also leads to the modification of tyrosine’s side chain.14 Due
to the lack of available chemical methods which can effectively modify abundant amino acid
residues and afford cleavage of complex cyclic peptides, their feasibility for the sequencing of
unique biologically active peptides remains limited.
While many advancements have been made in the field of sequencing technology, their
practical utility in the sequencing of naturally available cyclic peptides remains problematic. 15
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Typically, tandem mass spectroscopy is the most rapid and efficient method to determine the
sequence of a peptide. While this holds true for linear peptides, structure and sequence assignment
becomes more complicated for cyclic peptides. Cyclic peptides undergo ring opening at various
positions to generate a family of mass degenerate ions which further fragments to generate
complex mixtures of various short fragments.16-20 The interpretation of the various fragmentation
patterns becomes difficult and impractical. Moreover, analysis of the MS/MS spectra is also
hindered by the lack of defined N and C termini. Additionally, many biologically active peptides
are synthesized through non-ribosomal pathways which increases the likelihood that unnatural
amino acid residues may be present in the peptide which adds to the complexity of spectroscopic
analysis. To this end, nuclear magnetic resonance spectroscopy (NMR) remains the only viable
method for accurately predicting the structure and sequence of cyclic peptides, lasso peptides, and
other peptides with distinct topologies. Furthermore, wrongful assignment of NOE contacts can
lead to an inaccurate structure determination.21 For example, a branched- cyclic peptide can be
mistaken for a lasso structure and the opposite is also true.21 Therefore, careful, lengthy, and
tedious data interpretation are required in order to yield the correct sequence and structure
assignment of peptide natural products through NMR.
In this chapter, a simple and convenient approach for sequence determination of nonribosomally produced highly stable lasso peptides and cyclic peptides with unnatural amino acid
residues and N-methylation is reported. The methodology entails the site-selective amine
backbone activation at Ser, Thr, Glu, and/or Cys. Upon activation, the amide bond at the Nterminal side of the residue(s) becomes susceptible to cleavage thereby converting the peptide into
its linear counterpart which can easily be sequenced by MS/MS. The proposed strategy has a broad
substrate scope and is compatible with some of the most highly abundant amino acids found in
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nature.13 To implement this approach, at least one Ser, Thr, Glu, or Cys should be present in the
desired cyclic peptide, which is of high probability due to the presence of at least one of the
abovementioned residues in approximately 60% of naturally occurring cyclic peptides and 66% of
lasso peptides as determined by a survey sample screened through NORINE,
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a cyclic peptide

database, and a comprehensive list of all lasso peptides discovered to date.21 Additionally, this
methodology can also be utilized to modify various unnatural amino acid residues that are readily
found in numerous bioactive cyclic peptides obtained from nature. Unnatural amino acids with a
reactive side chain functionality such as a hydroxyl group or an amine and have the ability to form
a five membered or six membered ring would be compatible with this strategy. For example,
homoserine, beta-hydroxy-Phe (β-OH-Phe), β-OH-Asn, β-OH-Gln, β-OH-Asp, β-OH-Val, β-OHTyr, and beta homoserine (β-Hse) are amongst the unnatural amino acids which fulfill these
criteria. Moreover, this method is chemo-selective and does not interfere with any other
unprotected amino acid side chain; it does not generate byproducts or lead to side reactions. To
the best of our knowledge, this is the only chemical method available that has a potential of
sequencing more than 60% of lasso peptides and N-methylated cyclic peptides which is a
significant advancement as compared to pre-existing techniques.

3.5 RESULTS AND DISCUSSION
Due to the difficulties associated with utilizing tandem mass spectroscopy for cyclic
peptide analysis, we developed a strategy that converts these peptides to their linear counterparts.
Upon linearization of the cyclic peptide, the previously mentioned obstacles related to the use of
MS/MS for sequence determination become eliminated thereby simplifying the process of MS/MS
analysis. The proposed strategy involves the conversion of Ser to an oxazolidinone moiety, thereby
making the amide bond susceptible to cleavage at the Ser N-terminus under hydrolytic conditions.
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The modification of Ser encompasses the reaction of its hydroxymethyl group with N,Ndisuccinimidyl carbonate (DSC) to generate an intermediate (Scheme 3.1). Next, nucleophilic
attack of the amide nitrogen of the peptide backbone produces the desired 2-oxazolidinone moiety.
Upon formation of 2-oxazolidinone, the C-N bond is easily hydrolyzed under mild conditions to
generate a ring-opened (linear) peptide. Earlier attempts at the formation of this moiety on
Fmoc/Boc protected peptides led to the formation of dehydroalanine.23 This methodology is also
applicable to Thr and Cys which exhibit similar side chain functionalities as serine. Moreover,
glutamic acid also serves as a substrate for this modification due to its nucleophilic side chain
which has the ability to form a pyroglutamyl imide moiety. Our group previously reported the
application of this moiety for the synthesis of thioesters and for the cleavage of linear peptides.24,25

Scheme 3.1 Macrocyclic Peptide Sequencing Strategy. Scheme adopted from reference (1) with
permission.
Using previously determined reaction conditions,25 we proceeded to sequence
Polycarponin C, a mono-methylated cyclic peptide with anti-cancer activity.26 First, we incubated
the peptide with chymotrypsin27 since it contains a phenylalanine to assess if enzymes can be
utilized for opening of these N-methylated peptides. After 48 hours, no detectable cleavage of
Polycarponin C was noted which confirmed the limitation of using enzymatic degradation in
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sequencing of these peptides (Figure 3.2a). Next, direct MS/MS analysis was carried out in an
effort to determine the peptide sequence without any modification (Figure 3.2b). However, the
spectra generated complex fragmentation patterns that were difficult to assign. Moreover, several
fragments corresponded to the same mass, which made accurate assignment a challenging task.
We then proceeded to selectively modify the peptide backbone chain at the N-terminus of Thr by
using DSC, which is otherwise very stable and has a half-life of 500-1000 years at pH 4-8.28
Following the treatment with DSC, the peptide was hydrolyzed to its linear counterpart under mild
aqueous buffer conditions (pH 7.4) at room temperature (Figure 3.2c). Noteworthy, the cleavage
proceeded smoothly even in the presence of a Pro residue neighboring the site of cleavage which
highlights a key advantage over enzymatic digestion which cannot proceed in the presence of a
nearby Pro.29 Upon analysis of the linear counterpart by MS/MS, the spectra clearly showed the
ring opened peptide with a clear fragmentation pattern that is easier to decipher as compared to the
MS spectra obtained by direct analysis of the cyclic peptide (Figure 3.2c).
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Figure 3.2 Sequencing polycarponin C. a) HRMS spectrum after 48 h incubation with
chymotrypsin showing proteolytic resistance, b) complex MS/MS spectrum of polycarponin C,
and c) simplified MS/MS spectrum of its ring-opened analogue. Figure adopted from reference (1)
with permission.
Next, we sought to sequence a stable tri-N-methylated Somatostatin analogue.30 After
incubation with a mixture of trypsin and chymotrypsin27 for 48 hours, the peptide remained intact,
with no observable cleavage (Figure 3.3). Direct MS/MS analysis was also troublesome due to the
complications noted above. Conversely, upon utilizing our method for sequencing, the peptide was
opened to its linear counterpart following Thr activation and hydrolysis (Figure 3.3). By applying
our methodology on these two cyclic peptides, we have demonstrated the efficiency of our strategy
in the sequencing of bioactive cyclic peptides containing multiple methyl groups.

Figure 3.3 Sequencing data for a somatostatin analog. A) HRMS spectrum after protease
incubation showing no detectable cleavage, b) MS/MS spectrum of cyclized peptide, and c)
MS/MS spectrum of ring-opened peptide. Figure adopted from reference (1) with permission.
To demonstrate compatibility of our method with unnatural amino acids which are
abundant in cyclic peptides isolated from nature, we synthesized one such model cyclic peptide
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Gly-Tyr-Val-Hse-Phe-Leu-Ala containing homoserine (Hse). Due to hydroxyl side chain of
homoserine and the side chain proximity to the amidic nitrogen, we hypothesized that homoserine
can effectively react with DSC to form a six-membered oxazinanone ring making the homoserine
N-terminal amide bond susceptible to hydrolysis (Figure 3.4). As predicted, homoserine in a cyclic
peptide underwent modification upon treatment with DSC to a 6-membered ring followed by
hydrolysis to its linear counterpart under neutral buffer conditions.
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Figure 3.4 Cleavage data for Homoserine (Hse)-containing macrocyclic peptide. HRMS spectra
of (a) cyc-Gly-Tyr-Val-Hse-Phe-Leu-Ala, (b) activated six-membered oxazinanone moiety, and
(c) hydrolytically-cleaved linear peptide, which is amenable for MS/MS sequencing. Figure
adopted from reference (1) with permission.

We have also applied this approach for sequencing a model cyclic peptide with serine
residue cyc(Ser-Phe-Arg-Tyr-Ala-Glu) by selective modification of serine to 5-membered 2oxazolidinone moiety followed by the cleavage of the backbone chain at the N-terminus of serine
under hydrolytic conditions (Figure 3.5). The resulting linear peptide was then sequenced by
tandem mass spectrometry. By displaying applicability to homoserine in addition to Ser, Cys, Thr,
and Glu, we can effectively apply our method to sequence over 60% of naturally occurring cyclic
peptides.

Figure 3.5 Serine activation to cyclic urethane moiety. a) 4: Rt = 9.3 min, b) 5: Rt = 10.8 min, c)
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6: Rt = 10.3 min. Rt = retention time. Inset shows MS of compounds 4, 5 and 6. Figure adopted
from reference (1) with permission.
To further assess the scope of our methodology, we explored the applicability of our
strategy with lasso peptides which are known for their wide range of bioactivity including
antimicrobial, enzyme inhibitory, and receptor antagonistic in addition to their unique topology
which contains a ring, loop, and a tail component.21,31 Sequencing of this distinctive class of
peptides is problematic due to the unique lasso topology which is highly stable toward enzymatic
cleavage by common digestive enzymes. On the other hand, isopeptidases have been found in
organisms that express lasso peptides. These isopeptidases have the ability to cleave only the
isopeptide bond present in the ring to yield a ring opened linear peptide.32-35 However, each
isopeptidase is specific only to the lasso peptide isolated from the same prokaryote.32-35 Therefore,
there is a need for chemical cleavage methods since there is no general method that can further
assist in the sequence determination of the majority of lasso peptides.
To test the stability of lasso peptides towards enzymes before proceeding with cleavage
through chemical modifications, we chose lariatin A and albusnodin. Lariatin A is an antimicrobial
lasso peptide which contains an Arg residue in the ring region,36 while albusnodin, another lasso
peptide, contains two consecutive Arg residues in the loop region.37 Since Arg is a substrate for
trypsin, we treated both peptides with trypsin to investigate if cleavage would occur. After
incubating the peptides with trypsin overnight, no observable cleavage was detected, thereby
confirming the resistance of lasso peptides to proteolytic degradation. As further proof, we also
incubated lariatin A with a mixture of trypsin and chymotrypsin since it also contains Trp, a
substrate for chymotrypsin. After 24 hr, lariatin A remained completely intact. In fact, the lasso
spectra after treatment with enzymes looks more complicated because these enzymes cleave
themselves and generate multiple small fragments.
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Figure 3.6 Sequencing data for lasso peptide, lariatin A. MS/MS spectra of the fully ring-opened
peptide, C, and cleavage product, A, from reaction at Ser-13, which is present at the steric lock
region. Figure adopted from reference (1) with permission.
We then proceeded to utilize our methodology for the cleavage of lariatin A and albusnodin
since both peptides contain Ser within their sequence. Since lariatin A contains two Ser, one in the
ring and the other in the loop region, we expected that treatment with DSC overnight will modify
only the Ser which is present in the ring because the serine present in the loop region is threaded
inside the ring making it less exposed. To our surprise, the major product was modification of Ser13, and after hydrolysis, this generated a branched, cyclized peptide (A) and a short, linear peptide
(B). A small amount of the expected branched, ring-opened product (C) was also observed;
however, unexpectedly Lys17 was converted into a cycloocta-urea moiety (Figure 3.6). Previously
on short model peptides, modification of the Lys side chain amino group was observed after
treatment with DSC to the corresponding carbamic acid that subsequently would regenerate Lys
under the hydrolytic conditions.25a However, in this case, Lariatin A’s molecular topology may
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facilitate intramolecular ring formation. Meanwhile, albusnodin has one Ser located in the ring
region of the peptide which was expected to afford a linear peptide upon hydrolysis.25b Treatment
with DSC and subsequent hydrolysis efficiently yielded the conversion of albusnodin to a ring
open peptide. Although albusnodin has two Arg residues, no lasso peptide cleavage was observed
upon treatment with carboxypeptidase and trypsin which emphasizes the high stability of lasso
peptides towards enzymes even in the presence of two enzymatic cleavage sites.
Notably, efficiency of the reaction conditions decreases when applied to lasso peptides due
to variations in structure such as loop size, ring size, steric locks, and residues threaded through
the ring making them difficult to access. However, even with lower conversion rates, the cleaved
product is enough to conduct MS/MS analysis thereby providing insight into lasso sequencing and
structure determination.
In addition to exploring our strategy with the above-mentioned lasso peptides, we also
studied reactivity with benenodin-1, another lasso peptide. Benenodin-1 is unique to our study
since it contains three possible cleavage sites. It contains Ser, Thr, and Glu in the loop region of
the peptide.32 It was interesting to monitor if modification and cleavage of Glu would occur since
it serves as a steric lock.31 Interestingly, we observed the modification and cleavage of only Ser in
benenodin-1 which resulted in the formation of a rotaxane structure (Figure 3.7). Rotaxanes have
an interlocked architecture where a dumbbell shaped molecule is threaded through a macrocyclic
ring which gives them immense potential as molecular machines.38-40 In the case of benenodin-1,
Glu and Gln serve as steric locks which prevent the un-threading of the linear peptide obtained
after cleavage at the N-terminus of Ser thereby disconnecting the loop from the ring portion. This
result showed that our methodology has the potential to utilize lasso peptides as scaffolds for the
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formation of rotaxanes and various other interlocked peptide based molecular machines which are
challenging to make through the available synthetic methods.41

Figure 3.7. LC-MS of a rotaxane obtained from the modification/cleavage at Ser-9 of benendonin1 ΔC5. Figure adopted from reference (1) with permission.
Other benenodin-1 ΔC5 cleavage products were also observed from Ser, Thr, and Glu residues
that facilitated sequencing (Scheme 3.2). In these cases, linear peptides were generated from the
loop region. Cleavage at or near the steric lock unthreads the loop from the ring, while distal site
cleavage generates the rotaxane structure through conservation of the threaded architecture.

Scheme 3.2 Benenodin-1 ΔC5 Cleavage Products. Figure adopted from reference (1) with
permission.
67

Overall, our approach simplifies the complicated lasso topology to simple fragments such as
linear peptides and/or ring-tail peptides which can then be easily sequenced by further enzymatic
digestion and/or tandem mass spectroscopy. Importantly, this method also has the potential to
make peptide rotaxanes from lasso scaffolds.

3.6 CONCLUSIONS
We have developed a general method for the cleavage and sequencing of peptides with
unique topologies. We have demonstrated the effectiveness of our method for the cleavage of
cyclic peptides, N-methylated cyclic peptides, and lasso peptides. As compared to other cleavage
methodologies, this method is the first chemical method to be applied for the cleavage of Nmethylated peptides and lasso peptides which provides a gateway to further probe the mechanics
of how the lasso structure is threaded and the effectiveness of steric locks post cleavage. Moreover,
this methodology has a broad substrate scope due to its reactivity with highly abundant residues
including Ser, Thr, Glu, and Cys as well as it compatibility with several unnatural amino acid
residues such as homoserine and other beta-hydroxy amino acids. Overall, this methodology
provides a means with the potential to sequence over 60% of naturally occurring cyclic peptides
and 66% of all lasso peptides. Adding to its attractiveness, this methodology is selective to the
abovementioned residues; it does not react with other unprotected amino acid side chains, generate
byproducts, or lead to any side reactions. By utilizing this methodology, we are able to sequence
peptides with unique structures, study the effect of loop size and residue location on lasso peptide
cleavage, make interlocked structures like rotaxanes from lasso scaffolds, and provide a platform
for discovering newly isolated biologically active peptides.
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3.7 EXPERIMENTAL SECTION
General: All commercial materials (Sigma-Aldrich, Fluka, and Novabiochem) were used without
further purification. All solvents were reagent or HPLC (Fisher) grade. Diethyl ether,
dichloromethane, and N,N-dimethylformamide were obtained from a dry solvent system (passed
through an alumina column) and used without further drying. All reactions were performed under
air in glass vials. HPLC was used to monitor reaction progress.
Materials: Fmoc-amino acids were obtained from Novabiochem (EMD Millipore Corporation,
Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide, Wang, and 2chlorotrityl (2-ClTrt) resins were obtained from ChemPep Inc. (Wellington, Florida). N,N,N′,N′Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) was obtained from
CreoSalus (Louisville, Kentucky). N,N′-Disuccinimidyl carbonate (DSC) was obtained from
Novabiochem (EMD Millipore Corporation, Billerica, Massachusetts). 4-Dimethylaminopyridine
(DMAP) was obtained from Merck KGaA (Darmstadt, Germany). N,N-Dimethylformamide
(DMF) was obtained from Macron Fine Chemicals (Center Valley, Pennsylvania). Acetonitrile,
N,N- diisopropylethylamine (DIEA), triisopropylsilane (TIPS), and N,N'-diisopropylcarbodiimide
(DIC) were purchased from Novabiochem

(EMD Millipore Corporation, Billerica,

Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts).
Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road Radnor,
Pennsylvania). Diethyl ether, dichloromethane (DCM), methanol (MeOH), phenylsilane, 1hydroxy-7-azabenzotriazole (HOAt), tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4], 2nitrobenzenesulfonyl
tetrahydrofuran

chloride

(THF),

(o-NBS-Cl),

diisopropyl

2,4,6-trimethylpyridine,

azodicarboxylate

(DIAD),

triphenylphosphine,

mercaptoethanol,

1,8-

diazabicyclo[5.4.0]undec-7-ene (DBU), acetonitrile, toluene, dimethyldichlorosilane, and
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1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) were obtained from Sigma-Aldrich (St. Louis,
Missouri). Water was purified using a Millipore Milli-Q water purification system. Lariatin A was
purchased from Abcam (Cambridge, Massachusetts).
LC-MS:
A Portion of analysis was done at Seton Hall University; the other portion was done at Merck
facilities at Rahway, NJ by Ryan Cohen. Peptide compositions were evaluated by high
performance liquid chromatography (HPLC) on an Agilent 1100 series HPLC equipped with a
4.6x150 mm (5µm) C18 column. All separations used mobile phases of 0.1% formic acid (v/v) in
water (solvent A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). A linear gradient of 0–
80% solvent B in 30 minutes at room temperature with a flow rate of 1.0 mL min-1 was used. The
eluent was monitored by UV absorbance at 220 nm unless otherwise noted. Mass spectrometry to
check reaction mixtures was performed on an Agilent 1100 Series HPLC with MSD VL mass
spectrometer using positive polarity electrospray ionization (+ESI).
LC-HRMS:
Analysis was done at Merck facilities at Rahway, NJ by Ryan Cohen. High resolution MS data
were acquired using an Agilent 1290 UHPLC with a 6520 Q-ToF mass spectrometer under positive
polarity electrospray ionization (+ESI) with capillary and fragmentor voltages set to 3.5 kV and
175 V, respectively. The instrument was calibrated prior to data acquisition using Agilent’s
reference standard solution, which provided accurate masses within 5 ppm. A reversed phase,
linear gradient separation was performed at a flow rate of 1.0 mL min-1 on a C18 column (Waters
Acquity UPHLC peptide BEH C18, 1.7 µm particle size, 50 mm x 2.1 mm I.D.) thermostatted at
45°C and gradient from 95% solvent A (0.1% formic acid in water) to 99% solvent B (0.1% formic
acid in acetonitrile) in 4 minutes, followed by 1 minute re-equilibration.
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MS/MS:
A portion of analysis was done was done at Merck facilities at Rahway, NJ by Ryan Cohen;
the other portion was done at Princeton University by Chuhan Zong. Tandem MS analyses
were performed either on an Agilent 1260 HPLC coupled with a 6530 Q-ToF or on an Agilent
1290 HPLC coupled with a 6520 Q-ToF mass spectrometer. Both mass spectrometers were
operated under electrospray ionization in positive polarity (+ESI). Reverse phase C18 gradient
separation conditions were used (mobile phase A = 0.1% formic acid in water and mobile phase B
= 0.1% formic acid in acetonitrile). Spectra were acquired in profile mode with collision energies
ranging from 25-90 V and nitrogen (N2) as collision gas.
General Procedure for Fmoc Solid-Phase Peptide Synthesis:
Peptides were synthesized manually using standard protocols42 with either Rink amide resin (0.25mmol scale) for Ser-Phe-Arg-Tyr-Ala-Glu or 2-ClTrt resin (0.175-mmol scale) for N-methylated
peptides. Fmoc-protected amino acids were sequentially coupled on the resin with an excess of
HBTU and DIEA for 2 hrs at room temperature. Fmoc was deprotected with a 20% v/v piperidine
in DMF solution for 20 min.
Macrocyclization of Linear Peptide, Ser-Phe-Arg-Tyr-Ala-Glu, on Solid Support:
To peptide, Ser-Phe-Arg-Tyr-Ala-Glu, containing O-allyl protected glutamic acid on solid support
(50 mg, 0.69 mmol/g) was added a 3 mL solution of 20 mg Pd(PPh3)4 and 72 µL phenylsilane in
DCM. This solution was incubated on a shaker at room temperature for 40 minutes. The resin was
washed with DCM (3 X 2 min). The above reaction was repeated, and then the resin was washed
with DCM (3 X 2 min), MeOH (3 X 2 min), and DMF (3 X 2 min). The palladium catalyst was
removed from the resin by washing with DIEA in DMF (2% v/v) (2 X 2 min) and then with DMF
(2 X 2 min). Next, the peptide was treated with 20% piperdine in DMF to remove the Fmoc
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protection. Macrocyclization was achieved by exposing the resin to DIC, HOAt, and a catalytic
amount of DMAP in DMF on a shaker for 15 hrs. The solution was drained, and the resin was
washed with DMF. To confirm complete macrocyclization, the Kaiser test43 was performed, which
showed yellow bead coloration indicating absence of free amino groups. The peptide was then
cleaved from the resin by 2 hrs incubation with a solution of TFA:TIPS:water (95/2.5/2.5, v/v/v).
Resin was removed by filtration, and the resulting solution was evaporated. The peptide was
purified by reversed-phase semi-preparative chromatography.
N-Methylation of Linear Peptides on Solid Support:
N-methylated residues were synthesized on solid support using a reported method involving oNBS
protection.43 A 155 mg o-NBS-Cl and 230 µL trimethylpyridine solution in 5 mL DMF was added
to the resin and shaken at room temperature for 30 minutes, which was then filtered and washed
with DMF. The protection step was then repeated, followed by 5X washing with DMF. The resin
was soaked in THF and then dried under vacuum. A solution of 230 mg triphenylphosphine and
2.5 µL MeOH in 2.5 mL THF was added to the resin and shaken for 5 minutes. The resin was then
treated with a solution of 175 µL DIAD in 2.4 mL THF (added portion-wise at 500 µL each time
and shaken for 10 minutes). The resin was then filtered and washed with DMF. Mitsunobu
conditions were repeated once more. Finally, oNBS deprotection proceeded by soaking the resin
in DMF, followed by 10 minute exposure at room temperature while shaking in a 5 mL DMF
solution containing 122 µL 2-mercaptoethanol and 131 µL DBU, and then filtering and washing
with DMF. Deprotection was repeated once.
Macrocyclization of N-methylated Peptides in Solution:
Peptides were cleaved from the resin with a 20% v/v HFIP solution in DCM. The DCM was
evaporated, and linear peptides were purified by chromatography. Cyclization occurred with 20
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mg HOAt, 20 µL DIC in dry DMF per 2 mg of peptide. Side chain protecting groups were then
deprotected by adding a solution of TFA:TIPS:water (95/2.5/2.5, v/v/v) and incubating the solution
for 2 hrs. N-methylated macrocyclic peptides were then purified by reversed-phase semipreparative chromatography.

Albusnodin Expression and Purification:
This portion of work was done by Chuhan Zong at Princeton University. For a typical
heterologous production of albusnodin, Streptomyces strains were cultured in GYM medium with
total volume of 1 L. All strains were cultured in 5 x 1000 mL Erlenmeyer flasks (each flask
contained 200 mL of GYM medium) that were treated with 1 mL dimethyldichlorosilane in toluene
to minimize the culture from sticking to the glass wall and a stainless steel spring was placed at
the bottom of each flask to improve aeration. Starting cultures were inoculated with 2 x 109 spores
in 150 mL 2YT medium and incubated at 30 °C with orbital shaking (350 rpm) for 8 h. The
germlings were harvested by centrifugation at 2,000 x g, resuspended in 25 mL of GYM medium,
dispersed by a quick sonication pulse, and used to inoculate production cultures at a starting OD450
of 0.005. Production cultures were incubated at 30°C with orbital shaking (250 rpm) for an
additional 7 days. The cell lysate and supernatant of the samples were separated by centrifugation
at 8,000 x g at 4 ◦C for 20 minutes. The cells were lysed in methanol. The insoluble fraction was
removed by centrifugation at 8,000 x g at 4 ◦C for 10 minutes, and the methanol-soluble fraction
was dried using rotary evaporation and then resuspended in 500 μL of 50% acetonitrile and 50%
water solution. The supernatant was extracted using a Strata C8 column (Phenomenex 6 mL size).
The crude extract was eluted from the column using methanol, and dried using rotary evaporation,
and then reconstituted in 500 μL of a solution of acetonitrile / water (1:1, v/v).
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Benenodin-1 ΔC5 Expression and Purification:
This portion of work was done by Chuhan Zong at Princeton University. Benenodin-1 ΔC5
was obtained as previously described.32 Briefly, the lasso peptide was expressed using E. coli BL21
cells with the plasmid, pCZ35, containing the lasso peptide gene cluster. Cultures were grown at
37°C in 100 µg/mL LB-ampicillin broth. Cells were harvested by centrifugation and then lysed in
MeOH. The lysate containing the peptide was purified by solid phase extraction followed by
reversed-phase semi-preparative chromatography.
General Procedure for Activation of Ser, Thr, Cys, Glu, and Hse Residues within
Macrocyclic Peptides and Lasso Peptides:
Per cleavage site in 1 mg of peptide, excess DSC (25 mg), DIEA (20 µl of a 20% vol/vol solution
in DMF), and a crystal of DMAP were added to macrocyclic or lasso peptides in 450 µl DMF in a
5 mL round bottom flask. The reaction mixture was agitated using an orbital shaker for 16 hours
to modify desired cleavage residues. The mixture was then removed and DMF was evaporated.
General Procedure for Ring-Opening of Macrocyclic and Lasso Peptides:
0.45 mL of phosphate buffer (pH 7.6) was added to the activated macrocyclic or lasso peptide.
This mixture was then agitated on an orbital shaker at 37°C for 48 hours and then checked by LCMS to ensure complete cleavage.
Procedure for Protease Incubation.
Incubation of macrocyclic and lasso peptides with chymotrypsin and/or trypsin were conducted
using a 50 mM NH4HCO3 digestion buffer. The peptide substrates were treated with 50 μl of 0.1
μg/μL protease (sequencing grade) in a total volume of 800 μL for each protease alone or 1600 µL
for both trypsin and chymotrypsin together. Incubation was carried out for 48 hours at 37°C and
samples were then analyzed by LC-HRMS.
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CHAPTER 4: OXAZOLIDINONE MEDIATED SEQUENCE
DETERMINATION OF ONE BEAD ONE COMPOUND CYCLIC
PEPTIDE LIBRARIES
4.1 ABSTRACT
Cyclic peptides are attractive therapeutics for drug discovery due to high proteolytic
stability, permeability, and high binding affinity. The therapeutic ability of cyclic peptides
prompted the synthesis of cyclic peptide libraries by split and pool methods for High Throughput
Screening (HTS) against various biological targets. A major obstacle associated with this approach
is the sequencing difficulty of hit cyclic peptides obtained by HTS using traditional sequencing
methods such as NMR, MS/MS, and enzymatic digestion. Therefore, we developed a one bead
one compound (OBOC) dual ring opening/cleavage approach for sequencing of hit cyclic peptides
by selective modification of a serine residue to an oxazolidinone moiety within the cyclic peptide
and as a linker to allow for the liberation of the protected linear peptide into solution. Formation
of the oxazolidinone moiety increases the susceptibility of the amide bond at the N-terminus of
serine towards hydrolysis and leads to the opening of a cyclic peptide to its linear counterpart and
simultaneous release of the resulting linear peptide from the solid support. The resulting linear
peptide in solution was then sequenced in one minute by a liquid chromatography, ion mobility
spectrometry, tandem mass spectrometry (LC-IMS-MS/MS) method, which provided faster
sequencing of the ring opened peptides due to its inherently high peak capacity. To extend this
approach, libraries of cyclic peptides (4-10 amino acids) containing different combinations of
amino acids were successfully synthesized and sequenced with 98% overall accuracy,
demonstrating the robustness and versatility of this methodology.
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4.2 CHAPTER OBJECTIVES
In this chapter, a simple and versatile one bead one compound approach for determining
the sequence of libraries of cyclic peptides on solid support is described. A methodology based on
the selective-activation of the backbone amine chain of cyclic peptide libraries was developed,
which will facilitate the sequencing of HIT peptides post biological screening. This technique can
be revolutionary in decreasing the amount of time spent in determining HIT sequences, thereby
paving the way for rapid development of lead compounds into therapeutic drugs.
The strategy entails the selective activation of the amide backbone chain at serine,
threonine, and/or cysteine residues for the ring opening and sequencing of HIT cyclic peptides.
The significance of this approach is that encoding tags or toxic reagents are not required for
determining the sequence, which makes it distinct from the currently used methods. Moreover,
this method is compatible with free amino acid side chains and does not lead to any side reactions.
Another major advantage of this approach is that disulfide bonds remain stable under the reaction
conditions, thus it has a potential to be applicable for the sequencing of cyclic peptides rich in
disulfide bonds. In addition, the IMS-MS technique was used in an unprecedented manner for the
rapid sequencing of cyclic peptides from the crude mixture; this portion of the study was done by
Ryan Cohen. The use of IMS-MS reduces the time for sequencing of one cyclic peptide by 20-fold
as compared to traditional MS/MS methods.

4.3 GRAPHICAL ABSTRACT
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Figure 4.1 Graphical abstract for Oxazolidinone Mediated Sequence Determination of One Bead
One Compound Cyclic Peptide Libraries. Figure adopted with permission from: Elashal, H. E.;
Cohen, R. D.; Elashal, H. E.; Raj, M. Org. Lett. 2018, 20 (8), 2374.1

4.4 INTRODUCTION
Cyclic peptides are of considerable interest due to their powerful potential as therapeutic
agents.2-5 Compared to their linear counterparts, cyclic peptides exhibit high receptor-binding
affinity, specificity, and stability due to their high conformational rigidity.6 Owing to their unique
character, cyclic peptides are suitable tools for drug discovery. The therapeutic ability of cyclic
peptides has prompted the synthesis of cyclic peptide libraries by split and pool methods7 followed
by high-throughput screening against biological targets to determine “hit” peptides.8 However,
their utility is hindered by the challenges that accompany the sequencing of the cyclic peptides.
While enzymatic cleavage is one of the most utilized methods for peptide sequencing, it is
incompatible with cyclic peptides; cyclic peptides are resistant to enzymatic cleavage by 20-300
folds as compared to their linear conterparts.9 Mechanistically, the decrease in cleavage results
from both a lower rate of cleavage (kcat) and a weaker interaction with proteases (Km).10 Since
cyclic peptides lack a free N-terminal amine, they cannot be sequenced via Edman’s degradation.11
Meanwhile, tandem mass spectroscopy (MS/MS), another widely employed sequencing method,
affords complex fragmentation patterns, which are difficult to interpret.12-16 Many attempts have
been made in developing methods to overcome the challenges associated with sequencing hit
macrocyclic peptides. The first utilized method in sequencing of hit cyclic peptides consisted of
one-bead one-compound (OBOC) libraries that employed genetic encoding tags to record
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synthesis history (Scheme 4.1).17-19 Nonetheless, OBOC is mainly compatible with natural amino
acid containing peptides therefore its use in sequencing of cyclic peptides is of limited practicality.
Meanwhile, the ladder synthesis involves capping small amounts of the peptide after each coupling
before the final macrocyclization of the peptide to track the cyclic peptide sequence (Scheme 4.1).
However, this approach is limited by interference from the small linear peptides (encoding tags)
during the screening process.20
To combat the abovementioned limitations, Pei and co-workers developed a one-bead twocompound (OBTC) method consisting of segregated bilayer beads allowing each bead to constitute
two elements.21,22 A cyclic peptide is exposed on the surface for screening, while the inside
contains its linear counterpart for sequencing (Scheme 4.1). The disadvantage of this approach is
that the cyclization step cannot be monitored due to the presence of the linear peptide tag. 21
Another major limitation associated with this method is that it cannot be used for sequencing cyclic
peptides obtained from nature. More recently, strategies based on opening the macrocyclic ring
post screening have been developed as an alternative to bead-based assays.23 These methods rely
on incorporation of specific moieties into the cyclic peptide that can be chemically cleaved,
resulting in the linear form which allows sequencing of hit cyclic peptides via MS/MS.
In this manner, Lim and co-workers introduced an alkylthioaryl bridge into cyclic peptides,
which is cleavable upon oxidation of the thioether by mCPBA to generate the linear peptide. 24
However, the oxidation reaction is not specific to the thioether, consequently, other functional
groups such as guanidines and primary amines are also oxidized during the ring-opening reaction
leading to complicated MS/MS fragmentation. Moreover, this method utilizes toxic cyanogen
bromide (CNBr) for the cleavage of cyclic peptides.
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Scheme 4.1 Literature methods for sequencing of cyclic peptides. A) One-bead-one-compound
method (Adopted from reference [22] with permission) B) Ladder synthesis method (Adopted
from reference [20] with permission) C) One-bead-two-compound method (Adopted from
reference [21] with permission) D) Alkylthioaryl bridge method (Adopted from reference [24]
with permission)
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Recently, the Kodadek25 and Biron26 groups reported the use of a methionine residue for
linearization and cleavage of cyclic peptides/peptoids from the solid support which is appealing in
the sense that a natural amino acid is incorporated into different sequences for ring opening
(Scheme 4.2). Nonetheless, complicated inverse peptide synthesis, side reactions, long cleavage
times, and the use of toxic CNBr for cleavage detract from the attractiveness of this method.
Most reported methods require aggressive chemical reagents or post-screening reactions
that could lead to side-chain modifications. Conversely, Biron and coworkers have reported the
utilization of a photo-cleavable moiety, β-amino acid 3-amino-3-(2-nitrophenyl)propionic acid
(ANP), for the ring opening and release of the peptide from the resin (Scheme 4.2).27 Although
this approach is reagent free and utilizes UV radiation for the opening of the cyclic ring, it remains
limited by the formation of a mixture of various linear peptide side products, leading to
complicated HPLC and MS/MS data interpretation. Another major limitation is that this method
leads to the oxidation of the Met and Trp side chains. In addition, the synthesis and screening of
these cyclic peptides must be done in the dark to prevent opening of the macrocycle or cleavage
from the resin.27 Due to the sensitivity of the ANP moiety towards light, the cyclic peptides
containing the ANP unit cannot be stored for long term use. A major advantage of the ring-opening
strategy is that the same chemical entity is displayed inside and on the surface of the bead thus
eliminating the risk of interference by coding tags during the screening, which is in contrast to the
OBTC and ladder synthesis methods. Moreover, the cyclization step can be easily monitored to
ensure a complete conversion to the cyclic peptide. Based on these strategies, our research goal
was related to the development of an efficient and single-step ring-opening approach that would
be compatible with free amino acid side chains and would not require the use of harsh chemical
reagents.
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Scheme 4.2 Literature methods for cleavage of cyclic peptides. A) Kodadek’s CNBr method
(Adopted from reference [25] with permission) B) Biron’s CNBr method (Adopted from reference
[26] with permission) C) ANP method (Adopted from reference [27] with permission)
This chapter reports a simple and convenient approach for fast sequence determination of
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cyclic peptides from OBOC libraries that overcome the challenges associated with existing
methods. The methodology entails the selective activation of the amide backbone chain at the
serine residue for the cleavage and sequencing of hit cyclic peptides. The significance of this
approach is that encoding tags or toxic reagents are not required for determining the sequence,
which makes it distinct from the currently used methods. Moreover, this method is compatible
with free amino acid side chains and does not lead to any side reactions.

Scheme 4.3 Rationale for the sequencing of cyclic peptides by ring-opening/cleavage strategy.
Reagents: (a) standard Fmoc/HBTU chemistry; (b) Pd(PPh3)4, phenylsilane; 20% piperdine (c)
HOAt, DIC; (d) TFA (25%); (e) DSC, DIEA, DMAP; and (f) H2O: ACN (1:1), DIEA. Scheme
adopted from reference (1) with permission.

4.5 RESULTS AND DISCUSSION
This approach utilizes two serine residues, one as part of the linker and one within the
macrocycle (Scheme 4.3). The strategy involves the conversion of Ser to an oxazolidinone moiety,
thereby making the amide bond susceptible to cleavage at the Ser N-terminus under hydrolytic
conditions. Earlier attempts at the formation of this moiety on Fmoc/Boc protected peptides led to
the formation of dehydroalanine.28 Our group recently reported the application of this moiety in
the synthesis of thioesters.29 This methodology simultaneously converts cyclic peptides into their
linear counterparts and releases them from the solid support. The linear peptides obtained from
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solid support could then be easily sequenced by mass spectrometry. Scheme 4.3 illustrates the
ring-opening/cleavage reaction for sequencing of cyclic peptides. Notably, only those resin-bound
peptides that complete both the activation and displacement steps would be released. Thus, the
released linear peptides should exhibit high purity, eliminating the need for extensive purification.
To implement this strategy, a serine (trt) trityl residue with a selectively removable sidechain protecting group (pg) as a linker was anchored onto the solid support. To this linker, a linear
peptide with another serine (trt) residue, with a selectively removable side-chain pg, was
synthesized on solid support by standard Fmoc chemistry.29 After removal of the allyl21 and Fmoc
protecting groups, the peptides were cyclized on resin by using HOAt and DIC. 30 The Kaiser test
was used to monitor the macrocyclization reaction qualitatively.31 After macrocyclization, the (trt)
groups from both the serine residues were selectively removed with TFA/DCM (1:3).32
Initially, we assessed the efficiency of the activation of serine residues within a
macrocyclic peptide and as a linker. The serine residues were activated with N,N’-disuccinimidyl
carbonate (DSC) to generate two five-membered oxazolidinone rings on a model cyclic peptide
cyc(GFSFAE)-S 1a (Table 4.1). To optimize the formation of two oxazolidinone moieties on the
model cyclic peptide cyc(GFSFAE)-S on solid support, various reaction conditions such as time,
temperature, and equivalents of DSC were explored (entries 1-6, Table 4.1). A mixture of mono
oxazolidinone moiety-containing cyclic peptide 2a’ and desired bis oxazolidinone moietiescontaining cyclic peptide cyc(GF-Oxd-FAE)-Oxd 2a was obtained by using 10-15 equiv. of DSC
at room temperature in 15 hrs (entries 1-2, Table 4.1).

Table 4.1 Optimization of the activation of cyclic peptide cyc(Gly-Phe-Ser-Phe-Ala-Glu)-Ser86

Rink 1a on solid support.a

Entry

DSC (equiv.)

Temp. (oC)

Time (h)

Conversion (%)b
2a
2a’

1
10
RT
15
50
50
2
15
RT
15
75
25
3
20
RT
15
>99
4
20
RT
6
90
10
5
20
65
6
ND
ND
6
20
65
15
ND
ND
a
Cyclic peptide 1a (50 mg) was reacted with DSC (10-20 equiv.), DIEA (10-20 equiv.) and a
crystal of DMAP in DMF for (3-15 hrs). bConversion to desired two oxazolidinone-containing
cyclic peptide cyc(GF-Oxd-FAE)-Oxd 2a and one oxazolidinone-containing cyclic peptide 2a’
was calculated from the absorbance at 220 nm using HPLC after release from solid support ND =
not detected. Table adopted from reference (1) with permission.
When 20 equiv. of DSC was used at room temperature, the conversion to 2a was 90% in 6
h, whereas when the reaction was run for 15 hrs, the conversion increased to 99% (entries 3-4,
Table 4.1). Similar reactions at high temperature (65 oC) gave a mixture of various unidentified
side-products (entries 5-6, Table 4.1). To confirm the absence of the unmodified cyclic peptide, a
small amount of the resin was cleaved and analyzed by HPLC and MS (Figure 4.2).
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Figure 4.2 HPLC and MS of cyc(GF-Oxd-FAE)-Oxd 2a. Figure adopted from reference (1) with
permission.
Subsequently, serine activation was explored on solid support with various cyclic peptides
of different sequences and different ring sizes (4-9 membered) (1b-1f, entries 1-5, Table 2). It is
noteworthy that formation of the activated oxazolidinone moiety is independent of the nature of
the amino acid preceding serine, and high conversion to the oxazolidinone moiety was obtained
with cyclic peptides of various sizes. Moreover, the results in Table 2 showed that activation of
serine does not depend on its position in the cyclic peptide. This is in contrast to the methioninebased ring cleavage method where a C-terminal Met lead to formation of two homoserine lactone
residues after ring opening, resulting in difficult sequencing of the linearized peptide, while an Nterminal Met led to moderate cyclization efficiency.
Table 4.2 Substrate scope of the activation of cyclic peptides 1b-1i on solid support to 2b-2i.a

Entry

Cyclic Peptides 1

Conversion (%)b

1
cyc(SFFAE)-S 1b
85
2
cyc(SGVFAE)-S 1c
89
3
cyc(GSFAE)-S 1d
92
4
cyc(GFKSYGLE)-S 1e
90
5
cyc(AFSIGFE)-S 1f
88
6
cyc(AFSFE)-T 1g
95
7
cyc(GFCE)-C 1h
92
8
cyc(AMPFISFPE)-C 1i
85
a
Cyclic peptide 1b-1i (50 mg) was reacted with DSC (20 equiv.), DIEA (20 equiv.) and a crystal
of DMAP in DMF for (15 hrs) at RT. bConversion to desired two oxazolidinone-containing cyclic
peptide 2b-2i was calculated from the absorbance at 220 nm using HPLC after release from solid
support. Table adopted from reference (1) with permission.
Next, the peptide backbone activation on cyclic peptides was investigated with threonine
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cyc(AFSFE)-T 1g, whose side chain functionality exhibits strong similarity to serine. As expected,
threonine underwent smooth cyclization under the optimized reaction conditions and generated a
methylated oxazolidinone moiety cyc(AF-Oxd-FE)-MeOxd 2g (entry 6, Table 4.2). In a similar
manner, cysteine-containing cyclic peptides cyc(GFCE)-C 1h and cyc(AMPFISFPE)-C 1i
generated thiazolidinone-activated cyclic peptides cyc(GF-Thz-E)-Thz 2h and cyc(AMPFI-OxdFPE)-Thz 2i under the reaction conditions (entries 7 and 8, Table 4.2).
The stability of the oxazolidinone moiety on the resin-bound macrocyclic peptide was also
evaluated. The resin-bound oxazolidinone moiety containing cyclic peptide was found to be stable
in a desiccator for longer than a month, which is in contrast to the previously reported photocleavable ANP method.27
Nucleophilic displacement of the oxazolidinone moieties under basic hydrolytic conditions
simultaneously opened the cyclic peptide to its linear variant and released the resulting linear
peptide acid from the solid support. Initially, the reaction was performed at room temperature in
water:ACN (1:1, v/v) without base (entry 1, Table 4.3). This resulted in release of 10% linear
peptide acid 3a from the resin after 15 hrs at room temperature.
To optimize the cleavage of the activated cyclic model peptide cyc(GF-Oxd-FAE)-Oxd 2a to its
linear counterpart and simultaneous release of the resulting linear peptide Oxd-FAEGF 3a into
solution, various reaction conditions, such as base and temperature, were investigated (entries 26, Table 4.3 and Figure 4.3). Hydrolytic cleavage under neutral conditions indicates that
macrocyclic ring opening occurs more rapidly than peptide release from the resin (entries 1-2,
Table 4.3). This was confirmed by acidic cleavage of the peptide from the resin after treatment
with hydrolytic conditions for brief amount of time. Another advantage of this approach is that
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only the serine activated peptide chain is released from the resin, thus delivering a highly pure
linear peptide into the solution. The resin was then filtered, and the solvent was evaporated to
obtain linear peptide Oxd-FAEGF 3a, which was then analyzed by HPLC and MS/MS (Figure
4.3).

Table 4.3 Optimization of the reaction conditions for dual ring-opening/cleavage of cyclic peptide
2a to its linear counterpart 3a on solid support.a

Entry

Base

Temp. (oC)

Time (h)

Conv.(%)b

1

-

RT

15

10

2

DIEA

RT

4

70

3

DIEA

RT

8

97

4

DIEA

RT

15

99

5

DIEA

65

4

>99

6

DIEA

65

2

99

a

Activated cyclic peptide 2a (50 mg) was treated with water:ACN (1:1) 1 mL and DIEA (40 µL).
Conversion and release of resulting linear peptide Oxd-FAEGF 3a into the solution was calculated
from the absorbance at 220 nm using HPLC. Table adopted from reference (1) with permission.
b
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Figure 4.3 a) HPLC and MS of linear peptide Oxd-FAEGF 3a, b) MS/MS spectra of peptide OxdFAEGF 3a. Figure adopted from reference (1) with permission.
Next, various cyclic peptides with different amino acids and sizes were evaluated for the
ring-opening and release strategy on solid support (Table 4.4).
Table 4.4 Substrate scope of the ring-open/cleavage strategy on activated cyclic peptides 2b-2i.a

Entry

Activated Cyclic Peptides 2

Conversion (%)b

1

cyc(OxdFFAE)-Oxd 2b

85

2

cyc(Oxd-GVFAE)-Oxd 2c

89
91

3

cyc(G-Oxd-FAE)-Oxd 2d

92

4

cyc(GFK-Oxd-YGLE)-Oxd 2e

90

5

cyc(AF-Oxd-IGFE)-Oxd 2f

88

6

cyc(AF-Oxd-FE)- MeOxd 2g

95

7

cyc(GF-Thz-E)-Thz 2h

92

8

cyc(AMPFI-Oxd-FPE)-Thz 2i

85

a

Activated cyclic peptide 2b-2i (50 mg) was treated with water:ACN (1:1) 1 mL and DIEA (40
µL). bConversion and release of resulting linear peptide 3b-3i into the solution was calculated from
the absorbance at 220 nm using HPLC. Table adopted from reference (1) with permission.
It was noted that opening of the oxazolidinone activated cyclic peptides 2 on solid support
to their linear counterparts 3 is independent of the nature of the amino acid residues preceding
serine. For example, cyclic peptides with bulky amino acid residues next to serine such as
Tyr(tBu), Phe, Lys(Boc), and a cyclic peptide with β-branched residues such as Ile generated linear
peptides cleanly in high yields (entries 4-8, Table 4.4). Noteworthy, backbone activation is also
possible at Thr and Cys due to similar side chain functionality exhibited by these resides. The
possibility of modification at Ser, Cys, and/or Thr residues provides an additional advantage to the
utility of this method affording multiple cleavage sites to aid in the sequencing process. Moreover,
possible activation at any of the abovementioned residues allows variation in the generation of
OBOC libraries generated; the peptide library is not limited to include only Ser residues. In the
presence of Thr or Cys, sequencing post screening becomes feasible as demonstrated in peptides
2g, 2h, and 2i which contain methylated oxazolidinone and thiazolidinone (entries 6-8, Table 4.4)
By demonstrating an expanded substrate scope, oxazolidinone formation efficiently mimics
enzyme function by providing multiple cleavage sites under mild conditions.
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After the ring-opening/cleavage of a cyclic peptide, one oxazolidinone residue remained
attached to the N-terminus of the linear peptide chain. Since only the activated serine residue can
be released from the solid support after hydrolysis, the result is release of a highly pure linear
peptide into solution. In contrast to other methods, we did not observe any oxidation of the
unprotected side chain residues after dual ring opening/cleavage of cyclic peptides from the solid
support.

Figure 4.4 a) LC-MS separation of Oxd-YIGE, b) 2D separation – ion mobility drift time versus
total ion chromatogram, c) MS/MS spectrum without quadrupole selection of parent ion
(interfering signals marked with green asterisks), and d) MS/MS spectrum including ion mobility
filtering to remove chemical interference. Figure adopted from reference (1) with permission.
Sequencing was then accomplished by tandem mass spectrometry on a quadrupole timeof-flight (Q-ToF) instrument incorporating a two-dimensional liquid chromatography, ion
mobility spectrometry separation (LC-IMS-MS/MS) (Figure 4.3).33 Peak capacity can be
significantly increased by pairing IMS with ultra-high-pressure liquid chromatography; thereby,
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allowing for a ballistic reversed gradient to be employed. The overall separation time was just one
minute, which would enable the analysis of large combinatorial cyclic peptide libraries. Both
HRMS identification of the precursor ion and MS/MS were performed in a single run by passing
all ions through the quadrupole to the collision cell for collision induced dissociation (CID). For
traditional LC-MS/MS instrument setups, this would result in significant interference from
impurities and system contaminants; however, here IMS filtering in this method allows for the
production of a clean MS/MS spectra (Figure 4.3).34 Spectra were then interpreted either manually
or in most cases via de novo sequencing software (viz., PEAKS Studio).
To demonstrate the compatibility of our strategy with OBOC libraries, a small cyclic
peptide library of varying amino acid composition and ring sizes ranging from 4 to 10 amino acids
was prepared on Tenta Gel resin with Glu(OAll) as the first amino acid on the solid support. The
library was prepared by split-and-pool synthesis using standard Fmoc/tBu solid-phase peptide
chemistry. Following Glu(OAll), the next positions within the peptide library were filled by a
random combination of 20 L-amino acids. Serine was added randomly within varying positions
within the peptide sequence, and the peptide was cyclized after selective deprotection of Fmoc and
OAllyl groups as described above. This was followed by Ser activation using DSC. After removal
of the side-chain protecting groups, 34 beads were randomly selected and individually hydrolyzed
under basic conditions at 65 oC on a heated shaker for 4 hrs. The resulting crude linear peptides
were then sequenced by the LC-IMS-MS/MS method (Figure 4.4, Table 4.5).35-37 These results
demonstrated the wide scope of the ring-opening OBOC strategy in sequencing of cyclic peptides
of varying size and composition.
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Table 4.5 High throughput screening of various cyclic peptides with varying ring sizes and composition on beads.
Cyclic Peptide
Calculatedb
Observedb
Conversion
Entry
MS/MS Sequence Coveragea
+
Sequence
[M+H]
[M+H]+
(%)c
1
SMRE
547.2293
547.2303
>99
2

SAFE

478.1932

478.1918

>99

3

STFVE

607.2722

607.2716

>99

4

SFRVE

662.3257

662.3265

>99

5

SYFAE

641.2566

641.2561

>99

6

SNYAE

608.2311

608.2335

>99

7

SYIGE

593.2566

593.2584

99

8

SFNTE

622.2467

622.2461

>99

9

SVRFAE

733.3628

733.3651

>99

10

SFRYAE

797.3577

797.3595

>99

11

SNYAAE

679.2682

679.2676

>99

12

SYIGAE

664.2937

664.2947

99

13

SYFVGE

726.3093

726.3115

99

14

SKIFEG

705.3566

705.3576

>99

15

SHVDEF

758.3104

758.3105

>99

16

STLDEF

736.3148

736.3156

>99

17

SRQFEA

762.3529

762.3531

99

18

SKIFAGE

776.3937

776.3944

99

19

SAHDVGE

739.3006

739.2987

99

20

STYDAFE

857.3312

857.3307

>99

21

STFKRVE

891.4683

891.4704

>99

22

SIGFEAF

795.3672

795.3683

>99

23

SRVDYGAE

921.4061

921.4053

>99

24

SAVFMNAE

893.3822

893.3811

>99

25

SKVRNYAE

496.2514d

496.2513d

99

SRYQVANE

496.2332

d

496.2330

d

99

SKARFGVE

459.7432

d

459.7430

d

99

28

SAQVFRFTE

1109.5374

1109.5393

99

29

SYTFNDKLE

1141.5160

1141.5174

>99

30

SRVKNGFEA

1032.5221

1032.5232

99

31

SYLFDWREK

1268.6058

1268.6067

>99

32

SGYVKDFRAE

1196.5695

1196.5672

99

33

SAYKFGPSAE

541.2511d

541.2519d

99

d

d

26
27

34
SATKFESRVE
589.7937
589.7917
>99
MS/MS sequence coverage indicates observed y and b ions as right (red) and left (blue) cleavages, respectively
b
Calculated and observed [M+H]+ are for ring-opened peptides
c
Reaction conditions: Conversion was determined by cleavage of the pre-treated resin under TFA cleavage
conditions
d
Doubly charged ions, [M+2H]2 Table adopted from reference (1) with permission.
a
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Another unique feature of this approach is that peptides with glutamic acid residues can also be
selectively modified to a pyro-glutamyl amide moiety with the backbone peptide chain leading to
the ring opening of the cyclic peptide at the N-terminus of Glu under hydrolytic conditions
(Scheme 4.4). We synthesized and sequenced a potent p53 cyclic peptide analogue which is
implicated in the p53/MDM2 interaction38 and contains two glutamic acid residues.

Scheme 4.4 Rationale for the sequencing of cyclic peptides containing glutamic acid by the
formation of pyro-glutamyl amide moiety. Reagents: DSC, DIEA, DMAP; followed by H2O: ACN
(1:1), DIEA. Scheme adopted from reference (1) with permission.

96

4.6 CONCLUSIONS
We developed a general one bead one compound (OBOC) method for sequencing cyclic
peptides obtained from combinatorial libraries. Our method is compatible with both on-bead and
solution-phase library screening. As compared to encoding tag methods, one bead two compound
(OBTC) approaches or other one bead one compound (OBTC) methods, the major advantage of
this method is that it is direct, without the need to tag each bead, which makes the synthesis of
libraries of cyclic peptides easier. By excluding the encoding tag component, chances of
interferences during the screening process are greatly reduced, if not abolished. Our method has
high substrate scope and ring opening of cyclic peptides can be achieved at serine, threonine,
cysteine, and glutamic acid residues, which is a significant advantage over the current OBOC
approaches that rely either on a methionine residue or an unnatural entity. This method is
compatible with free amino acid side chains due to the fact that they remain unmodified under
reaction conditions.39 Furthermore, our method does not require any special residues and is stable
to light and air thus eliminating the requirement of special handling conditions. The activated
peptides can be stored in a desiccator for a month without any degradation. Therefore, this
methodology can be readily applied in any chemical or biochemical laboratory.
In addition, we utilized the higher separation power of ion mobility spectrometry paired
with ultra-high-pressure liquid chromatography to develop a high throughput tandem MS
sequencing method. Precursor ion selection was found to be unnecessary as interfering signals
could be removed via ion mobility filtering, and this allowed for compound libraries to be analyzed
in a single run. Using this method, over 1000 cyclic peptides can be sequenced in one day.
Moreover, interpretation of the data has the capability of being automated as the spectra were
found to be compatible with de novo sequencing software. The main attributes of our method are
97

its simplicity, facile synthesis without major side product formation, high substrate scope, and
high-throughput capability. This robust method will better enable the search for cyclic peptides as
novel therapeutics.

4.7 EXPERIMENTAL SECTION
General: All commercial materials (Sigma-Aldrich, Fluka, and Novabiochem) were used without
further purification. All solvents were reagent or HPLC (Fisher) grade. Diethyl ether, CH2Cl2, and
DMF were obtained from a dry solvent system (passed through column of alumina) and used
without further drying. Conversions were obtained by comparison of HPLC peak areas of products
and starting materials. HPLC was used to monitor reaction progress.
Materials: Fmoc-amino acids were obtained from Novabiochem (EMD Millipore Corporation,
Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained
from ChemPep Inc (Wellington, Florida). N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky).
N,N′-Disuccinimidyl carbonate (DSC) was obtained from Novabiochem (EMD Millipore
Corporation, Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP) was obtained from
Merck KGaA (Darmstadt, Germany). N,N-Dimethylformamide (DMF) was obtained from Macron
Fine Chemicals (Center Valley, Pennsylvania). Acetonitrile, N,N- Diisopropylethylamine (DIEA),
and N,N'-diisopropylcarbodiimide (DIC) were purchased from Novabiochem (EMD Millipore
Corporation, Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill,
Massachusetts). Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road
Radnor, Pennsylvania). Diethyl ether was obtained from Sigma-Aldrich (St. Louis, Missouri).
Water was purified using a Millipore Milli-Q water purification system.
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Purification: Semi-preparative chromatography was performed using a Beckman Coulter
equipped with a System Gold 168 detector, a 125P solvent module, and a 10 mm C-18 reversedphase column. All separations involved a mobile phase of 0.1% formic acid (v/v) in water (solvent
A) and 0.1% formic acid (v/v) in acetonitrile (solvent B). The semi-preparative HPLC method
employed a linear gradient of 0–80% solvent B over 30 minutes at ambient temperature with a
flow rate of 3.0 mL min-1. The separation was monitored by UV absorbance at both 220 and 254
nm unless otherwise noted.
HPLC:
Peptide compositions were evaluated by high performance liquid chromatography (HPLC) on an
Agilent 1200 series HPLC equipped with a 4.6x150mm (5µm) C-18 reversed-phase column. All
separations used mobile phases of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic
acid (v/v) in acetonitrile (solvent B). A linear gradient of 0–80% solvent B in 30 minutes at room
temperature with a flow rate of 1.0 mL min-1 was used. The eluent was monitored by UV
absorbance at 220 nm unless otherwise noted.
LC-MS:
Mass spectrometry to check reaction mixtures was performed using an Agilent 1100 Series HPLC
with MSD VL mass spectrometer using positive polarity electrospray ionization (+ESI).
HRMS:
Analysis was conducted by Ryan Cohen at Merck facilities in Rahway, NJ. HRMS data were
recorded on an Agilent 1290 UHPLC with 6560 ion mobility Q-ToF mass spectrometer using
positive polarity electrospray ionization (+ESI).
LC-IMS-MS/MS for sequencing peptides:
Analysis was conducted by Ryan Cohen at Merck facilities in Rahway, NJ. An Agilent 1290
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UHPLC and 6560 ion mobility Q-ToF mass spectrometer using positive polarity electrospray
ionization (+ESI) were used to sequence peptides. LC-IMS-MS conditions are provided in Table
4.6. Collision induced dissociation (CID) was used to generate MS/MS spectra using N2 as
collision gas and energies ramped from 20 to 60 V.

Table 4.6. LC-IMS-MS conditions
Parameter
Condition
Column
Waters Acquity CSH C18, 1.7 m particle size, 50 mm x 2.1 mm I.D.
Column temperature
50°C
Mobile phase A
0.1% formic acid in water
Mobile phase B
Acetonitrile
time (min)
%A
%B
0.00
95
5
0.65
1
99
Gradient
0.75
1
99
0.76
95
5
1.00
95
5
Injection volume
1.0 L
Flow rate
1.0 mL/min
Ionization
(+)ESI using Agilent’s jet stream source
Voltages
capillary = 3.5 kV, fragmentor = 175 V, nozzle = 1100 V
Drying gas
N2, 300°C, 10 L/min
Nebulizer
45 psig
Sheath gas
N2, 275°C, 12 L/min
Mass range
m/z 150 to 3200
IM trap
fill time = 40,000 s, release time = 150 s
Acquisition rate
frames = 1/s, IM transients = 19/frame, max drift time = 50 ms

Fmoc Solid-Phase Peptide Synthesis:40 Peptides were synthesized manually on a 0.25 mmol
scale using Rink amide, Wang, Chem Matrix and TentaGel resins. Fmoc was deprotected using
20% piperidine–DMF for 20 min to obtain a deprotected peptide-resin. Fmoc-protected amino
acids (0.75 mmol) were sequentially coupled on the resin using HBTU (0.75 mmol) and DIEA
(0.75 mmol) for 2 hrs at room temperature. Peptides were synthesized using standard protocols.1
Peptides were cleaved from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl
silane:water for 2 hrs. The resin was removed by filtration and the resulting solution was
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concentrated. The oily residue was triturated with diethyl ether to obtain a white suspension. The
resulting solid was purified by semi-preparative chromatography.
General Procedure for Cyclization of Linear Peptides on Solid Support: To a peptide
containing Glu(Oallyl)OH amino acid on the solid support (50 mg, 0.69 mm/g) was added a
solution of tetrakis(triphenylphosphine)palladium(0), Pd(PPh3)4 (20 mg), phenylsilane (72 µL) in
DCM (3 mL), and the peptide was left on the shaker for 40 minutes. The resin was washed with
10 mL DCM (3 X 2 min). The above reaction was repeated, and then the resin was washed with
10 mL DCM (3 X 2 min), 10 mL MeOH (3 X 2 min), and 10 mL DMF (3 X 2 min). The palladium
catalyst was removed from the resin by washing it with 10 mL DIEA (2 X 2 min), followed by
washing with 10 mL DMF (2 X 2 min). Next, the peptide was treated with 20% piperdine/DMF to
remove the Fmoc protecting group. Macrocyclization was achieved by exposing the resin to 50µL
DIC, 50 mg HOAt, and a catalytic amount of DMAP in DMF per 50mg of resin on a shaker for
15 hrs. The solution was drained, and the resin was washed with DMF. To confirm the complete
macrocyclization, the Kaiser test was performed. Yellow bead coloration indicated absence of free
amines, while blue coloration indicated incomplete macrocyclization. To further confirm
formation of cyclic peptides, the resin was cleaved using a cocktail of 95:2.5:2.5 trifluoroacetic
acid:triisopropyl silane:water (v/v/v) for 2 hrs. The resin was then removed by filtration, and the
resulting solution was evaporated. Cyclic peptides were purified by semi-preparative
chromatography and analyzed by MS.
General Procedure for Serine Activation to Cyclic Urethane Moiety within Cyclic Peptides
on Solid Support: The trityl protecting groups on serine residues were selectively removed by
exposing the peptide on solid support to a 30% TFA in DCM 10 mL solution (3 X 5 min). Both
serine groups (one as a linker and the other within the macrocycle) were activated on solid support
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(25-100 mg, 0.25-0.69 mm/g) using a solution of DSC (25 equiv.), DIEA (25 equiv.), and a
catalytic amount of DMAP in DMF on shaker for 17 hrs. The solution was drained, and the resin
was washed with DMF, followed by peptide cleavage using a cocktail of 95:2.5:2.5 trifluoroacetic
acid:triisopropyl silane:water (v/v/v) for 2 hrs. The resin was removed by filtration, and the
resulting solution was concentrated. The oily residue was triturated with diethyl ether to obtain a
white suspension. The resulting solid was purified by semi-preparative chromatography for MS
analysis.
General Procedure for Dual Ring-Opening/Cleavage of Cyclic Peptides on Solid Support for
MS/MS Sequencing: A solution of 1 mL H2O:ACN (1:1, v/v) and 40 µL of DIEA was added to
the resin containing the activated cyclic urethane-containing macrocyclic peptide. This reaction
was left on a heated shaker at 65 °C for 4 hrs. The resin was then filtered, followed by solvent
removal under vacuum. The resulting ring-opened peptide acid was then sequenced by LC-IMSMS/MS.
General procedure for macrocyclization in solution phase. Peptide was cleaved from the resin
with a 20% v/v HFIP solution in DCM. The DCM was evaporated, and the linear peptide was
purified by chromatography. Cyclization occurred with 20 mg HOAt, 20 µL DIC in dry DMF per
2 mg of peptide. Side chain protecting groups were then deprotected by adding a solution of
TFA:TIPS:water (95/2.5/2.5, v/v/v) and incubating the solution for 2 hrs. The macrocyclic peptide
was then purified by reversed-phase analytical chromatography.
General Procedure for the activation of glutamic acid in cyclic peptide in solution phase. To
a 5-mL round-bottom flask containing peptide 2-20mg (1 equiv.) in 0.5-2 mL dimethylformamide
(DMF) was added a solution of DSC (15 equiv.), DIEA (15 equiv.) and crystal of DMAP in DMF
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(0.2-0.5 mL). The mixture was stirred at room temperature for 10 hrs. The reaction was
concentrated under vacuum and resulting peptide was dissolved in 1:1 mixture of water and
acetonitrile and purified by HPLC.
General Procedure for ring-opening of cyclic peptide in solution phase. To an activated cyclic
peptide, 1 mL phosphate buffer (pH 7.4) was added. The reaction was stirred at 25 °C and
monitored by analytical HPLC at regular intervals. The reaction mixture was lyophilized, purified
by HPLC and isolated.
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CHAPTER 5: FMOC SOLID PHASE SYNTHESIS OF
PROTECTED C-TERMINAL MODIFIED PEPTIDES BY
FORMATION OF A BACKBONE CYCLIC URETHANE MOIETY
5.1 ABSTRACT
C-terminally modified peptides are of high significance due to the therapeutic properties
that accompany various C-terminal functional groups and the ability to manipulate them for further
applications. In this chapter, a universal solid phase strategy for the synthesis of various C-terminal
modified peptides is reported. The method is independent of the type of resins, linkers, and
unnatural moieties typically needed for C-terminal modifications. The technique proceeds by the
modification of a C-terminal serine to a cyclic urethane moiety which results in the activation of
the backbone amide chain for the nucleophilic displacement by various nucleophiles to generate
C-terminally modified acids, esters, N-alkyl amides, alcohols, and hydrazides. This cyclic urethane
technique (CUT) also provides a general strategy for synthesis of C-terminal protected peptides
which can be used for convergent synthesis of large peptides. The C-terminal protecting groups
can be cleaved by hydrolysis to release the free peptide.

5.2 CHAPTER OBJECTIVES
This chapter describes a universal method for the solid phase synthesis of various Cterminal modified peptides which is independent of the nature of resins, linkers, and unnatural
moieties typically needed for C-terminal modifications. This strategy is highly versatile and
generates peptides with various C-terminal end groups such as acids, esters, alcohols, hydrazides,
and N-alkyl amides. Another unique feature of this methodology is that it provides a semipermanent protecting group at the C-terminus which allows for various modifications in solution;
hydrolysis can be performed to remove the protecting group and release the free peptide post106

modification if desired.
C-terminal modified peptides are of high significance because of the therapeutic properties
that accompany various C-terminal functional groups. As a result, there is a necessity for an
effective solid-phase synthesis approach for the preparation of peptides with various C-terminal
functional groups. Currently, these modifications are generally attainable by using special resins
that are appropriately designed to allow the anchoring of the peptide’s C-terminus and generate a
specific end group at the C-terminus upon cleavage. Other methods include: use of unnatural
linkers or handles, side-chain or backbone amide anchoring, and inverse solid-phase peptide
synthesis. Despite their obvious attractiveness, all these methodologies have specific
disadvantages that need to be addressed. This strategy provides a universal method that relies on
a natural amino acid (e.g., serine), which is modified to provide a cyclic urethane moiety that
undergoes nucleophilic displacement with various nucleophiles to generate peptides with the
desired C-terminal end group.
In this chapter, we describe the Cyclic Urethane Technique (CUT) that relies on the
modification of C-terminal serine to the cyclic urethane moiety on solid support and its potential
for detachability by various nucleophiles under mild conditions to generate C-terminal modified
protected peptides.
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5.3 GRAPHICAL ABSTRACT

Figure 5.1 Graphical abstract for Fmoc Solid-Phase Synthesis of Protected C-terminal Modified
Peptides by Formation of Backbone Cyclic Urethane Moiety. Figure adopted with permission
from: Elashal, H. E.; Cohen, R. D.; Raj, M. Chem. Commun. 2016, 52, 9699.1

5.4 INTRODUCTION
C-terminal modified peptides such as acids and amides have been extensively used in
chemical synthesis of proteins, semi-synthesis, catalysis, and in various therapeutic applications.2
Other C-terminal peptide modifications of potential interest in therapeutics include esters, N-alkyl
amides, and alcohols. These C-terminally modified peptides exhibit a wide range of biological
activities; for instance, N-alkyl amides enhance metabolic stability and biological activity.3,4 Key
processes of cell growth and differentiation embody ester groups at their C- terminus.5 Moreover,
peptide alcohols, such as peptaibols are well known antibiotics and exhibit a wide range of
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biological activities.6
In general, C-terminal modified peptides are synthesized in solution after cleavage of
peptides from solid support.7 For subsequent biological investigations, however, a series of peptide
derivatives are often required, which calls for the development of flexible solid phase synthesis
techniques. Modifications at the N-terminus of peptides can be easily achieved on a solid support
because synthesis of peptides takes place from the C to the N terminus. On the other hand,
modification at the C-terminus is a challenge due to its direct attachment to the solid support.
Therefore these modifications are generally attainable by using special resins that are appropriately
designed to allow the anchoring of the peptide’s C-terminus and generate a specific end group at
the C-terminus upon cleavage.8 Due to the therapeutic potential of C-terminally modified peptides,
a growing number of studies reported alternative methods such as the use of (i) special linkers
between the peptide chain and a solid support which rely on unique oxidative conditions to activate
the linker for attack by various nucleophiles.9 However, this approach is limited due to the
undesirable oxidation of sensitive residues such as Cys, Met, and Trp. Other methods include (ii)
side-chain or backbone amide anchoring approach, whereby the C-terminal carboxyl group is not
involved as an attachment point to the resin.10 And (iii) inverse solid-phase peptide synthesis (viz.,
from N to C-terminus).11 One major drawback of this approach is potential epimerization at all
coupling stages due to repeated resin-bound carboxyl activation. Another method is (iv) internal
resin-capture technique which also involves the use of special linkers or handles.12-14 All of the
reported methods require special resins, unnatural linkers, or handles for the synthesis of Cterminally modified peptides.
This chapter describes the discovery of a novel general strategy that circumvents the use
of special resins, linkers, or handles and affords peptides with various types of C-terminal
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modifications such as acids, esters, N-alkyl amides, and alcohols. Another advantage of this
approach is that it provides a semi-permanent protection at the C-terminus of peptides after
cleavage of the peptide from the insoluble polymer resin. The semi-permanent protecting group at
the C-terminus of a peptide is highly desirable for further manipulation in solution, such as for the
synthesis of large peptides.15

5.5 RESULTS AND DISCUSSION
This method is based on the activation of the peptide backbone amide bond. We reasoned
that the activation of a peptide backbone amide bond by increasing its nucleofugality could render
the C-N bond susceptible to nucleophilic attack and provide peptides with various C-terminal
modifications depending upon the nucleophile. The backbone amide chain is activated by the
formation of a backbone cyclic urethane moiety, which, after nucleophilic displacement, provides
the C-terminally modified peptide (Scheme 5.1A and 5.1B). Another application of the cyclic
urethane technique (CUT) is to generate a peptide with semi-permanent protection at the Cterminus. Peptides with a C-terminal protecting group can potentially be used for further
modifications in solution, followed by the removal of a protecting group under basic hydrolysis
conditions (Scheme 5.1C).
Synthesis of C-terminally modified peptides by this strategy entails anchoring of a Cterminal serine residue with a selectively removable side-chain protecting group to a solid support
(Scheme 5.1A). Upon peptide chain assembly, the serine side-chain is selectively deprotected. In
the first key step, strong activation of the serine’s hydroxymethyl group results in the formation of
the cyclic urethane moiety on-resin (Scheme 5.1A). Earlier attempts at the formation of the cyclic
urethane moiety on Fmoc/Boc peptides were unsuccessful and led to the formation of
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dehydroalanine.16 Our group recently reported the solution phase synthesis of such cyclic urethane
moiety between the side chain of serine and the amidic nitrogen of the backbone peptide chain. 17
In the second key step, nucleophilic displacement of the cyclic urethane moiety by treatment with
various nucleophiles releases the protected C-terminal modified peptides from the solid support,
which are subsequently deprotected in solution (Scheme 5.1B).

Scheme 5.1 Rationale for the development of cyclic urethane technique (CUT). (a) Methodology
for the synthesis of cyclic urethane moiety on solid support. (b) Synthesis of C-terminally modified
peptides by nucleophilic displacement of cyclic urethane moiety. (c) Synthesis of protected Cterminal peptides using (CUT) and synthesis of large peptides via convergent approach followed
by nucleophilic displacement. Scheme adopted from reference (1) with permission.
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This cyclic urethane moiety also acts as a semi-permanent protecting group (pg) for the Cterminus upon cleavage of the peptide from the solid support (Scheme 5.1C). Such protection is
of significance due to the potential use of the C-terminally protected peptides for the formation of
large peptides via convergent synthesis approach. Finally, the protecting group (pg) at the Cterminus can be easily removed by mild, hydrolysis conditions (Scheme 5.1C). It is noteworthy
that special linkers or handles are not required for CUT, which is in contrast to current methods
for synthesis of C-terminally protected peptides.15
To implement this strategy for the synthesis of a C-terminally modified protected peptide,
a model hexamer peptide, Ac-GPMLAS-Rink was synthesized on Rink Amide resin using the
SPPS approach with serine(trt) as the C-terminal residue. The trityl (trt) group from serine was
selectively removed with TFA/DCM (1:3) to generate peptide A (Scheme 5.2). This was followed
by activation of serine’s hydroxymethyl group with N,N’-disuccinimidyl carbonate (DSC) to
generate activated intermediate B.17

Scheme 5.2 Synthesis of peptide acid by using CUT. Scheme adopted from reference (1) with
permission.
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Next, intramolecular nucleophilic attack of the amidic nitrogen of the peptide backbone on
the activated intermediate B generated a five-membered cyclic urethane ring Ac-GPMLAOxd 1a
(Scheme 5.2). After formation of the cyclic urethane moiety 1a, nucleophilic release of the
protected peptide acid 2a from the solid support was achieved by carrying out hydrolysis under
basic conditions (Scheme 5.2). The solvent was then removed, and the protected peptide acid 2a
was analyzed by HPLC and LCMS (Scheme 5.2). Initially, hydrolysis was carried out at ambient
temperature but longer reaction time (> 24hrs) was required to fully release peptide acid 2a from
the resin (entry 1, Table 5.1). To achieve maximum conversion, reaction conditions such as time,
solvent, and temperature were optimized (Table 5.1). For the complete liberation of peptide acid
2a from the solid support, DMF was used as a co-solvent with water due to beneficial resin
swelling in DMF (entries 3-5, Table 5.1).
Table 5.1 Optimization of Reaction Conditions for Synthesis of Protected Peptide Acids.a

Entry

pg

1
2
3

Ac
Ac
Ac

4

Ac

5

Ac

Solvent

H2O
H2O
H2O: DMF
(4:1)
H2O: DMF
(1:1)
H2O: DMF
(1:1)

Time
(h)

Conv
(%)b

RT
50
50

15
15
15

30
45
77

50

15

99

65

4

59

Temp
(°C)
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6

Ac

7

NH2

8c

Fmoc

H2O: ACN
(1:1)
H2O: ACN
(1:1)
H2O: ACN
(1:1)

65

2

99

65

2

99

65

2

99

a

Reaction conditions: Peptide (25 mg, 0.7 mm/g) on solid support was reacted with DSC (100 mg),
DIEA (70 uL) and a crystal of DMAP in DMF at room temperature followed by hydrolysis.
b
Conversion to 2a was calculated from the absorbance at 220 nm using HPLC. The entry in bold
represents the optimized reaction conditions for hydrolysis. cMixture of completely protected
peptide and Fmoc deprotected peptide was observed. DIEA = Diisopylethylamine, DMAP = 4(N,N-dimethylamino)- pyridine. Table adopted from reference (1) with permission.
To decrease the release time of peptide acid 2a, hydrolysis was performed on a heated
shaker at temperatures ranging from RT to 65 ºC (entries 1-5, Table 5.1). Since it is difficult to
remove DMF from the cleaved peptide, a more volatile solvent such as acetonitrile was preferred
(entries 6-8, Table 5.1).
The extent of epimerization from formation of the cyclic urethane moiety and nucleophilic
displacement was investigated. Diastereomer, Ac-GPML-(D)-A-OH (D2a), was synthesized using
the optimized conditions (entry 6, Table 5.1), and peptide acids 2a and D2a’ were subsequently
analyzed by HPLC (Figure 5.2). No detectable levels of epimerization were observed.
To evaluate the compatibility of all the amino acids and various protecting groups towards
serine’s activation as a cyclic urethane moiety and its nucleophilic displacement, various peptides
with different sequences and protecting groups were synthesized and screened under the reaction
conditions (Table 5.2).
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Figure 5.2 (a) HPLC trace of purified peptide acid 2a Ac-GPML-(L)-A-OH (b) HPLC trace of
purified peptide acid diastereoisomer D2a’ Ac-GPML-(D)-A-OH (c) HPLC trace of mixture
containing both diastereoisomers 2a and D2a’. Figure adopted from reference (1) with permission.
The results indicate that all the peptides underwent smooth activation to generate activated
peptides 1b-1k followed by hydrolysis to corresponding protected peptide acids 2b-2k with
varying HPLC conversions ranging from 70% to greater than 99% (entries 1-8, Table 5.2). To
determine the effect of the bulky neighboring residue on serine’s activation and nucleophilic
peptide release, the hexapeptides, FESQIS-Rink (1e), and TCDVS-Rink (1k) were synthesized.
The results indicate that the activated peptides 1e and 1k with bulky amino acids (Ile and Val)
adjacent to serine underwent complete conversion to peptide acids 2e and 2k (entries 4 and 10,
Table 5.2). The reaction with peptide, FESQIS-Rink 1e, also showed that the technique was
applicable to peptides with multiple serine residues by selective activation and displacement of
serine at the C-terminus (entry 4, Table 5.2).
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Table 5.2 Substrate scope of CUT in synthesis of peptide acids.a

Entry

Substrate

Peptide

PG

Conv (%)b

1
2

1b
1c

LFK(Boc)N(Trt)A
LFK(Boc)N(Trt)A

Ac
NH2

95
95

3c

1d

LFK(Boc)N(Trt)A

Fmoc

80

4

1e

FE(tBu)S(tBu)Q(Trt)I

NH2

90

5

1f

R(Pbf)D(tBu)PMLG

Ac

95

6

1g

R(Pbf)D(tBu)PMLG

NH2

90

7

1h

Y(tBu)LFK(Boc)N(Trt)A

Ac

95

8

1i

Y(tBu)LFK(Boc)N(Trt)A

NH2

90

9
10

1j
1k

VWR(Pbf)A
T(tBu)C(tBu)D(tBu)V

Ac
Ac

90
90

a

Reaction conditions: Peptide 1 (25 mg, 0.7 mmol/g) on solid support was reacted with DSC (100
mg), DIEA (70 uL) and a crystal of DMAP in DMF at room temperature followed by hydrolysis
with H2O:ACN in DIEA (20 uL) at 65 °C for 2-4 hrs. bConversion to peptide acid was calculated
from the absorbance at 220 nm using HPLC. cMixture of completely protected peptide and Fmoc
deprotected peptide was observed. Table adopted from reference (1) with permission.

Next, to demonstrate that the cyclic urethane technique (CUT) is resin independent, model
pentapeptide, WVRAS was synthesized on Rink Amide, Wang, Chem Matrix, and Tentagel resins.
The results indicate that both the activation of serine and nucleophilic displacement gave high
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yields of the protected peptide acid independent of the type of resin, which is in contrast to other
methods.8
Protected peptide acids have been extensively useful for the synthesis of macrocyclic
peptides of therapeutic importance.18 To demonstrate the application of CUT in the synthesis of
macrocyclic peptides, AKDPYRGS-Rink AM was synthesized on solid support, followed by
serine selective deprotection, activation 3a, and cleavage with water to obtain the protected linear
peptide acid AK(Boc)D(tBu)PY(tBu)R(Pbf)G-OH 3b (Scheme 5.3). Next, the protected peptide
acid 3b was subjected to coupling reagents to obtain the desired head to tail macrocyclized
protected peptide cyc(AK(Boc)D(tBu)PY(tBu)R(Pbf)G) 3c. This was followed by removal of the
side-chain protecting groups of the macrocyclic peptide using the TFA cocktail to generate the
deprotected macrocyclic peptide cyc(AKDPYRG) 3d which was analyzed by NMR, HPLC, and
MS (Scheme 5.3). In comparison, peptide acid AKDPYRG-OH generated by using Wang resin19
gave an undesired double cyclized product. Double cyclization can arise from side-chain to head
or side-chain to side-chain reactions (Scheme 5.4).

117

Scheme 5.3 Application of CUT in synthesis of macrocyclic peptide 3d. Pg = protecting group.
Scheme adopted from reference (1) with permission.

Scheme 5.4 Various possibilities for macrocyclization using an unprotected peptide. Scheme
adopted from reference (1) with permission.
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Next, we applied CUT for the synthesis of protected peptides with various C-terminal
modifications such as esters, amides and alcohols (Scheme 5.5). To obtain the desired C-terminally
modified peptide, the corresponding nucleophile was added to a solid support with the cyclic
urethane moiety at the C-terminus (Scheme 5.5). The cyclic urethane moiety underwent
nucleophilic displacement and generated the C-terminally modified protected peptide in solution.
The peptide methyl ester, AVGPPGVA-OMe 5 was obtained by treatment of activated peptide 4
with methanol in the presence of a base (a, Scheme 5.5). These peptide methyl esters play a
significant role in key processes of cell growth and differentiation.5 This technique was also
utilized for the synthesis of peptide methyl ester PFFFOMe 5’ (Scheme 5.6). Synthesis of these
peptide methyl esters has previously been reported in solution-phase, which is a tedious process
and requires purification at each step with the constant risk of epimerization.20 It has been shown
that the presence of a methyl ester group is critical for the catalytic activity of the peptide 5’.20

Scheme 5.5 CUT for synthesis of peptide amides, esters and alcohols. peptide = X-AVGPPGVAOxd, 4. X = NH2 or Ac. Scheme adopted from reference (1) with permission.
Next, benzylamine was used as a nucleophile on the cyclic urethane moiety to obtain
peptide an N-alkyl amide peptide 6, an important class of biologically active peptides (b, Scheme
5.4). The presence of an alkyl amine group at the C-terminus enhances its biological activity,
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metabolic stability, and hydrophobicity.3,4 This technique was also applied for synthesis of
peptides with a C-terminal alcohol functionality. Such peptides occur in nature among these,
peptaibols are well-known antibiotic peptides that exhibit a wide range of biological activity.6 To
obtain an alcohol group at the C-terminus 7, the cyclic urethane containing activated peptide 4 was
treated with a solution of sodium borohydride in THF (c, Scheme 5.4).

Scheme 5.6 Application of CUT in synthesis of a catalyst 5’ for aldol reaction. Scheme adopted
from reference (1) with permission.
Moreover, this methodology was implemented in the synthesis of hydrazides. The critical
importance of a peptide hydrazide is to synthesize complex proteins and bioconjugates; therefore,
it is an added advantage that the cyclic urethane moiety is capable of providing long peptide
hydrazides with diverse functional groups that can be utilized directly in NCL. A multi-serine
containing bioactive peptide hydrazide S(tBu)GIS(tBu)GPLS(tBu)-CONHNH2 3k, a fragment of
antimicrobial bovine β-defensin 13, was successfully synthesized from the corresponding cyclic
urethane activated peptide S(tBu)GIS(tBu)GPLS(tBu)-Oxd 2k by treatment of the peptide with
hydrazine monohydrate under basic conditions using a heated shaker at 65 °C for 2 h in acetonitrile
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as a solvent for optimal release (Figure 5.3).

Figure 5.3 Activated serine for the synthesis of the fragment of antimicrobial bovine β-defensin
13 bioactive peptide hydrazide 3k. (a) HPLC trace of pure bioactive peptide hydrazide
S(tBu)GIS(tBu)GPLS(tBu)-CONHNH2 3k and inset shows MS of protected peptide hydrazide 3k.

Given the importance of peptide hydrazides in protein chemical synthesis, we envisioned
the application of this methodology in an efficient one-pot strategy, comprising solid-phase
synthesis, hydrazinolysis, and the direct ligation of crude peptide hydrazides to cysteine-containing
peptide (Figure 5.4). Peptide hydrazide Ac-GPMLA-CONHNH2 3l was cleanly released from AcGPMLA-Oxd 2l by treatment with hydrazine monohydrate and DIEA in acetonitrile at 65 °C for
2 h and ligated with a cysteine containing peptide CRFAS-NH2.
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Figure 5.4 Native Chemical Ligation of peptide hydrazide Ac-GPMLA-CONHNH2 3l with Nterminal cysteine peptide CRFAS-NH2. HPLC/MS traces of peptide hydrazide 3l and ligated
product 4.
The main advantage of the described approach is that the elongation of the peptide chain
can be carried out by means of standard techniques after attachment of the first amino acid as
serine. Another significant advantage of this approach is that only those resin-bound peptides that
complete both activation and displacement steps are released. Thus, the released C-terminally
modified peptides exhibit high purity, eliminating the need for extensive purification.
Next, we demonstrated the application of CUT for synthesis of peptides with a semipermanent protecting group (pg) at the C-terminus (Scheme 5.7). This is of significance because
C-terminally protected peptides can be used for various manipulations in solution. This technique
is in contrast to the current methods that require reprotection of the C-terminal carboxyl group in
solution, with a consequent risk of racemization and low yields.21 Another method for synthesis of
peptides with a semi-permanent protecting group at the C-terminus utilizes click chemistry based
handles but is limited by the use of special linkers and the requirement of harsh deprotection
conditions.21 Our method does not require any special linkers or handles and it employs mild
deprotection conditions for removal of pg at the C-terminus.
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For the synthesis of peptides with a semi-permanent C-terminus pg, activated peptide
Fmoc-AR(Pbf)FPPFR(Pbf)AOxd 4 on a solid support was cleaved from the resin by using the
TFA cleavage cocktail to generate peptide Fmoc-ARFPPFRAOxd 8 with protection at the Cterminus (Scheme 5.7). The C-terminally protected peptide Fmoc-ARFPPFRAOxd 8 can be used
for the synthesis of large peptides by a convergent approach. Subsequently, the protecting group
at the C-terminus of the resulting large peptide can be easily removed under basic hydrolysis
conditions as shown above.

100 a)
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691.5
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Scheme 5.7 (a) CUT technique for synthesis of protected C-terminus peptide 8. (b) HPLC and MS
chromatogram of C-terminal protected peptide Fmoc-ARFPPFRA-Oxd, 8. peptide = FmocARFPPFRA. Scheme adopted from reference (1) with permission.

5.6 CONCLUSIONS
A backbone amide activation approach has been developed for the synthesis of Cterminally modified peptides of therapeutic importance such as acids, amides, esters, N-alkyl
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amides, alcohols, and hydrazides. This approach is resin and linker independent thus
circumventing limitations associated with earlier methods. The main advantage of the described
approach is that the elongation of the peptide chain can be carried out by means of standard
methodologies after attachment of the first amino acid residue as serine. After construction of the
peptide, the backbone chain is activated as a cyclic urethane moiety and cleavage is carried out
under mild nucleophilic displacement conditions that allow easy formation of the desired Cterminally modified peptide. The target peptides are released from the resin without racemization.
This cyclic urethane technique (CUT) has also been applied to the synthesis of peptides with the
protected C-terminus, which can undergo various modifications in solution after release from solid
support (e.g., large peptides synthesis by a convergent strategy). Moreover, the C-terminal
protecting group can be easily removed under mild basic hydrolytic conditions. A universal solid
phase strategy has been effectively developed and applied for the synthesis of various C-terminal
modified peptides, which are of therapeutic importance due to biological properties that
accompany the attachment of various C-terminal functional groups.

5.7 EXPERIMENTAL SECTION
General: All commercial materials (Aldrich, Fluka, Nova) were used without further purification.
All solvents were reagent grade or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2,
and DMF were obtained from a dry solvent system (passed through column of alumina) and used
without further drying. Conversion were obtained by comparison of HPLC peak areas of products
and starting material.
Materials: Fmoc-amino acids were obtained from Nova Biochem (EMD Millipore Corporation)
(Billerica, Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained
from ChemPep Inc (Wellington, Florida). N,N,N′,N′-Tetramethyl-O (1H benzotriazol-1124

yl)uronium hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky).
N,N-Disuccinimidyl carbonate (DSC) was obtained from Nova Biochem, under (EMD Millipore
Corporation) (Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP): Merck KGaA
(Darmstadt, Germany). N,N-Dimethylformamide (DMF): Macron Fine Chemicals (Center Valley,
Pennsylvania). Dichloroethane (DCE), acetonitrile, N,N- Diisopropylethylamine (DIEA), N,N'
diisopropylcarbodiimide (DIC), were purchased from (EMD Millipore Corporation)(Billerica,
Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts).
Trifluoroacetic acid (TFA) was purchased from VWR 100 Matsonford Road Radnor, PA. Diethyl
Ether: Sigma Aldrich (St. Louis, Missouri). Water was purified using a Millipore MilliQ water
purification system.

NMR:
This was done by Ryan Cohen at Merck facilities at Rayway, NJ. NMR spectra were recorded
on a 600 MHz spectrometer and carbon NMR spectra on a 151 MHz, spectrometer at ambient
temperature. All NMR chemical shifts () are referenced in ppm relative to residual solvent or
internal tetramethylsilane. 1H NMR chemical shifts referenced to residual DMSO-d5 at 2.50 ppm,
and
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C NMR chemical shifts referenced to DMSO-d6 at 39.52ppm. Carbon NMR spectra are

proton decoupled. NMR spectral data are reported as chemical shift (multiplicity, coupling
constants (J), integration). Multiplicity is reported as follows: singlet (s), broad singlet (bs),
doublet (d), doublet of doubles (dd), doublet of triplet (td), triplet (t) and multiplet (m). Coupling
constant (J) in Hertz (Hz).
HPLC
Semi-Preparative HPLC:
Preparative HPLC chromatography (HPLC) was performed on Beckman Coulter equipped with
System Gold 168 detector and 125P solvent module HPLC with a 10 mm C-18 reversed-phase
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column. All separations involved a mobile phase of 0.1% FA (v/v) in water (solvent A) and 0.1%
FA (v/v) in acetonitrile (solvent B). Semi-preparative HPLC method using a linear gradient of 0–
80% acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate of 3.0
mL min-1. The eluent was monitored by absorbance at 220 nm and 254 nm unless otherwise
noted.
Analytical HPLC:
Analytical HPLC chromatography (HPLC) was performed on an Agilent 1200 series HPLC
equipped with a 4.6x 150 mm (5µm) C-18 reversed-phase column. All separations involved mobile
phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Peptide
compositions were evaluated by analytical reverse phase HPLC using a gradient of 0.1% FA in
acetonitrile versus 0.1% FA in water. Analytical HPLC method using a linear gradient of 0–80%
0.1% FA (v/v) acetonitrile in 0.1% aqueous FA over 30 min at room temperature with a flow rate
of 1.0 mL min-1. The eluent was monitored by absorbance at 254 nm unless otherwise noted.
LCMS:
Mass spectrometry was performed using ultra high-performance liquid chromatography-mass
spectrometry using the Agilent 1100 Series LCMSD VL MS Spectrometer.

HRMS:
This was done by Ryan Cohen at Merck facilities at Rayway, NJ. HRMS data were recorded
on an Agilent 6520 Q-ToF mass spectrometer using positive polarity
electrospray ionization (+ESI).
Fmoc Solid-Phase Peptide Synthesis.22 Peptides were synthesized manually on a 0.25 mmol
scale using Rink amide, Wang, Chem Matrix and TentaGel resins. Fmoc–group was deprotected
using 20% piperidine–DMF for 20 min to obtain a deprotected peptide-resin. Fmoc-protected
amino acids (1.25 mmol) were sequentially coupled on the resin using a HBTU (1.25 mmol) and
DIEA (1.25 mmol) for 2 hrs at room temperature. Peptides were synthesized using standard
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protocols.22 The peptide was cleaved from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic
acid:triisopropyl silane:water for 2 hrs. The resin was removed by filtration and the resulting
solution was concentrated. The oily residue was triturated with diethyl ether to obtain a white
suspension. The resulting solid was purified by HPLC.
General procedure for the activation of serine to cyclic urethane moiety on solid support:
To a peptide on the solid support (25-100 mg (0.25-0.69 mmol/g) was added a solution of DSC
(15 equiv.), DIEA (15 equiv.) and catalytic amount of DMAP in dimethylformamide (DMF). The
resin was left on shaker for 17 hrs. The solution was drained and resin was washed with DMF
followed by cleavage using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water
for 2 hrs. The resin was removed by filtration and the resulting solution was concentrated. The
oily residue was triturated with diethyl ether to obtain a white suspension. The resulting solid
was purified by HPLC for analysis by MS and NMR.
General procedure for the synthesis of peptide acids from solid support: To an activated
peptide as cyclic urethane moiety on the solid support, 1 mL H2O:ACN (1:1) and 20 µL of DIEA
was added and resin was left on the heated shaker at 65 °C for 2 hrs. The resin was filtered which
is followed by the removal of solvent under high vacuum. The resulting peptide acid was
analyzed by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v) in water
(solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA (v/v) acetonitrile
in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm.

General procedure for the synthesis of peptide esters from solid support: To an activated
peptide as cyclic urethane moiety on the solid support, 1 mL MeOH and 100 µL of DIEA was
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added and resin was left on the heated shaker at 65 °C for 4 hrs. The resin was filtered which is
followed by the removal of solvent under high vacuum. The resulting peptide ester was analyzed
by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v) in water (solvent A):
0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA (v/v) acetonitrile in 25 min,
flow rate = 1.0 mL/min, detection wavelength 220 nm.

General procedure for the synthesis of peptide N-aryl amide from solid support: To an
activated peptide as cyclic urethane moiety on the solid support, 1 mL ACN and 100 µL of
benzyl amine was added and resin was left on the heated shaker at 65 °C for 4 hrs. The resin was
filtered which is followed by the removal of solvent under high vacuum. The resulting peptide
N-aryl amide was analyzed by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA
(v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA
(v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm.

General procedure for the synthesis of peptide alcohol from solid support: To an activated
peptide as a cyclic urethane moiety on the solid support, 100 mg sodium borohydride in 1 mL THF
was added and resin was left on the shaker overnight at room temperature. The resin was filtered
which is followed by the removal of solvent under high vacuum. The resulting peptide alcohol was
analyzed by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v) in water
(solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA (v/v) acetonitrile
in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm.
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General procedure for the synthesis of peptide hydrazides from solid support: To an activated
peptide as a cyclic urethane moiety on the solid support, 20 µL hydrazine monohydrate in 1mL
acetonitrile was added to 25 mg of resin and left on the shaker for 2 hrs at 65ºC. The resin was
filtered which is followed by the removal of solvent under high vacuum. The resulting peptide
hydrazide was analyzed by MS and purified by HPLC to obtain white solid. HPLC: 0.1% FA (v/v)
in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA (v/v)
acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm.
Deprotection of protecting groups from C-terminal modified peptides: C-terminally modified
peptides were deprotected by using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl
silane:water for 2 hrs in solution and the resulting solution was concentrated. The oily residue was
triturated with diethyl ether to obtain a white suspension. The resulting solid was purified by HPLC
and analyzed by MS.
General procedure for the synthesis of protected C-terminal peptides: To an activated peptide
as cyclic urethane moiety on the solid support, cleavage cocktail of 95:2.5:2.5, trifluoroacetic
acid:triisopropyl silane:water was added and left on shaker for 2 hrs. Resulting solution was
concentrated and oily residue was triturated with diethyl ether to obtain a white suspension. The
resulting protected C-terminal peptide was purified by HPLC and analyzed by MS. HPLC: 0.1%
FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); gradient 0-80 %, 0.1% FA
(v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 220 nm.

Procedure for Native Chemical Ligation: Peptide hydrazide Ac-GPMLA-CONHNH2 was
cleanly released from Ac-GPMLA-Oxd by treatment with hydrazine monohydrate and DIEA in
acetonitrile at 65 °C for 2 hrs. After the filtration of the resin and removal of acetonitrile by a
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stream of nitrogen, an aqueous phosphate (0.2 M) buffer containing 6.0 M guanidinum chloride
followed by addition of cysteine containing peptide CRFAS-NH2 was added (final peptide
concentration of 1.5 and 2.0 mM, respectively). At low pH (3.0) and temperature (−10 °C), an
aqueous NaNO2 solution was added to the ligation mixture. After 20 min, 4-mercaptophenylacetic
acid (MPAA) was added, the pH value was adjusted to 7.0, and the reaction was left at room
temperature for 16 hrs. The formation of the ligation product Ac-GPMLACRFAS-NH2 was
analyzed by injecting the sample in the HPLC and MS after regular intervals of time.
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CHAPTER 6: SERINE PROMOTED SYNTHESIS OF PEPTIDE
THIOESTER-PRECURSOR ON SOLID SUPPORT FOR NATIVE
CHEMICAL LIGATION
6.1 ABSTRACT
Fmoc solid phase peptide synthesis of thioesters for the chemical synthesis of proteins via
native chemical ligation is a challenge. We have developed a versatile approach for the direct
synthesis of peptide thioesters from a solid support utilizing Fmoc chemistry. Peptide thioester
synthesis is performed by the formation of a cyclic urethane moiety via a selective reaction of the
backbone amide chain with the side group of serine. The activated cyclic urethane moiety
undergoes displacement by a thiol to generate the thioester directly from the solid support.
Importantly, the method activates the serine residue for the synthesis of peptide thioesters; it is
fully automated and free of the types of resins, linkers, handles, and unnatural amino acids typically
needed for the synthesis of peptide thioesters using Fmoc chemistry. The resulting thioester is free
of epimerization and is successfully applied for the synthesis of longer peptides using NCL.

6.2 CHAPTER OBJECTIVES
This chapter describes a simple and versatile approach for the Fmoc solid phase synthesis
of peptide thioesters for chemical synthesis of proteins by native chemical ligation (NCL). A novel
methodology for the activation of serine to generate peptide thioesters from solid support was
developed and resulting peptide thioesters can be directly used in NCL to yield the desired protein
without further modifications.
Fmoc SPPS of peptide thioesters are of high significance because they are precursors for
convergent synthesis of proteins via NCL. As a result, there is a great necessity for an effective
Fmoc solid-phase approach for the preparation of peptide thioesters. Currently, peptide thioesters
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are synthesized by the use of sulfonamide safety catch linkers, O/N to S acyl shift methods, an
activated N-acylurea linker, a backbone pyro-glutamyl imide linker, and peptide hydrazides.
Despite these significant advances, current approaches for the synthesis of peptide thioesters are
limited by a ‘slow rate’ of ligation, the requirement of acidic conditions, formation of various side
products, and the need for unnatural linkers at the C-terminus. Our strategy provides a novel way
for the modification of serine on a solid support which acts as a thioester surrogate. The modified
serine as a thioester surrogate undergoes nucleophilic displacement with a thiol to generate a
peptide thioester directly from the solid support. The technique relies on reactivity of the side
chain of serine for the acylation of backbone amide chain to generate the cyclic urethane moiety
on solid support. The cyclic urethane moiety has a potential to act as a thioester surrogate to
generate peptide thioesters directly from a solid support and post synthetic steps prior to NCL are
not required.

6.3 GRAPHICAL ABSTRACT
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Figure 6.1 Graphical abstract for Serine Promoted Synthesis of Peptide Thioester-Precursor on
Solid Support for Native Chemical Ligation. Figure adopted with permission from: Elashal, H.;
Sim, Y. E.; Raj, M. Chem. Sci. 2017, 8, 117.1

6.4 INTRODUCTION
Total chemical synthesis of proteins provides easy access to various modified proteins with
high stability and improved biological activity which can be key in understanding the importance
of various post translational modifications.2,3 Native Chemical Ligation (NCL) has revolutionized
the field of chemical synthesis of proteins and relies on the reaction of a peptide thioester with a
cysteinyl peptide.4 Thus, considerable effort has been applied for synthesis of peptide thioesters
using Fmoc or Boc solid- phase peptide synthesis (SPPS) approach.
The common method for generation of peptide thioesters by Boc-based SPPS utilizes
special thioester linkers but Boc chemistry is limited by the use of harsh cleavage conditions,
usually hydrofluoric acid (HF), thus is not suitable for synthesis of post-translationally modified
peptides such as glyco- or phospho-peptides.5 Fmoc SPPS is not applicable on thioester resins
because of the instability of the peptide thioesters towards the piperidine treatment used for the
deprotection of Fmoc group. Substantial efforts have been utilized for the synthesis of peptide
thioesters by Fmoc SPPS approach such as use of less basic Fmoc deprotection protocol,6 use of
sulfonamide safety catch linkers,7 activation of protected peptides in solution,8 O/N to S acyl shift
methods,9-15 and peptide hydrazides.16-18 Activation of protected peptides in solution for synthesis
of thioesters is limited by the susceptibility of the C-terminal residue to racemization. Despite the
significant advances of O/N to S acyl shift methods, they are limited by slow ligation kinetics,14
and peptide hydrazides require acidic conditions,14 which is unsuitable for synthesis of acid
sensitive post translationally modified peptides.
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Another significant approach for the formation of a thioester is the activation of a relatively
inert backbone amide bond followed by subsequent thiolysis. Examples include, an activated Nacylurea linker,19,20 a backbone pyro-glutamyl imide linker.21 An activated N-acylurea approach
has been extensively used for synthesis of variety of proteins19,20 but is limited by the use of an
unnatural amino acid, formation of various side products,22,23 and requirement of additional steps
for the synthesis of N-methylated unnatural amino acid. Whereas, a backbone pyro-glutamyl imide
linker is limited by the instability of the resin.21 Thus, an efficient and versatile route to peptide
thioesters via Fmoc-SPPS is highly desirable.
This chapter describes an approach for the Fmoc synthesis of peptide thioesters for use in
NCL that is based on the activation of the amide backbone chain at a serine residue. The
significance of this approach is that it utilizes a natural serine residue that can be automatically
assembled onto the solid support and does not require special unnatural amino acids and loading
procedures, which makes it distinct from the currently used methods.19,20 We believe that this
accessible and robust Fmoc-based thioesterication technique provides a significant advance to
chemical protein synthesis due to its uncomplicated nature, therefore eliminating special
precautions and additional steps typically needed for the synthesis of peptide thioesters.19,20
This approach relies on the site-selective activation of a backbone amide bond at the Cterminal serine residue for the generation of a cyclic urethane moiety on the solid support.
Synthesis of peptide thioesters by this strategy entails anchoring of a C-terminal serine residue
with a selectively removable side-chain protecting group to a solid support (Scheme 6.1). Next,
the side-chain of serine is selectively deprotected and activated by an electrophile that results in
the formation of a cyclic urethane moiety on resin (Scheme 6.1). Next, nucleophilic displacement
of the cyclic urethane moiety by treatment with a thiol releases the peptide thioester from the solid
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support, which can then be deprotected in the solution (Scheme 6.1). It is noteworthy that this
approach utilizes a natural serine during chain assembly followed by acylation of the backbone
amide chain and is compatible with various amino acids and protecting groups commonly utilized
in Fmoc solid phase peptide synthesis. Moreover, the thioester is directly obtained from the solid
support thus reduces the need for extra steps before proceeding with NCL.

Scheme 6.1 Rationale for the development of cyclic urethane technique (CUT) for the synthesis
of peptide thioesters and its application in native chemical ligation for chemical synthesis of
proteins. Scheme adopted from reference (1) with permission.

6.5 RESULTS AND DISCUSSION
To test the proposed methodology for the synthesis of thioesters, the first step was the
synthesis of the cyclic urethane moiety from a serine residue on the solid support. The serine
activation reaction was explored on a solid support with the peptide Fmoc-Gly-Xaa-Ser-Phe-AlaGly, where various amino acids were substituted in the Xaa position.(Table 6.1) It is noteworthy
that the formation of the activated cyclic urethane moiety is independent of the nature of the amino
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acid preceding serine and a high conversion to cyclic urethane moiety was obtained even with
bulky amino acid residues next to serine such as Tyr, Trp, and Val (Table 6.1, substrates 1e’-1g’).
Moreover, activation of serine does not depend upon the relative position of serine and the resin.
Table 6.1 Substrate scope of Ser Cyclization on Fmoc-Gly-Xaa-Ser-Phe-Ala-Gly

Table 6.1 adopted from reference (1) with permission.
The stability of the cyclic urethane moiety on the resin bound peptide was evaluated. The
resin bound cyclic urethane moiety is very stable in a desiccator for longer than a month, which is
in contrast to previously reported pyroglutamyl imide precursor method.21 Moreover, formation of
the cyclo-urethane moiety on the peptide Fmoc-GFA(L)Oxd (2f) and the corresponding
diastereoisomer Fmoc-GFA(D)Oxd (2f’) showed no sign of epimerization when analyzed by
HPLC (Figure 6.2).

137

Figure 6.2 HPLC traces of (a) purified peptide with cyclic urethane moiety 2f Fmoc-GFA(L)-Oxd
(b) purified peptide diastereoisomer 2f’ Fmoc-GFA(D)-Oxd and (c) mixture containing both
diastereoisomers of cyclic urethane activated peptides 2f and 2f’, demonstrating lack of detectable
epimerization. Figure adopted from reference (1) with permission.
After activating the peptide backbone as a cyclic urethane moiety on model peptide AcGPMLA-Oxd-Rink AM (2g) on solid support, the thiolysis reaction was performed (Table 6.2).
The resin was treated with varying amounts of thiol/base mixtures and solvents at different
temperatures, in order to release the peptide into solution as a peptide thioester Ac-GPMLA-COSR
3g. The resin was then filtered and solvent was evaporated to obtain peptide thioester 3g which
was analyzed by HPLC, MS and NMR.
Table 6.2 Synthesis of peptide thioester 3g/3G from activated peptide Ac-GPMLA-Oxd-Rink AM
2g on solid support.a
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Conv. (%)b
3g
3G

Entry

Base (equiv.)

Solvent

Temp.
(°C)

Time
(h)

1

-

DMF

RT

20

10

15

2

DBU
(5 equiv.)

DMF

RT

20

40 c

60

3

DIEA
(20 equiv.)

DMF

RT

20

60 c

65

4

PhSNa
(0.5 equiv.)

DMF

RT

20

85 c

99

5

PhSNa
(0.5 equiv.)

ACN

RT

20

10 c

20

6

PhSNa
(0.5 equiv.)

DMF

RT

5

30

35

7

PhSNa
(0.5 equiv.)

DMF

HS, 60 °C

20

10 c

70 c

8

PhSNa
(0.5 equiv.)

DMF

HS, 60 °C

5

30 c

99

9

PhSNa
(0.5 equiv.)

DMF

HS, 60 °C

3

50 c

99

a

Reaction conditions: Cyclic urethane activated peptide Ac-GPMLA-Oxd, 2g (25 mg, 0.7 mmol/g)
on solid support was reacted with thiol (100 µL), and base (0.5-20 equiv.), in DMF (1 mL).
b
Conversion to peptide thioester Ac-GPMLA-COSR 3g or Ac-GPMLA-COSR 3G was calculated
from the absorbance at 220 nm using HPLC. cActivated peptide was completely released from the
resin but hydrolysis product was observed along with the thioester 3g. RSH = SH-(CH2)2-OH or
R’SH = SH-(CH2)2-COOC2H5, HS = heated shaker, RT = room temperature, Entries in bold:
optimized conditions. Thioesterification at HS leads to 5-10% epimerization. Table adopted from
reference (1) with permission.
Initially, the reaction was performed at room temperature using DMF as a solvent in the
presence of a thiol without use of any base (entry 1, Table 6.2). This resulted in the release of 10%
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peptide thioester 3g from the resin after treatment for 20 h. To increase the conversion to peptide
thioester 3g, various bases such as DIEA, DBU and sodium thiolate were investigated (entries 24, Table 2.3). Addition of a catalytic amount of sodium thiolate as a base significantly increased
the yield of peptide thioester 3g released from the resin (80%; entry 4, Table 6.2). Since it is
difficult to remove DMF from the reaction mixture, a less volatile solvent such as ACN was
explored, but resulted in very low conversion to a peptide thioester 3g (20 %; entry 5, Table 6.2).
The final yields in ACN were low due to the poor solubility of sodium thiolate in ACN.
Temperatures higher than 60 °C resulted in the significant hydrolysis of peptide thioester 3g into
the corresponding acid (entries 7-9, Table 6.2). The formation of the hydrolyzed product was
circumvented by the use of ethyl-3-mercaptopropionate, which gave stable peptide thioesters 3G
that are less susceptible to hydrolysis. All reactions were clean at room temperature irrespective
of the nature of thiol used and did not show significant amounts of hydrolysis.
Potential epimerization during the thioesterification process was rigorously examined by
synthesizing a peptide thioester Ac-GPMLA(L)-COS(CH2)2OH 3g under optimized reaction
conditions and epimer Ac-GPMLA(D)-COS(CH2)2OH 3g’. No detectable levels of epimerization
were observed as analyzed by HPLC (Figure 6.3). Next, we investigated epimerization studies on
peptide thioester Ac-GVALF(L)-(CH2)2-COOC2H5 3j with bulky Phe residue at the C-terminus
by analyzing it with epimer Ac-GVALF(D)-(CH2)2-COOC2H5 3j’. Less than 1 % of epimerization
was observed as analyzed by HPLC. Indeed, Phe is known as an amino acid relatively prone to
epimerization, and thus these results indicate that our new methodology did not afford substantial
epimerization.
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Figure 6.3 HPLC traces of (a) purified peptide thioester Ac-GPMLA(L)-COS(CH2)2OH 3g (b)
purified peptide thioester diastereoisomer Ac-GPMLA(D)-COS(CH2)2OH 3g’and (c) mixture
containing both diastereoisomers of peptide thioesters 3g and 3g’, demonstrating lack of detectable
epimerization. RSH = HS(CH2)2OH. Figure adopted from reference (1) with permission.
Various peptides with different amino acids and protecting groups were evaluated for the
synthesis of peptide thioesters (Table 6.3). Protecting groups from peptide thioesters were removed
by using a TFA cleavage cocktail in solution. It was noted that the formation of peptide thioesters
is independent of nature of amino acid residues preceding serine. For example, peptides with a
bulky amino acid residue next to serine such as Val, Phe, Glu(tBu), and Ser(tBu) generated the
protected peptide thioesters in a clean manner and with high yields (entries 2-5, Table 6.3). From
these studies, we conclude that the cyclic urethane (Oxd) peptide will be a versatile precursor for
synthesis of peptidyl thioesters.
Table 6.3 Fmoc SPPS synthesis of peptide thioesters via activated serine.a
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Entry

Substrate

Peptide

Conv
(%)b
95

1

2h

2

2i

3

2j

Ac-AVGPPGVA-Oxd
AcR(Pbf)AFK(Boc)Y(tBu)GLE(tBu)
-Oxd
Ac-GVALF-Oxd

4

2k

Ac-Y(tBu)FD(tBu)IR(Pbf)AV-Oxd

90

5

2l

Ac-S(tBu)GIS(tBu)GPLS(tBu)Oxd

95

6
7

2m
2n

Ac-GPMLA-MeOxd
Ac-GPMLA-Thz

90
95

95
95

a

Reaction conditions: Activated peptide, 2 (25 mg, 0.7 mm/g) on solid support was reacted with
ethyl-3-mercaptopropionate (100 µL), and catalytic amount of sodium thiolate (0.5 equiv.), in
DMF (1 mL). bConversion to peptide thioester 3 was calculated from the absorbance at 220 nm
using HPLC. SR = S-(CH2)2-COOC2H5. Table adopted from reference (1) with permission.
Next, the peptide backbone activation was investigated with threonine, because of its side
chain functional group which exhibits similarity with serine. As expected, threonine underwent
smooth cyclization under the optimized reaction conditions and generated

Me

Oxd activated

intermediate (entry 6, Table 6.3). In a similar manner, cysteine generated cyclic thiozolidinone
(Thz) intermediate under the reaction conditions (entry 7, Table 6.3). The activated intermediates;
Me

Oxd and Thz on thiolysis generated peptide thioester 3G.

Importantly, our method was successfully applied for the synthesis of a multi-serine
containing bioactive peptide thioester Ac-SGISGPLS-S(CH2)2CO2C2H5 3L, a fragment of
antimicrobial

bovine

beta-defensin

13,24

from

cyclic

urethane

activated

peptide

S(tBu)GIS(tBu)GPLS(tBu)-Oxd 2l (Figure 6.4). This result and table 6.3 demonstrated the
versatility of cyclic urethane technique in the synthesis of peptide thioesters.
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Figure 6.4 Cyclic urethane technique for the synthesis of the fragment of antimicrobial bovine
beta-defensin 13 bioactive peptide thioester 3L RSH = SH-(CH2)2-COOC2H5. (a) HPLC trace of
pure bioactive peptide thioester 3L and inset shows MS of peptide thioester 3L. Figure adopted
from reference (1) with permission.
Next, we utilized peptide thioesters Ac-GPMLA-COS-(CH2)2-COOC2H5 3G and AcAVGPPGVA-COS-(CH2)2-COOC2H5 3h generated by the cyclic urethane technique in Native
Chemical Ligation (NCL) with an N-terminal cysteine containing peptide Ac-SFARC (Figures 6.5
and 6.6).
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Figure 6.5 Native chemical Ligation of peptide thioester Ac-GPMLA-COSR 3G with Nterminal cysteine peptide Ac-SFARC. RSH = HS-(CH2)2-COOC2H5. Figure adopted from
reference (1) with permission.
Relatively dilute conditions were used for the peptide reactants (1.2 mM) as well as low
concentrations of the 4-mercaptophenylacetic acid catalyst (25 mM). The ligation was completed
after 24 hrs at 37 °C, demonstrating the utility of cyclic urethane technique in the synthesis of
peptide thioesters for the formation of large peptides using NCL.

Figure 6.6 Native Chemical Ligation of peptide thioester Ac-AVGPPGVA-COSR 3h with
N-terminal cysteine peptide Ac-SFARC. RSH = SH-(CH2)2-COOC2H5. Figure adopted
from reference (1) with permission.
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6.6 CONCLUSIONS
We have developed a cyclic urethane activation technique for the rapid synthesis of peptide
thioesters directly from solid support. The cyclic urethane technique carries out the acylation of
the peptide backbone with Ser’s side chain undergoing nucleophilic displacement by a thiol to
release a corresponding thioester into the solution. The significant advantage of this technique is
that unnatural handles or linkers are not required, and peptide synthesis is carried out by FmocSPPS without a need for any special reaction conditions and can be fully automated, thus
constituting a major advance in the field. It is noteworthy that only those peptides that undergo
complete activation are displaced by the thiol into the solution thus delivering very pure thioesters
in the solution. Moreover, activation of serine to the cyclic urethane moiety is compatible with
both unhindered Ala and bulky Phe/Val amino acids next to serine and is resistant to epimerization.
The results suggest that the cyclic urethane activation technique will be utilized in organic
synthesis, including peptide and protein chemistry. Moreover, the cyclic urethane ring is stable
and can be stored in the desiccator for long periods of time without any disintegration.
Applicability of the strategy was demonstrated by the synthesis of long peptides using NCL. As a
result, access to C-terminally activated cyclic urethane peptides will be applicable for the synthesis
of complex post-translationally modified peptides and other biomolecules.

6.7 EXPERIMENTAL SECTION
General: All commercial materials (Aldrich, Fluka, Nova) were used without further purification.
All solvents were reagent grade or HPLC grade (Fisher). Anhydrous THF, diethyl ether, CH2Cl2,
and DMF were obtained from a dry solvent system (passed through column of alumina) and used
without further drying. Conversion % were obtained by comparison of HPLC peak areas of
products and starting material. HPLC was used to monitor the reaction progress. Materials. Fmoc-
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amino acids were obtained from Nova Biochem (EMD Millipore Corporation)(Billerica,
Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained from
ChemPep Inc (Wellington, Florida). N,N,N′,N′-Tetramethyl-O-(1Hbenzotriazol-1-yl)uronium
hexafluorophosphate (HBTU) was obtained from CreoSalus (Louisville, Kentucky). N,N′Disuccinimidyl carbonate (DSC) was obtained from Nova Biochem, under (EMD Millipore
Corporation) (Billerica, Massachusetts). 4-Dimethylaminopyridine (DMAP): Merck KGaA
(Darmstadt, Germany). N,N-Dimethylformamide (DMF): Macron Fine Chemicals (Center Valley,
Pennsylvania). Dichloromethane (DCM), acetonitrile, N,N- Diisopropylethylamine (DIEA), N,N'diisopropylcarbodiimide (DIC), Triethylsilane (TES), were purchased from (EMD Millipore
Corporation)(Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill,
Massachusetts). Trifluoroacetic acid (TFA) was purchased from VWR 100 Matsonford Road
Radnor, PA. Diethyl Ether, 4-mercaptophenylacetic acid (MPAA), sodium thiophenolate (NaSPh),
and Tris(2-carboxyethyl)phosphine hydrochloride TCEP.HCl : Sigma Aldrich (St. Louis,
Missouri). Water was purified using a Millipore MilliQ water purification system.
NMR: Analysis done by Ryan Cohen at Merck facilities located at Rahway, NJ. Proton NMR
spectra were recorded on a 600 MHz spectrometer and carbon NMR spectra on a 151 MHz,
spectrometer at ambient temperature. All NMR chemical shifts (δ) are referenced in ppm relative
to residual solvent or internal tetramethylsilane. 1H NMR chemical shifts referenced to residual
DMSO-d5 at 2.50 ppm, and

13

C NMR chemical shifts referenced to DMSO-d6 at 39.52 ppm.

Carbon NMR spectra are proton decoupled. NMR spectral data are reported as chemical shift
(multiplicity, coupling constants (J), integration). Multiplicity is reported as follows: singlet (s),
broad singlet (bs), doublet (d), doublet of doubles (dd), doublet of triplet (td), triplet (t) and
multiplet (m). Coupling constant (J) in Hertz (Hz).
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Semi-Preparative HPLC: Preparative HPLC chromatography (HPLC) was performed on
Beckman Coulter equipped with System Gold 168 detector and 125P solvent module HPLC with
C-18 reversed-phase column. All separations involved a mobile phase of 0.1% FA (v/v) in water
(solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Semi-preparative HPLC method using
a linear gradient of 0– 80% acetonitrile in 0.1% aqueous FA over 30 min at room temperature with
a flow rate of 3.0 mL min-1 . The eluent was monitored by absorbance at 220 nm unless otherwise
noted.
Analytical HPLC: Analytical HPLC chromatography (HPLC) was performed on an Agilent 1100
series HPLC equipped with a 4.6x150 mm (5µm) C-18 reversed-phase column. All separations
involved mobile phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile
(solvent B). Peptide compositions were evaluated by analytical reverse phase HPLC using a
gradient of 0.1% FA in acetonitrile versus 0.1% FA in water. HPLC method using a linear gradient
of 0–80% 0.1% FA (v/v) acetonitrile in 0.1% aqueous FA over 30 min at room temperature with
a flow rate of 1.0 mL min-1 . The eluent was monitored by absorbance at 220 nm unless otherwise
noted.
LCMS: Mass spectrometry was performed using ultra high-performance liquid chromatographymass spectrometry using the Agilent 1100 Series LCMSD VL MS Spectrometer.
Fmoc Solid-Phase Peptide Synthesis:25 Peptides were synthesized manually on a 0.25 mmol
scale using Rink amide resin. The Fmoc–group was deprotected using 20% piperidine–DMF for
20 min to obtain a deprotected peptide-resin. Fmoc-protected amino acids (1.25 mmol) were
sequentially coupled on the resin using a HBTU (1.25 mmol) and DIEA (1.25 mmol) for 2 hrs at
room temperature. Peptides were synthesized using standard protocols.1 The peptide was cleaved
from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl silane:water for 2 hrs.
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The resin was removed by filtration and the resulting solution was concentrated. The oily residue
was triturated with diethyl ether to obtain a white suspension. The resulting solid was purified by
HPLC.
General procedure for the native chemical ligation for synthesis of large peptides: 900 μL of
ligation buffer pH 7.1 (0.2 M sodium phosphate buffer and 6 M guanidine hydrochloride) was
added to 1.0 mg of the peptide thioester 3G/3h (final concentration 1.3 mM) and 1.3 mg of peptide
CRAFS (final concentration 2 mM) under argon. The mixture was treated with MPAA (3.8 mg,
20 mM) and TCEP.HCl (5.5 mg, 17 mM) and pH of solution was adjusted to 7.0 by using 2N
NaOH solution. The ligation was carried out at 37°C and monitored by RP HPLC. After
completion of reaction, TCEP.HCl (30 mM in water) was added into the reaction mixture and it
was left for stirring at room temperature for 1 hr followed by purification of ligated peptide using
RP-HPLC.
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CHAPTER 7: CONCLUSIONS AND CONTRIBUTIONS TO
KNOWLEDGE
7.1 CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE MADE IN
THIS THESIS
7.1.1 SITE-SELECTIVE CHEMICAL CLEAVAGE OF PEPTIDE BONDS
The second chapter of this thesis focuses on the development of an artificial protease mimic
by site-selective modification of Ser, Thr, Cys, and Glu residues. In this study, we optimized
formation of the cyclic urethane-derived moieties and applied them to site-selective cleavage of
peptide bonds. The substrate scope was explored to determine the effect of neighboring residues
on the effectiveness of cleavage. Generally, neighboring residues had no effect; however, bulky
residues such as Val required longer incubation times in buffer to yield the cleavage product.
Notably, cleavage proceeded even in the presence of Pro which is of significance due to the
resistance of amide bonds neighboring Pro to enzymatic cleavage. Furthermore, the methodology
was successfully applied to peptides containing modifications such as D, β, and N-methylated
residues which are known to hinder enzymatic cleavage in native sequences. Finally, the scope of
the reaction was extended to the scission of bioactive peptides including an amyloid beta peptide
and a fragment of antimicrobial Bovine β-defensin 13. The significance of this research lies in the
ability to cleave peptide bonds even in the presence of post-translational modifications and
mutations which is vital in probing age-related disease and the function of these modifications.
This study was recognized by a publication in Chemical Communications, and it set the foundation
for further exploration of oxazolidinone mediated peptide bond cleavage and its various
applications.
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7.1.2 SEQUENCING OF PROMINENT NATURAL PRODUCTS
The third chapter of this thesis focuses on expanding the application of cyclic urethanemediated cleavage of peptide bonds to sequencing of cyclic peptides and lasso peptides which are
natural products with unique therapeutic and structural properties. This study was accomplished
in collaboration with the Link group at Princeton University, which facilitated expanding the scope
of the study to lasso peptides. By modifying Ser to a cyclic urethane moiety, linearization of these
unique peptides became a feasible task. The methodology was applied to a broad substrate scope
including the ability to modify peptides containing Thr, Cys, Glu, and unnatural amino acids such
as homoserine which account for 60% of naturally occurring cyclic peptides. Utilizing this
methodology, the cleavage and sequencing of stable N-methylated cyclic peptides, Polycarponin
C, and a Somatostatin analogue in addition to lasso peptides lariatin A, albusnodin, and benenodin1 have also been validated. Additionally, we created a peptide rotaxane by the selective cleavage
of benenodin-1. The impact of this work lies in application of a chemical cleavage methodology
for the first time to effectively cleave lasso peptides which is a major milestone in simplifying
sequence determination of lasso peptides, studying the lasso topology, monitoring the effect of
cleavage on sterically locked residues, using lasso peptides as scaffolds for making rotaxane type
interlocked machines, and providing a platform for discovering newly isolated biologically active
peptides. This work was reported in a publication in Angewandte Chemie.

7.1.3 SEQUENCING OF ONE-BEAD-ONE-COMPOUND LIBRARIES
In chapter four, oxazolidinone mediated cleavage of peptide bond is explored on solid
support to facilitate sequencing of HIT peptides post high throughput screening against biological
targets. Since cyclic peptides are attractive therapeutics for drug discovery due to high proteolytic
stability, permeability, and high binding affinity, simplifying the sequencing process is of utmost
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importance in developing lead compounds. Toward this end, we developed a one bead one
compound (OBOC) dual ring opening/cleavage approach for sequencing of hit cyclic peptides by
selective modification of a serine residue to an oxazolidinone moiety within the cyclic peptide and
as a linker to allow for the liberation of the protected linear peptide into solution. The major
advantage of this method is that it is direct, without the need to tag each bead, which makes the
synthesis of libraries of cyclic peptides easier. In addition, our method has high substrate scope
and ring opening of cyclic peptides can be achieved at serine, threonine, cysteine, and glutamic
acid residues, which is a significant advantage over the current OBOC approaches that rely either
on a methionine residue or an unnatural entity. This work was published in Organic Letters.

7.1.4 SYNTHESIS OF C-TERMINALLY MODIFIED PEPTIDES
In this chapter, a universal solid phase strategy for the synthesis of various C-terminal
modified peptides is reported; the method is independent of the type of resins, linkers, and
unnatural moieties typically needed for C-terminal modifications. The technique proceeds by the
modification of C-terminal serine to a cyclic urethane moiety which results in the activation of the
backbone amide chain for the nucleophilic displacement by various nucleophiles to generate Cterminally modified acids, esters, N-alkyl amides, alcohols, and hydrazides. This cyclic urethane
technique (CUT) also provides a general strategy for synthesis of C-terminal protected peptides
which can be used for convergent synthesis of large peptides. A universal solid phase strategy has
been effectively developed and applied for the synthesis of various C-terminal modified peptides,
which are of therapeutic importance due to biological properties that accompany the attachment
of various C-terminal functional groups. This cyclic urethane application has been reported in a
publication in Chemical Communications.
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7.1.5 SYNTHESIS OF THIOESTERS DERIVED FROM FMOC SPPS
In chapter six, we developed a versatile approach for direct synthesis of peptide thioesters
from a solid support utilizing Fmoc chemistry. Fmoc SPPS of peptide thioesters are of high
significance because they are precursors for convergent synthesis of proteins via NCL. As a result,
there is a great necessity for an effective Fmoc solid-phase approach for the preparation of peptide
thioesters. To this end, the modified serine acts as a thioester surrogate and undergoes nucleophilic
displacement with a thiol to generate peptide thioesters directly from the solid support.
Applicability of the strategy was demonstrated by the synthesis of long peptides using NCL. As a
result, access to C-terminally activated cyclic urethane peptides will be applicable for the synthesis
of complex post-translationally modified peptides and other biomolecules. The significance of this
work was recognized by a publication in Chemical Science.
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CHAPTER 2 SUPPLEMENTAL MATERIAL
All of the following figures have been reproduced with permission from: Elashal, H. E.; Raj, M.
Chem. Commun. 2016, 52, 6304.
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Figure A1 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-Ala-Ser-Phe-Ala-Gly-NH2 (1a). LCMS: m/z 730.20 (calcd [M+H]+ = 730.01), Purity:
>95% (HPLC analysis at 254 nm). Retention time: 17.85 min.
Fmoc-Gly-Ala-Oxd-Phe-Ala-Gly-NH2 (2a). LCMS: m/z 756.40 (calcd [M+H]+ = 756.10), 778.5
(calcd [M+Na]+ = 778.0). Purity: >95% (HPLC analysis at 254 nm). Retention time: 17.9 min.
Fmoc-Gly-Ala-OH (3a). LCMS: m/z 369.20 (calcd [M+H]+ = 369.13). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 18.6 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.20 (calcd [M+H]+ = 406.0), 428.2 (calcd [M+Na]+
= 428.3). Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.9 min.
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Figure A2 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-Gly-Oxd-Phe-Ala-Gly-NH2 (2b). LCMS: m/z 742.40 (calcd [M+H]+ = 742.50), 371.9
(calcd [(M+2/)2] + = 371.75). Purity: >95% (HPLC analysis at 254 nm). Retention time: 20.1 min.
Fmoc-Gly-Gly-OH (3b). LCMS : m/z 355.20 (calcd [M+H]+ = 355.1). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 13.8 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 6.9 min.
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Figure A3 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-Met-Oxd-Phe-Ala-Gly-NH2 (2c). LCMS: m/z 816.0 (calcd [M+H]+ = 816.20), 408.2
(calcd [(M+2/)2] + = 408.8). Purity: >95% (HPLC analysis at 254 nm). Retention time: 21.8 min.
Fmoc-Gly-Met-OH (3c). LCMS : m/z 429.60 (calcd [M+H]+ = 429.2). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 21.6 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.1 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min.

169

Figure A4 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
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Fmoc-Gly-His-Oxd-Phe-Ala-Gly-NH2 (2d). LCMS: m/z 822.10 (calcd [M+H]+ = 822.60), 411.2
(calcd [(M+2/)2] + = 411.79). Purity: >95% (HPLC analysis at 254 nm). Retention time: 16.9 min.
Fmoc-Gly-His-OH (3d). LCMS : m/z 435.0 (calcd [M+H]+ = 435.19). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 15.8 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.3 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min.
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Figure A5 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-Tyr-Oxd-Phe-Ala-Gly-NH2 (2e). LCMS: m/z 848.20 (calcd [M+H]+ = 848.62), 424.1
(calcd [(M+2/)2] + = 424.81). Purity: >95% (HPLC analysis at 254 nm). Retention time: 21.1 min.
Fmoc-Gly-Tyr-OH (3e). LCMS : m/z 461.1 (calcd [M+H]+ = 461.22). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 20.9 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min.
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Figure A6 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-Trp-Oxd-Phe-Ala-Gly-NH2 (2f). LCMS: m/z 871.20 (calcd [M+H]+ = 871.6), 436.0
(calcd [(M+2/)2] + = 436.33). Purity: >95% (HPLC analysis at 254 nm). Retention time: 19.8 min.
Fmoc-Gly-Trp-OH (3f). LCMS : m/z 484.1 (calcd [M+H]+ = 484.26). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 16.7 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 6.8 min.
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Figure A7 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-Val-Oxd-Phe-Ala-Gly-NH2 (2g). LCMS: m/z 784.60 (calcd [M+H]+ = 784.58),
392.5 (calcd [(M+2/)2] + = 392.79). Purity: >95% (HPLC analysis at 254 nm). Retention time:
16.6 min.
Fmoc-Gly-Val-OH (3g). LCMS : m/z 397.1 (calcd [M+H]+ = 397.18). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 15.6 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 6.8 min.
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Figure A8 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-(N-hydroxysuccinimide-Lys)-Oxd-Phe-Ala-Gly-NH2 (2h). LCMS: m/z 928.10 (calcd
[M+H]+ = 928.62), 464.2 (calcd [(M+2/)2] + = 464.81). Purity: >95% (HPLC analysis at 254 nm).
Retention time: 17.1 min.
Fmoc-Gly-N-carboxy-Lys-OH (3h). LCMS : m/z 470.1 (calcd [M+H]+ = 470.2). Purity: >95%
(HPLC analysis at 254 nm). Retention time: 15.6 min.
Fmoc-Gly-Lys-OH (3h’). LCMS : m/z 426.1 (calcd [M+H]+ = 426.2). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 14.7 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min.
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Figure A9 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-Asp(cyc)-Oxd-Phe-Ala-Gly-NH2 (2i). LCMS: m/z 782.10 (calcd [M+H]+ = 782.53),
391.1 (calcd [(M+2/)2] + = 391.76). Purity: >95% (HPLC analysis at 254 nm). Retention time:
19.8 min.
Fmoc-Gly-Asp-OH (3i). LCMS : m/z 413.1 (calcd [M+H]+ = 413.14). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 18.8 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.8 min.
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Figure A10 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
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Fmoc-Gly-Pro-Oxd-Phe-Ala-Gly-NH2 (2j). LCMS: m/z 782.20 (calcd [M+H]+ = 782.56), 391.5
(calcd [(M+2/)2] + = 391.78). Purity: >95% (HPLC analysis at 254 nm). Retention time: 19.55
min.
Fmoc-Gly-Pro-OH (3j). LCMS : m/z 395.1 (calcd [M+H]+ = 395.16). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 18.54 min.
Oxd-Phe-Ala-Gly-NH2 (4). LCMS: m/z 406.0 (calcd [M+H]+ = 406.1), 428.0 (calcd [M+Na]+ =
428.2). Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.9 min.
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Figure A11 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Gly-Ala-Oxd-Phe-Arg-Phe-Gly-NH2 (5a). LCMS: m/z 1003.0 (calcd [M+H]+ = 1003.2),
502.0 (calcd [(M+2/)2] + = 501.91). Purity: >95% (HPLC analysis at 254 nm). Retention time:
19.6 min.
Fmoc-Gly-Ala-OH (5b). LCMS : m/z 369.2 (calcd [M+H]+ = 369.13). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 19.89 min.
Oxd-Phe-Arg-Phe-Gly-NH2 (5c). LCMS: m/z 652.3 (calcd [M+H]+ = 652.71), 674.2 (calcd
[M+Na]+ = 674.71). Purity: >95% (HPLC analysis at 254 nm). Retention time: 13.3 min.
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Figure A12 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Ala-Oxd-Phe-Val-Gly-Ala-(Oxd)-Phe-Arg-Phe-Gly-NH2 (6a). LCMS: m/z 1433.2 (calcd
[M+H]+ = 1433.3), 717.1 (calcd [(M+2/)2] + = 717.15). Purity: >95% (HPLC analysis at 254 nm).
Retention time: 13.04 min.
Fmoc-Ala-OH (6b). LCMS : m/z 312.0 (calcd [M+H]+ = 312.07). Purity: >95% (HPLC analysis
at 254 nm). Retention time: 12.9 min.
Oxd-Phe-Val-Gly-Ala-OH (6c). LCMS: m/z 506.3 (calcd [M+H]+ = 506.51), 528.2 (calcd
[M+Na]+ = 528.51). Purity: >95% (HPLC analysis at 254 nm). Retention time: 5.06 min.
Oxd-Phe-Arg-Phe-Gly-NH2 (6d). LCMS: m/z 653.1 (calcd [M+H]+ = 653.71), 675.2 (calcd
[M+Na]+ = 675.71). Purity: >95% (HPLC analysis at 254 nm). Retention time: 9.12 min.
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Figure A13 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Ala-Val-Arg-Oxd-Phe-Oxd-Ala-Arg-Gly-Phe-Gly-NH2 (7a). LCMS: m/z 1428.1 (calcd
[M+H]+ = 1428.29), 714.3 (calcd [(M+2/)2] + = 714.64). Purity: >95% (HPLC analysis at 254
nm). Retention time: 18.2 min.
Fmoc-Ala-Val-Arg-OH (7b). LCMS : m/z 567.2 (calcd [M+H]+ = 567.39). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 17.3 min.
Oxd-Phe-OH (7c). LCMS: m/z 279.1 (calcd [M+H]+ = 279.25), 301.1 (calcd [M+Na]+ = 301.25).
Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.8 min.
Oxd-Ala-Arg-Gly-Phe-Gly-NH2 (7d). LCMS: m/z 619.5 (calcd [M+H]+ = 619.63), 641.4 (calcd
[M+Na]+ = 641.63). Purity: >95% (HPLC analysis at 254 nm). Retention time: 11.87 min.
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Figure A14 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Arg-Ala-Gly-Ala-Ser-Val-Arg-Phe-Ala-Ser-Phe-Gly-OH (8a). LCMS: m/z 1499.1 (calcd
[M+H]+ = 1499.36), 750.0 (calcd [(M+2/)2] + = 750.18). Purity: >95% (HPLC analysis at 254
nm). Retention time: 16.8 min.
Fmoc-Arg-Ala-Gly-Ala-OH (8b). LCMS : m/z 596.2 (calcd [M+H]+ = 596.39). Purity: >95%
(HPLC analysis at 254 nm). Retention time: 12.9 min.
Oxd-Val-Arg-Phe-Ala-OH (8c). LCMS: m/z 605.3 (calcd [M+H]+ = 605.65), 627.4 (calcd
[M+Na]+ = 627.65). Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.71 min.
Oxd-Phe-Gly-OH (8d). LCMS: m/z 335.09 (calcd [M+H]+ = 335.32), 357.1 (calcd [M+Na]+ =
357.32). Purity: >95% (HPLC analysis at 254 nm). Retention time: 6.8 min.
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Figure A15 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-D-Val-D-Arg-D-Lys-D-Ala-D-Oxd-D-Arg-D-Ala- D-Ala-NH2 (9a). LCMS: m/z 1106.0
(calcd [M+H]+ = 1106.02), 553.1 (calcd [(M+2/)2] + = 553.5). Purity: >95% (HPLC analysis at
254 nm). Retention time: 16.9 min.
Fmoc-D-Val-D-Arg-D-Lys-D-Ala-OH (9b). LCMS : m/z 695.3 (calcd [M+H]+ = 695.55). Purity:
>95% (HPLC analysis at 254 nm). Retention time: 19.2 min.
D-Oxd-D-Arg-D-Ala-D-Ala-NH2 (9c). LCMS: m/z 429.3 (calcd [M+H]+ = 429.43), 451.3 (calcd
[M+Na]+ = 451.43), Purity: >95% (HPLC analysis at 254 nm). Retention time: 5.2 min.
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Figure A16 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-D-Val-D-Arg- D-Lys-D-Ala-L-Oxd-D-Arg-D-Ala- D-Ala-NH2 (10a). LCMS: m/z 1106.1
(calcd [M+H]+ = 1106.02), 553.0 (calcd [(M+2/)2] + = 553.5). Purity: >95% (HPLC analysis at
254 nm). Retention time: 16.89 min.
Fmoc-D-Val- D-Arg- D-Lys-D-Ala-OH (10b). LCMS : m/z 695.1 (calcd [M+H]+ = 695.55).
Purity: >95% (HPLC analysis at 254 nm). Retention time: 19.18 min.
L-Oxd-D-Arg-D-Ala-D-Ala-NH2 (10c). LCMS: m/z 429.3 (calcd [M+H]+ = 429.43), 451.7
(calcd [M+Na]+ = 451.43.Purity: >95% (HPLC analysis at 254 nm). Retention time: 4.7 min.
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Figure A17 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Cys-Gly-Arg-Arg-Ala-Cys-Gly-Oxd-Phe-Ala-Gly-NH2, disulfide bond (11a). LCMS: m/z
1330.1 (calcd [M+H]+ = 1330.24), 665.5 (calcd [(M+2/)2] + = 665.62). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 13.1 min.
Fmoc-Cys-Gly-Arg-Arg-Ala-Cys-Gly-OH, disulfide bond (11b). LCMS : m/z 942.5 (calcd
[M+H]+ = 942.84), 471.7 (calcd [(M+2/)2] + = 471.92). Purity: >95% (HPLC analysis at 254 nm).
Retention time: 12.2 min.
Oxd-Phe-Ala-Gly-NH2 (11c). LCMS: m/z 406.2 (calcd [M+H]+ = 406.39), Purity: >95% (HPLC
analysis at 254 nm). Retention time: 5.8 min.
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Figure A18 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
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Fmoc-Arg-Ala-Pyr-Ala-Gly-Oxd-Gly-Phe-NH2 (12a). LCMS: m/z 1023.4 (calcd [M+H]+ =
1023.83), 512.1 (calcd [(M+2/)2] + = 512.41). Purity: >95% (HPLC analysis at 254 nm). Retention
time: 13.9 min.
Fmoc-Arg-Ala-OH (12b). LCMS : m/z 468.09 (calcd [M+H]+ = 468.26). Purity: >95% (HPLC
analysis at 254 nm). Retention time: 12.5 min.
Pyr-Ala-Gly-OH (12c). LCMS: m/z 258.14 (calcd [M+H]+ = 258.24), 280.0 (calcd [M+Na]+ =
280.24). Purity: >95% (HPLC analysis at 254 nm). Retention time: 4.98 min.
Oxd-Gly-Phe-NH2 (12d). LCMS: m/z 335.2 (calcd [M+H]+ = 335.32), 357.4 (calcd [M+Na]+ =
357.32). Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.98 min.
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Figure A19 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Arg-Pro-Pro-Gly-Phe-Oxd-Pro-Phe-Arg-NH2 (13a). LCMS: m/z 1308.3 (calcd [M+H]+ =
1308.22), 654.3 (calcd [(M+2/)2] + = 654.61). Purity: >95% (HPLC analysis at 254 nm). Retention
time: 16.2 min.
Fmoc-Arg-Pro-Pro-Gly-Phe-OH (13b). LCMS : m/z 795.3 (calcd [M+H]+ = 795.64). Purity:
>95% (HPLC analysis at 254 nm). Retention time: 14.9 min.
Oxd-Pro-Phe-Arg-NH2 (13c). LCMS: m/z 531.3 (calcd [M+H]+ = 531.57), Purity: >95% (HPLC
analysis at 254 nm). Retention time: 7.28 min.
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Figure A20 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Leu-Asn-Asp-Arg-Leu-Ala-Oxd-Tyr-Leu-NH2 (14a). LCMS: m/z 1312.0 (calcd [M+H]+
= 1312.2), 656.1 (calcd [(M+2/)2] + = 656.6). Purity: >95% (HPLC analysis at 254 nm). Retention
time: 21.18 min.
Fmoc-Leu-Asn-Asp-Arg-Leu-Ala-OH (14b). LCMS : m/z 923.4 (calcd [M+H]+ = 923.77). Purity:
>95% (HPLC analysis at 254 nm). Retention time: 15.1 min.
Oxd-Tyr-Leu-NH2 (14c). LCMS: m/z 407.2 (calcd [M+H]+ = 407.42), 429.3 (calcd [M+Na]+ =
429.42). Purity: >95% (HPLC analysis at 254 nm). Retention time: 7.9 min.
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Figure A21 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
OAc-Ala-Val-Ala-Pro-Ala-Ala-Oxd-Ile-Val-Ala-NH2 (15a). LCMS: m/z 937.1 (calcd [M+H]+
= 937.02), Purity: >95% (HPLC analysis at 254 nm). Retention time: 10.9 min.
OAc-Ala-Val-Ala-Pro-Ala-Ala-OH (15b). LCMS : m/z 541.4 (calcd [M+H]+ = 541.56). Purity:
>95% (HPLC analysis at 254 nm). Retention time: 8.2 min.
Oxd-Ile-Val-Ala-NH2 (15c). LCMS: m/z 414.3 (calcd [M+H]+ = 414.46), Purity: >95% (HPLC
analysis at 254 nm). Retention time: 6.1 min.
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Figure A22 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
OAc-Ala-Val-Ala-Pro-βAla-Ala-Oxd-Ile-Val-Ala-NH2 (16a). LCMS: m/z 937.1 (calcd [M+H]+
= 937.02), 975.1 (calcd [M+K] + = 975.02). Purity: >95% (HPLC analysis at 254 nm). Retention
time: 10.6 min.
OAc-Ala-Val-Ala-Pro-βAla-Ala-OH (16b). LCMS : m/z 541.4 (calcd [M+H]+ = 541.56). Purity:
>95% (HPLC analysis at 254 nm). Retention time: 7.6 min.
Oxd-Ile-Val-Ala-NH2 (15c). LCMS: m/z 414.3 (calcd [M+H]+ = 414.46), Purity: >95% (HPLC
analysis at 254 nm). Retention time: 5.9 min.
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Figure A23 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in buffer solution; the product peak is labeled.
Fmoc-Leu-Arg-Arg-Ala-Oxd-(N-methyl)Leu-Gly-NH2 (17a). LCMS: m/z 1033.5 (calcd [M+H]+
= 1033.91), 517.3 (calcd [(M+2/)2] + = 517.45). Purity: >95% (HPLC analysis at 254 nm).
Retention time: 11.9 min.
Fmoc-Leu-Arg-Arg-Ala-OH (17b). LCMS : m/z 737.4 (calcd [M+H]+ = 737.61), 369.1 (calcd
[(M+2/)2] + = 369.3)Purity: >95% (HPLC analysis at 254 nm). Retention time: 11.51 min.
Oxd-(N-methyl)Leu-Gly-NH2 (17c). LCMS: m/z 315.2 (calcd [M+H]+ = 315.3), 337.1 (calcd
[M+Na]+ = 337.3) Purity: >95% (HPLC analysis at 254 nm). Retention time: 8.88 min.
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CHAPTER 3 SUPPLEMENTAL MATERIAL
All of the following figures have been reproduced with permission from: Elashal, H. E.; Cohen,
R. D.; Elashal, H. E.; Zong, C.; Link, A. J.; Raj, M. Angew. Chem. 2018, DOI:
10.1002/anie.201801299.

Figure A24 MS/MS data for a) cyc(SFRYAE) 4, b) activated oxazolidinone (Oxd)-containing
macrocyclic peptide, cyc(Oxd-FRYAE) 5, and c) Oxd-FRYAE 6 showing that MS/MS of ringopened peptide is much simpler to interpret.
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Figure A25 Total ion chromatograms and HRMS spectra for lariatin A (1a/b) incubated with
trypsin (2a/b) and both trypsin and chymotrypsin (3a/b) for 48 h. Some protease degradation was
observed due to self-cleavage. Peak intensities and ion abundances were similar for each sample
indicating that lariatin A is stable to protealytic cleavage.
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Figure A26 Deconvoluted mass spectra for albusnodin (below) and chemical cleavage product
(above) at Ser-7.
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CHAPTER 4 SUPPLEMENTAL MATERIAL
All of the following figures have been reproduced with permission from: Elashal, H. E.; Cohen,
R. D.; Elashal, H. E.; Raj, M. Org. Lett. 2018, 20 (8), 2374.
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Figure A27 Macrocyclic ring-opening and resin-cleavage of peptide 1a, cyc(GFSFAE)-S-Rink
cyc(Gly-Phe-Ser-Phe-Ala-Glu)-Ser-CONH2 (1a). LC-MS: m/z 724.8 (calcd [M+H]+ = 725.3),
m/z 746.8 (calcd [M+Na]+ = 747.3), Purity: >95% (HPLC analysis at 220 nm). Retention time:
10.19 min
cyc(Gly-Phe-Oxd-Phe-Ala-Glu)-Oxd-CONH2 (2a). LC-MS: m/z 776.7 (calcd [M+H]+ = 777.2),
m/z 798.7 (calcd [M+Na]+ = 799.2), 1552.2 (calcd [2M+H]+ = 1554.4), 1574.3 (calcd [2M+Na]+
= 1576.4), Purity: >95% (HPLC analysis at 220 nm). Retention time: 13.5 min
Oxd-Phe-Ala-Glu-Gly-Phe (3a). LC-MS: m/z 682.7 (calcd [M+H]+ = 683.2), m/z 704.8 (calcd
[M+Na]+ = 705.2), Purity: >95% (HPLC analysis at 220 nm). Retention time: 11.3 min
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Figure A28 HPLC trace and mass spectrum of peptide 1a, cyc(GFSFAE)-S-CONH2 after resin
cleavage
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Figure A29 HPLC trace and mass spectrum of peptide 2a, Cyc(GF-Oxd-FAE)-Oxd-CONH2 after
resin cleavage
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Figure A30 HPLC trace and mass spectrum of peptide 3a, Oxd-FAEGF-OH

Figure A31 LC-IM-MS/MS data for linear peptide 3a, Oxd-FAEGF-OH. a) extracted MS spectrum, and
b) filtered MS/MS spectrum based on product peak drift time. Calcd [M+H]+ = 683.2671,
Found [M+H]+ = 683.2670
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Figure A32 Macrocyclic ring-opening and resin-cleavage of peptide 1b, cyc(SFFAE)-S-Rink
cyc(Ser-Phe-Phe-Ala-Glu)-Ser-CONH2 (1b). LCMS: m/z 668.0 (calcd [M+H]+ = 668.3), m/z
690.3 (calcd [M+Na]+ = 690.3), Purity: >95% (HPLC analysis at 220 nm). Retention time: 13.96
Oxd-Phe-Phe-Ala-Glu (3b). LCMS: m/z 625.8 (calcd [M+H]+ = 626.24), m/z 647.5 (calcd
[M+Na]+ = 648.24), Purity: >95% (HPLC analysis at 220 nm). Retention time: 11.71 min
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Figure A34 HPLC trace and mass spectrum of peptide 3b, Oxd-SFFAE-OH
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Figure A35 LC-IM-MS/MS data for linear peptide 3b, Oxd-FFAE-OH. a) extracted MS spectrum, and
b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 626.2457, Found [M+H]+ = 626.2450
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Figure A36 Macrocyclic ring-opening and resin-cleavage of peptide 1c, cyc(SGVFAE)-S-Rink
cyc(Ser-Gly-Val-Phe-Ala-Glu)-Ser-CONH2 (1c). LCMS: m/z 676.70 (calcd [M+H]+ = 677.3),
Purity: >95% (HPLC analysis at 220 nm). Retention time: 9.5 min
Oxd-Gly-Val-Phe-Ala-Glu (3c). LCMS: m/z 635.0 (calcd [M+H]+ = 635.6), Purity: >95% (HPLC
analysis at 220 nm). Retention time: 7.9 min
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Figure A39 Macrocyclic ring-opening and resin-cleavage of peptide 1d, cyc(GSFAE)-S-Rink
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cyc(Gly-Ser-Phe-Ala-Glu)-Ser-CONH2 (1d). LCMS: m/z 578.0 (calcd [M+H]+ = 578.2), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 9.68 min
Oxd-Phe-Ala-Glu-Gly (3d). LCMS: m/z 536.0 (calcd [M+H]+ = 536.1), Purity: >95% (HPLC
analysis at 220 nm). Retention time: 9.55 min
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Figure A42 Macrocyclic ring-opening and resin-cleavage of peptide 1e, cyc(GFKSYGLE)-SRink
cyc(Gly-Phe-Lys-Ser-Tyr-Gly-Leu-Glu)-Ser-CONH2 (1e). LCMS: m/z 967.7 (calcd [M+H]+ =
968.4), m/z 989.7, (calcd [M+Na]+ = 990.4), m/z 484.5 (calcd [(M+2)/2]+ = 484.7), Purity: >95%
(HPLC analysis at 220 nm). Retention time: 10.12
Oxd-Tyr-Gly-Leu-Glu-Gly-Phe-Lys (3e). LCMS: m/z 925.7 (calcd [M+H]+ = 926.4), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 9.5 min
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Figure A45 Macrocyclic ring-opening and resin-cleavage of peptide 1f, cyc(AFSIGFE)-S-Rink
cyc(Ala-Phe-Ser-Ile-Gly-Phe-Glu)-Ser-CONH2 (1f). LCMS: m/z 837.8 (calcd [M+H]+ = 838.4),
m/z 859.7 (calcd [M+Na]+ = 860.4), Purity: >95% (HPLC analysis at 220 nm). Retention time:
11.9
Oxd-Ile-Gly-Phe-Glu-Ala-Phe (3f). LCMS: m/z 795.8 (calcd [M+H]+ = 795.3), m/z 818.7, (calcd
[M+Na]+ = 817.3), Purity: >95% (HPLC analysis at 220 nm). Retention time: 12.8 min
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Figure A48 Macrocyclic ring-opening and resin-cleavage of peptide 1g, cyc(AFSFE)-T-Rink
cyc(Ala-Phe-Ser-Phe-Glu)-Thr-CONH2 (1g). LCMS: m/z 681.90 (calcd [M+H]+ = 682.3), m/z
1363.7 (calcd [2M+H]+ = 1364.6), Purity: >95% (HPLC analysis at 220 nm). Retention time:
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Oxd-Phe-Glu-Ala-Phe (3g). LCMS: m/z 625.8 (calcd [M+H]+ = 626.2), Purity: >95% (HPLC
analysis at 220 nm). Retention time: 11.31 min
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Figure A51 Macrocyclic ring-opening and resin-cleavage of peptide 1h, cyc(GFCE)-C-Rink
cyc(Gly-Phe-Cys-Glu)-Cys-CONH2 (1h). LCMS: m/z 539.0 (calcd [M+H]+ = 539.1), m/z
1076.0, (calcd [dimer]+ = 1076.2) m/z 1098.5 (calcd [dimer+Na]+ = 1099.2), Purity: >95% (HPLC
analysis at 220 nm). Retention time: 12.8
Thz-Glu-Gly-Phe (3h). LCMS: m/z 480.9 (calcd [M+H]+ = 481.1), Purity: >95% (HPLC analysis
at 220 nm). Retention time: 9.1 min
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Figure A54 Macrocyclic ring-opening and resin-cleavage of peptide 1i, cyc(AMPFISFPE)-CRink
cyc(Ala-Met-Pro-Phe-Ile-Ser-Phe-Pro-Glu)-Cys-CONH2 (1i). LCMS: m/z 1121.7 (calcd
[M+H]+ = 1122.5), m/z 1143.7, (calcd [M+Na]+ = 1144.5) 561.5 (calcd [M+Na]+ = 561.7), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 15.1 min
Oxd-Phe-Pro-Glu-Ala-Met-Pro-Phe-Ile (3i). LCMS: m/z 1063.6 (calcd [M+H]+ = 1064.4), m/z
1087.8, (calcd [M+Na]+ = 1086.4) m/z 532.5 (calcd [M+Na]+ = 532.7), Purity: >95% (HPLC
analysis at 220 nm). Retention time: 14.5 min
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Figure A57 LC-IM-MS/MS data for linear peptide 3a, Oxd-FAEGF-OH. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 683.2671, Found [M+H]+ = 683.2670
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Figure A58 LC-IM-MS/MS data for linear peptide 3b, Oxd-FFAE-OH. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 626.2457, Found [M+H]+ = 626.2450
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Figure A59 LC-IM-MS/MS data for linear peptide 3c, Oxd-GVFAE-OH. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 635.2671, Found [M+H]+ = 635.2663
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Figure A60 LC-IM-MS/MS data for linear peptide 3d, Oxd-FAEG-OH. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 536.1987, Found [M+H]+ = 536.1993
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Figure A61 LC-IM-MS/MS data for linear peptide 3e, Oxd-YGLEGFK-OH. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 926.4254, Found [M+H]+ = 926.4267
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Figure A62 LC-IM-MS/MS data for linear peptide 3f, Oxd-IGFEAF-OH. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 796.3512, Found [M+H]+ = 796.3514
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Figure A63 LC-IM-MS/MS data for linear peptide 3g, Oxd-FEAF-OH. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 626.2457, Found [M+H]+ = 626.2445

246

Figure A64 LC-IM-MS/MS data for linear peptide 3h, Thz-EGF-OH. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 481.1388, Found [M+H]+ = 481.1361
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Figure A65 LC-IM-MS/MS data for linear peptide 3i, Oxd-FPEAMPFI-OH. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time
Calcd [M+H]+ = 1064.4757, Found [M+H]+ = 1064.4731
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Figure A66 LC-IM-MS/MS data for linear peptide, Oxd-MRE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ =
547.2293, Found [M+H]+ = 547.2303
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Figure A67 LC-IM-MS/MS data for linear peptide, Oxd-AFE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time Calcd [M+H]+ =
478.1932, Found [M+H]+ = 478.1918
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Figure A68 LC-IM-MS/MS data for linear peptide Oxd-TFVE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
607.2722, Found [M+H]+ = 607.2716
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Figure A69 LC-IM-MS/MS data for linear peptide Oxd-FRVE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
662.3257, Found [M+H]+ = 662.3265
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Figure A70 LC-IM-MS/MS data for linear peptide Oxd-YFAE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
641.2566, Found [M+H]+ = 641.2561
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Figure A71 LC-IM-MS/MS data for linear peptide Oxd-NYAE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
608.2311, Found [M+H]+ = 608.2335
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Figure A72 LC-IM-MS/MS data for linear peptide Oxd-YIGE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
593.2566, Found [M+H]+ = 593.2584
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Figure A73 LC-IM-MS/MS data for linear peptide Oxd-FNTE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ =
622.2467, Found [M+H]+ = 622.2461
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Figure A74 LC-IM-MS/MS data for linear peptide Oxd-VRFAE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ =
733.3628, Found [M+H]+ = 733.3651
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Figure A75 LC-IM-MS/MS data for linear peptide Oxd-FRYAE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
797.3577, Found [M+H]+ = 797.3595
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Figure A76 LC-IM-MS/MS data for linear peptide Oxd-NYAAE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
679.2682, Found [M+H]+ = 679.2676
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Figure A77 LC-IM-MS/MS data for linear peptide Oxd-YIGAE-NH2. a) extracted MS spectrum, and b)
filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ = 664.2937, Found
[M+H]+ = 664.2947
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Figure A78 LC-IM-MS/MS data for linear peptide Oxd-YFVGE-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
726.3093, Found [M+H]+ = 726.3115
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Figure A79 LC-IM-MS/MS data for linear peptide Oxd-KIFEG-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
705.3566, Found [M+H]+ = 705.3576
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Figure A80 LC-IM-MS/MS data for linear peptide Oxd-HVDEF-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H]+ =
758.3104, Found [M+H]+ = 758.3105
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Figure A81 LC-IM-MS/MS data for linear peptide Oxd-TLDEF-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
736.3148, Found [M+H]+ = 736.3156
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Figure A82 LC-IM-MS/MS data for linear peptide Oxd-RQFEA-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
762.3529, Found [M+H]+ = 762.3531
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Figure A83 LC-IM-MS/MS data for linear peptide Oxd-KIFAGE-NH2. a) extracted MS spectrum, and
b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + = 776.3937,
Found [M+H]+ = 776.3944
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Figure A84 LC-IM-MS/MS data for linear peptide Oxd-AHDVGE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 739.3006, Found [M+H]+ = 739.2987
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Figure A85 LC-IM-MS/MS data for linear peptide Oxd-TYDAFE-NH2. a) extracted MS

spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 857.3312, Found [M+H]+ = 857.3307
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Figure A86 LC-IM-MS/MS data for linear peptide Oxd-TFKRVE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 891.4683, Found [M+H]+ = 891.4704
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Figure A87 LC-IM-MS/MS data for linear peptide Oxd-IGFEAF-NH2. a) extracted MS spectrum,
and b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+H] + =
795.3672, Found [M+H]+ = 795.3683
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Figure A88 LC-IM-MS/MS data for linear peptide Oxd-RVDYGAE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 921.4061, Found [M+H]+ = 921.4053
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Figure A89 LC-IM-MS/MS data for linear peptide Oxd-AVFMNAE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 893.3822, Found [M+H]+ = 893.3811
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Figure A90 LC-IM-MS/MS data for linear peptide Oxd-KVRNYAE-NH2. a) extracted MS spectrum, and
b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+2H] 2+ = 496.2514,
Found [M+2H]2+ = 496.2513
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Figure A91 LC-IM-MS/MS data for linear peptide Oxd-RYQVANE-NH2. a) extracted MS spectrum, and
b) filtered MS/MS spectrum based on product peak drift time; Calcd [M+2H] 2+ = 496.2332,
Found [M+2H]2+ = 496.2330
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Figure A92 LC-IM-MS/MS data for linear peptide Oxd-KARFGVE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+2H]2+ = 459.7432, Found [M+2H]2+ = 459.7430
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Figure A93 LC-IM-MS/MS data for linear peptide Oxd-AQVFRFTE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 1109.5374, Found [M+H]+ = 1109.5393
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Figure A94 LC-IM-MS/MS data for linear peptide Oxd-YTFNDKLE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 1141.5160, Found [M+H]+ = 1141.5174
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Figure A95 LC-IM-MS/MS data for linear peptide Oxd-RVKNGFEA-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 1032.5221, Found [M+H]+ = 1032.5232
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Figure A96 LC-IM-MS/MS data for linear peptide Oxd-YLFDWREK-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 1268.6058, Found [M+H]+ = 1268.6067
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Figure A97 LC-IM-MS/MS data for linear peptide Oxd-GYVKDFRAE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+H]+ = 1196.5695, Found [M+H]+ = 1196.5672
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Figure A98 LC-IM-MS/MS data for linear peptide Oxd-AYKFGPSAE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+2H]2+ = 541.2511, Found [M+2H]2+ = 541.2519
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Figure A99 LC-IM-MS/MS data for linear peptide Oxd-ATKFESRVE-NH2. a) extracted MS
spectrum, and b) filtered MS/MS spectrum based on product peak drift time; Calcd
[M+2H]2+ = 589.7937, Found [M+2H]2+ = 589.7917

282

CHAPTER 5 SUPPLEMENTAL MATERIAL
All of the following figures have been reproduced with permission from: Elashal, H. E.; Cohen,
R. D.; Raj, M. Chem. Commun. 2016, 52, 9699.
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Figure A106 1H NMR spectrum for cyclic unprotected peptide 3d, cyc(AKDPYRG), recorded at
600 MHz
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Figure A107 HRMS (+ESI) data for cyclized unprotected peptide 3d, cyc(AKDPYRG)

Figure A108 Synthesis of macrocyclic peptide from unprotected linear peptide acid AKDPYRG
obtained from Wang resin. Various possibilities of the cyclization of linear unprotected peptide
AKDPYRG. Double cyclization of unprotected peptide cyc2(AKDPYRG) was observed as shown
by LCMS.

287

Figure A109 1 H NMR spectrum for linear unprotected peptide, AKDPYRG, recorded at 600
MHz
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Figure A110 13C NMR spectrum for linear unprotected peptide, AKDPYRG, recorded at 151
MHz

Figure A111 HRMS (+ESI) data for linear unprotected peptide, AKDPYRG

Figure A112 1H NMR spectrum for catalyst PFFFOMe 5’, recorded at 600 MHz
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Figure A113 13C NMR spectrum for catalyst PFFFOMe 5’, recorded at 151 MHz

Figure A114 HRMS (+ESI) data for catalyst PFFFOMe 5’
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Figure A115 (a) Synthesis of peptide Fmoc-ARFPPFRAOxd, 9 with semi-permanent protecting
group on the C-terminus using cyclic urethane technique (CUT). (b) HPLC and MS chromatogram
of C-terminal protected peptide Fmoc ARFPPFRA-Oxd, 9.
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Figure A116 MS data for protected C-terminal peptide Fmoc-ARFPPFRA-Oxd, 9.
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Figure A117 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Ac-Gly-Pro-Met-Leu-Ala-Oxd (1A). LCMS: m/z 642.20 (calcd [M+H]+ = 642.28), Purity: >95%
(HPLC analysis at 220 nm). Retention time: 11.36
Ac-Gly-Pro-Met-Leu-Ala (2a). LCMS: m/z 530.1 (calcd [M+H]+ = 530.26), Purity: >95% (HPLC
analysis at 220 nm). Retention time: 11.49 min
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Figure A118 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Gly-Pro-Met-Leu-Ala-Oxd (1A’). LCMS: m/z 600.2 (calcd [M+H]+ = 600.27), Purity: >95%
(HPLC analysis at 220 nm). Retention time: 8.11 min
Gly-Pro-Met-Leu-Ala (2a’). LCMS: m/z 488.40 (calcd [M+H]+ = 488.25), Purity: >95% (HPLC
analysis at 220 nm). Retention time: 7.37 min
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Figure A119 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Fmoc-Gly-Pro-Met-Leu-Ala-Oxd (1A’’). LCMS: m/z 822.3 (calcd [M+H]+ = 822.34), 844.2
(calcd [M+Na]+ = 844.34); Purity: >95% (HPLC analysis at 220 nm). Retention time: 18.2 min.
Fmoc-Gly-Pro-Met-Leu-Ala (2a’’). LCMS: m/z 710.1 (calcd [M+H]+ = 710.31), (HPLC analysis
at 220 nm). Retention time: 20.8 min. Gly-Pro-Met-Leu-Ala (2a’’-Fmoc or 2a’). LCMS: m/z 488.4
(calcd [M+H]+ = 488.25), (HPLC analysis at 220 nm). Retention time: 7.89 min.
295

Figure A120 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Ac-Leu-Phe-Lys-Asn-Ala-Oxd (1B). LCMS: m/z 746.3 (calcd [M+H]+ = 746.38), Purity: >95%
(HPLC analysis at 220 nm). Retention time: 9.14 min.
Ac-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2b). LCMS: m/z 976.5 (calcd [M+H]+ = 976.51), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 22.97 min.
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Figure A121 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Leu-Phe-Lys-Asn-Ala-Oxd (1C). LCMS: m/z 704.3 (calcd [M+H]+ = 704.37), Purity: >95%
(HPLC analysis at 220 nm).
Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2c). LCMS: m/z 934.5 (calcd [M+H]+ = 934.57), Purity: >95%
(HPLC analysis at 220 nm). Retention time: 16.45 min.
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Figure A122 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Fmoc-Leu-Phe-Lys-Asn-Ala-Oxd (1D). LCMS: m/z 926.4 (calcd [M+H]+ = 926.43), 948.3 (calcd
[M+Na] + = 948.43), Purity: >95% (HPLC analysis at 220 nm). Retention time: 15.7 min.
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Fmoc-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2d). LCMS: m/z 1156.5 (calcd [M+H]+ = 1156.57),
1178.5 (calcd [M+Na] + = 1178.57), Purity: >95% (HPLC analysis at 220 nm). Retention time:
26.65 min.
Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2d-Fmoc or 2c). LCMS: m/z 934.5 (calcd [M+H]+ = 934.57),
Purity: >95% (HPLC analysis at 220 nm). Retention time: 16.37 min.

Figure A123 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Phe-Glu-Ser-Gln-Ile-Oxd (1E). LCMS: m/z 735.3 (calcd [M+H]+ = 735.32), Purity: >95% (HPLC
analysis at 220 nm).
Phe-Glu(tBu)-Ser(tBu)-Gln(Trt)-Ile (2e). LCMS: m/z 977.5 (calcd [M+H]+ = 977.53), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 16.96 min.
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Figure A124 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Ac-Arg-Asp-Pro-Met-Leu-Gly-Oxd (1F). LCMS: m/z 842.4 (calcd [M+H]+ = 842.38), 864.4
(calcd [M+Na] + = 864.38), Purity: >95% (HPLC analysis at 220 nm). Retention time: 14.57
min.
Ac-Arg(Pbf)-Asp(tBu)-Pro-Met-Leu-Gly (2f). LCMS: m/z 1038.5 (calcd [M+H]+ = 1038.49),
Purity: >95% (HPLC analysis at 220 nm). Retention time: 17.87 min.
300

Figure A125 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Arg-Asp-Pro-Met-Leu-Gly-Oxd (1G). LCMS: m/z 801.3 (calcd [M+H]+ = 801.36), 823.3 (calcd
[M+Na]+ = 823.36) Purity: >95% (HPLC analysis at 220 nm).
Arg(Pbf)-Asp(tBu)-Pro-Met-Leu-Gly (2g). LCMS: m/z 996.4 (calcd [M+H]+ = 996.48), 1018.5
(calcd [M+Na] + = 1018.48), Purity: >95% (HPLC analysis at 220 nm). Retention time: 15.09 min
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Figure A126 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Ac-Tyr-Leu-Phe-Lys-Asn-Ala-Oxd (1H). LCMS: m/z 909.4 (calcd [M+H]+ = 909.44) Purity:
>95% (HPLC analysis at 220 nm). Retention time: 10.13 min.
Ac-Tyr(tBu)-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2h). LCMS: m/z 1195.6 (calcd [M+H]+ =
1195.64), 1217.6 (calcd [M+Na]+ = 1217.64) Purity: >95% (HPLC analysis at 220 nm). Retention
time: 23.86 min
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Figure A127 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Tyr-Leu-Phe-Lys-Asn-Ala-Oxd (1I). LCMS: m/z 867.3 (calcd [M+H]+ = 867.43), 434.2 (calcd
[M+2H]2+ = 434.21), 889.3 (calcd [M+Na]+ = 889.43), Purity: >95% (HPLC analysis at 220 nm).
Retention time: 7.49 min.
Tyr(tBu)-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2i). LCMS: m/z 1153.6 (calcd [M+H]+ = 1153.63),
Purity: >95% (HPLC analysis at 220 nm). Retention time: 21.08 min.
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Figure A128 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Ac-Val-Trp-Arg-Ala-Oxd (1J). LCMS: m/z 685.3 (calcd [M+H]+ = 685.76), 707.4 (calcd [M+Na]
+ = 707.76), Purity: >95% (HPLC analysis at 220 nm). Retention time: 14.88 min.
Ac-Val-Trp-Arg(Pbf)-Ala (2j). LCMS: m/z 825.4 (calcd [M+H]+ = 825.63), 847.4 (calcd [M+Na]
+ = 847.63), Purity: >95% (HPLC analysis at 220 nm). Retention time: 18.69 min.
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Figure A129 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Ac-Thr-Cys-Asp-Val-Oxd (1K). LCMS: m/z 591.3 (calcd [M+H]+ = 591.5), Purity: >95% (HPLC
analysis at 220 nm). Retention time: 10.16 min.
Ac-Thr(tBu)-Cys(tBu)-Asp(tBu)-Val (2k). LCMS: m/z 647.3 (calcd [M+H]+ = 647.36), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 19.98 min.
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Figure A130 HPLC spectra of the cyclized starting material and the crude reaction mixture after hydrolysis;
the product peak is labeled.
Fmoc-Tyr-Leu-Phe-Lys-Asn-Ala-Oxd (1L). LCMS: m/z 1089.5 (calcd [M+H]+ = 1089.50), Purity: >95%
(HPLC analysis at 220 nm). Retention time: 14.79 min.
Fmoc-Tyr(tBu)-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2l). LCMS: m/z 1375.6 (calcd [M+H]+ = 1375.69),
1397.6 (calcd [M+Na]+ = 1397.69) Purity: >95% (HPLC analysis at 220 nm). Retention time: 18.48 min
Tyr(tBu)-Leu-Phe-Lys(Boc)-Asn(Trt)-Ala (2l-Fmoc). LCMS: m/z 1153.6 (calcd [M+H]+ = 1153.69),
Purity: >95% (HPLC analysis at 220 nm). Retention time: 14.9 min
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Figure A131 HPLC spectra of the cyclized starting material and the crude reaction mixture after hydrolysis;
the product peak is labeled.
Ac-Val-Trp-His-Ala-Oxd (1M). LCMS: m/z 666.3 (calcd [M+H]+ = 666.6), Purity: >95% (HPLC analysis
at 220 nm). Retention time: 9.2 min
Ac-Val-Trp-His(Trt)-Ala (2m). LCMS: m/z 796.4 (calcd [M+H]+ = 796.5), Purity: >95% (HPLC analysis
at 220 nm). Retention time: 15.58 min
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Figure A132 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Ac-Thr-Cys-Gly-Gly-His-Ala-Oxd (1N). LCMS: m/z 699.2 (calcd [M+H]+ = 699.66), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 14.46 min
Ac-Thr(Trt)-Cys-Gly-Gly-His(Trt)-Ala (2n). LCMS: m/z 1071.4 (calcd [M+H]+ = 1071.5),
1093.4 (calcd [M+Na]+ = 1093.5) Purity: >95% (HPLC analysis at 220 nm). Retention time: 20.52
min
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Figure A133 HPLC spectra of the cyclized starting material and the crude reaction mixture after
hydrolysis; the product peak is labeled.
Fmoc-Thr-Cys-Gly-Gly-His-Ala-Oxd (1O). LCMS: m/z 879.3 (calcd [M+H]+ = 879.66), 901.3
(calcd [M+Na] + = 900.66), Purity: >95% (HPLC analysis at 220 nm). Retention time: 19.05 min
Fmoc-Thr(Trt)-Cys-Gly-Gly-His(Trt)-Ala (2o). LCMS: m/z 1251.4 (calcd [M+H]+ = 1251.57,
Purity: >95% (HPLC analysis at 220 nm). Retention time: 23.46 min
Thr(Trt)-Cys-Gly-Gly-His(Trt)-Ala (2o-Fmoc). LCMS: m/z 1029.4 (calcd [M+H]+ = 1029.57),
Purity: >95% (HPLC analysis at 220 nm). Retention time: 15.62 min
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Figure A134 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in methanol solution; the product peak is labeled.
Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Oxd (4A). LCMS: m/z 779.3 (calcd [M+H]+ = 779.37), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 7.09 min
Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-OMe (5). LCMS: m/z 681.3 (calcd [M+H]+ = 681.46, Purity:
>95% (HPLC analysis at 220 nm). Retention time: 8.047 min
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Figure A135 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in solution of benzyl amine in DMF; the product peak is labeled.
Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Oxd (4A). LCMS: m/z 779.3 (calcd [M+H]+ = 779.37), Purity:
>95% (HPLC analysis at 220 nm). Retention time: 7.09 min
Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-NHBz (6). LCMS: m/z 756.3 (calcd [M+H]+ = 756.57, Purity:
>95% (HPLC analysis at 220 nm). Retention time: 9.58 min
311

Figure A136 HPLC spectra of the cyclized starting material and the crude reaction mixture after
incubation in sodium borohydride solution in THF; the product peak is labeled.
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Oxd (4’A). LCMS: m/z 821.3 (calcd [M+H]+ = 821.66), m/z 843.2
(calcd [M+Na] + = 843.66), Purity: >95% (HPLC analysis at 220 nm). Retention time: 8.407 min
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-CH2OH (7). LCMS: m/z 695.3 (calcd [M+H]+ = 695.37); 717.3
(calcd [M+Na]+ = 717.37) Purity: >95% (HPLC analysis at 220 nm). Retention time: 7.4 min
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CHAPTER 6 SUPPLEMENTAL MATERIAL
All of the following figures have been reproduced with permission from: Elashal, H. E.; Sim, Y.
E.; Raj, M. Chem. Sci. 2017, 8, 117.

Figure A137 HRMS Spectra Ac-Gly-Pro-Met-Leu-Ala(L)-COS(CH2)2CO2C2H5 - 3G
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Figure A138 NMR spectra Ac-Gly-Pro-Met-Leu-Ala(L)-COS(CH2)2CO2C2H5 - 3G
314

Figure A139 HPLC and MS traces for thiolysis product.
Ac-Gly-Pro-Met-Leu-Ala-COS(CH2)2OH (3g). LCMS: m/z 590.2 (calcd [M+H]+ = 590.6), m/z
612.2 (calcd [M+ Na] + = 612.6). Purity: >95% (HPLC analysis at 220 nm). Retention time:10.28
min
Ac-Gly-Pro-Met-Leu-Ala-OH. LCMS: m/z 530.2 (calcd [M+H]+ = 530.5), m/z 552.2 (calcd
[M+Na]+ = 552.5). Purity: >95% (HPLC analysis at 220 nm). Retention time: 9.36 min
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Figure A140 HPLC and MS traces for thiolysis product.
Ac-Gly-Pro-Met-Leu-Ala-COS(CH2)2CO2C2H5 (3G). LCMS: m/z 646.3 (calcd [M+H]+ =
646.7). Purity: >95% (HPLC analysis at 220 nm). Retention time: 13.87 min
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Figure A141 HPLC and MS traces for thiolysis product.
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-COS(CH2)2CO2C2H5 (3h). LCMS: m/z 825.3 (calcd
[M+H]+ = 825.7), m/z 847.3 (calcd [M+Na] + = 847.7). Purity: >95% (HPLC analysis at 220 nm).
Retention time: 11.94 min
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Figure A142 HPLC and MS traces for thiolysis product.
Ac-Arg-Ala-Phe-Lys-Tyr-Gly-Leu-Glu-COS(CH2)2CO2C2H5 (3i). LCMS: m/z 1140.9 (calcd
[M+H]+ = 1140.5), m/z 1163.9 (calcd [M+Na] + = 1163.5). Purity: >95% (HPLC analysis at 220
nm). Retention time: 19.45 min
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Figure A143 HPLC and MS traces for thiolysis product.
Ac-Gly-Val-Ala-Leu-Phe-COS(CH2)2CO2C2H5 (3j). LCMS: m/z 664.3 (calcd [M+H]+ =
664.6), m/z 686.3 (calcd [M+Na] + = 686.6). Purity: >95% (HPLC analysis at 220 nm).
Retention time: 16.30 min.
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Figure A144 HPLC and MS traces for thiolysis product.
Ac-Tyr(tBu)-Phe-Asp(tBu)-Ile-Arg(Pbf)-Ala-Val-COS(CH2)2CO2C2H5 (3k). LCMS: m/z
1404.7 (calcd [M+H]+ = 1404.3), m/z 1426.5 (calcd [M+Na] + = 1426.3). Purity: >95% (HPLC
analysis at 220 nm). Retention time: 25.09 min.
Ac-Tyr-Phe-Asp-Ile-Arg-Ala-Val-COS(CH2)2CO2C2H5 (3K). LCMS: m/z 1040.7 (calcd
[M+H]+ = 1040.8), m/z 1063.6 (calcd [M+Na] + = 1063.8). Purity: >95% (HPLC analysis at 220
nm). Retention time: 14.61 min.
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Figure A145 HPLC and MS traces for thiolysis product.
Ac-Ser-Gly-Ile-Ser-Gly-Pro-Leu-Ser-COS(CH2)2CO2C2H5 (3L). LCMS: m/z 875.3 (calcd
[M+H]+ = 875.7), m/z 897.2 (calcd [M+Na] + = 897.7). Purity: >95% (HPLC analysis at 220
nm). Retention time: 12.0 min.
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Figure A146 HPLC and MS traces for thiolysis product.
Ac-Arg-Phe-Ala-Thr-COS(CH2)2CO2C2H5 (3M). LCMS: m/z 651.8 (calcd [M+H]+ = 651.5),
m/z 673.8 (calcd [M+Na]+ = 673.5). Purity: >95% (HPLC analysis at 220 nm). Retention time:
11.01 min. Isolated yield = 50 %
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Figure A147 HPLC and MS traces for thiolysis product.
Ac-Gly-Pro-Met-Leu-Ala-COS(CH2)2CO2C2H5 (3G). LCMS: m/z 645.8 (calcd [M+H]+ =
645.5), m/z 667.7 (calcd [M+Na] + = 667.5). Purity: >95% (HPLC analysis at 220 nm).
Retention time: 13.97 min
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Figure A148 HPLC and MS traces for thiolysis product.
Ac-RMITYGNSARKGRSNTFID-COS(CH2)2CO2C2H5 (3P). LCMS: m/z 1172.8 (calcd
[M+2H] 2+ = 1172.5), m/z 782.1 (calcd [M+3H] 3+ = 782.0), m/z 586.6 (calcd [M+4H] 4+=
586.7). Purity: >95% (HPLC analysis at 220 nm). Retention time: 10.67 min. Isolated yield = 31%
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Figure A149 HPLC and MS traces for thiolysis product.
Ac-GNSARKGRSNTFID-COS(CH2)2CO2C2H5 (3Q). LCMS: m/z 840.4 (calcd [M+2H] 2+ =
840.9), m/z 560.7 (calcd [M+3H] 3+ = 560.9). Purity: >95% (HPLC analysis at 220 nm). Retention
time: 9.88 min. Isolated yield = 39 %
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Figure A150 HPLC and MS traces for ligated product.
Ac-Gly-Pro-Met-Leu-Ala-Cys(MPAA)-Arg-Phe-Ala-Ser. LCMS: m/z 1285.5 (calcd [M+Na] + =
1285.8). Purity: >95% (HPLC analysis at 220 nm). Retention time: 13.2 min.
Ac-Gly-Pro-Met-Leu-Ala-Cys-Arg-Phe-Ala-Ser. LCMS: m/z 1093.4 (calcd [M+H]+ = 1093.3),
m/z 547.2 (calcd [M+2] 2+ = 547.6). Purity: >95% (HPLC analysis at 220 nm). Retention time:
11.32 min.
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Figure A151 HPLC and MS traces for ligated product.
Ac-Ala-Val-Gly-Pro-Pro-Gly-Val-Ala-Cys-Arg-Phe-Ala-Ser. LCMS: m/z 1273.6 (calcd [M+H]+
= 1273.4), m/z 636.9 (calcd [M+2] 2+ = 637.2). Purity: >95% (HPLC analysis at 220 nm).
Retention time: 10.01 min.
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Figure A152 HPLC and MS traces for ligated product.
Ac-GNSARKGRSNTFIDCPTGPRPNEPMWITY-NH2. LCMS: m/z 3308.6 (calcd [M+H]+ =
3308.4), m/z 1654.8 (calcd [M+2]2+ = 1654.7). Purity: >95% (HPLC analysis at 220 nm).
Retention time: 11.14 min
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Figure A153 MALDI of ligated Product 29 amino acid long peptide
Ac-GNSARKGRSNTFIDCPTGPRPNEPMWITY-NH2
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Figure A154 HPLC spectra of the cyclic urethane containing peptide 2a’
Fmoc-Gly-Ala-Oxd-Phe-Ala-Gly-NH2 (2a’). LCMS: m/z 756.40 (calcd [M+H]+ = 756.10), 778.5
(calcd [M+Na]+ = 778.0). Purity: >95% (HPLC analysis at 254 nm). Retention time: 17.9 min.
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Figure A155 HPLC spectra of the cyclic urethane containing peptide 2b’
Fmoc-Gly-Gly-Oxd-Phe-Ala-Gly-NH2 (2b’). LCMS: m/z 742.40 (calcd [M+H]+ = 742.50), 371.9
(calcd [(M+2] 2+ = 371.75). Purity: >95% (HPLC analysis at 254 nm). Retention time: 20.1 min.
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Figure A156 HPLC spectra of the cyclic urethane containing peptide 2c’
Fmoc-Gly-Met-Oxd-Phe-Ala-Gly-NH2 (2c’). LCMS: m/z 816.0 (calcd [M+H]+ = 816.20), 408.2
(calcd (M+2) 2+ = 408.8). Purity: >95% (HPLC analysis at 254 nm). Retention time: 21.8 min.
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Figure A157 HPLC spectra of the cyclic urethane containing peptide 2d’
Fmoc-Gly-His-Oxd-Phe-Ala-Gly-NH2 (2d’). LCMS: m/z 822.10 (calcd [M+H]+ = 822.60), 411.2
(calcd (M+2)2+ = 411.79). Purity: >95% (HPLC analysis at 254 nm). Retention time: 16.9 min.
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Figure A158 HPLC spectra of the cyclic urethane containing peptide 2e’
Fmoc-Gly-Tyr-Oxd-Phe-Ala-Gly-NH2 (2e’). LCMS: m/z 848.20 (calcd [M+H]+ = 848.62), 424.1
(calcd [(M+2) 2+ = 424.81). Purity: >95% (HPLC analysis at 254 nm). Retention time: 21.1 min.
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Figure A159 HPLC spectra of the cyclic urethane containing peptide 2f’
Fmoc-Gly-Trp-Oxd-Phe-Ala-Gly-NH2 (2f’). LCMS: m/z 871.20 (calcd [M+H]+ = 871.6), 436.0
(calcd (M+2) 2+ = 436.33). Purity: >95% (HPLC analysis at 254 nm). Retention time: 19.8 min.
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Figure A160 HPLC spectra of the cyclic urethane containing peptide 2g’
Fmoc-Gly-Val-Oxd-Phe-Ala-Gly-NH2 (2g’). LCMS: m/z 784.60 (calcd [M+H]+ = 784.58), 392.5
(calcd (M+2) 2+ = 392.79). Purity: >95% (HPLC analysis at 254 nm). Retention time: 16.6 min.
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